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Abstract 
Epidemiological studies suggest a negative association between prostate cancer 
risk and dietary intake of cruciferous vegetables. These vegetables have a 
characteristic sulphur metabolism, delivering specialised compounds including 
glucosinolates, such as glucoraphanin, and S-methyl cysteine sulfoxide (SMCSO). 
An interim analysis of ongoing clinical trials at Quadram Institute Bioscience 
suggested an increase in inorganic sulphate, adenosine 5’-diphosphate (ADP) and 
potential antioxidant capacity of prostate tissue following broccoli consumption.  
Sulforaphane, a hydrolytic product of glucoraphanin, influences multiple pathways 
relevant to prostate cancer prevention. Furthermore, degradation of SMCSO 
produces reactive intermediates, which induce apoptosis in prostate cancer cells, 
and ultimately yields high proportions of inorganic sulphate in human metabolism. 
Sulphate is likely to drive synthesis of phosphoadenosine 5’-phosphosulphate. 
Adenosine 5’-triphosphate (ATP) fuels this process, producing ADP and phosphate. 
As cancerous cells are unable to adjust their metabolism, depleting ATP by diet 
could prove an effective strategy for cancer prevention.  
A high-dose, randomised, parallel-unblinded broccoli-intervention study was carried 
out in men awaiting trans-perineal prostate biopsies. Global metabolomic and 
targeted metabolite analyses were undertaken on prostate, adipose and urine 
samples to test the biological availability and activity of sulphur-containing 
metabolites from the study diet. In vitro experiments were undertaken to investigate 
the effects of sulforaphane and SMCSO on real-time prostate bioenergetics and 
redox status of proteins relevant to prostate cancer. 
SMCSO was present at significantly higher levels (p<0.01) in both the urine and 
prostates of men receiving a broccoli-enriched diet. Whereas sulforaphane and its 
conjugates were undetectable in tissue. Levels of ATP and sulphate were not 
different between study groups. At physiological concentrations neither 
sulforaphane nor SMCSO affected mitochondrial function or redox status in vitro.  
SMCSO accumulation in tissue after broccoli consumption may mediate the putative 
effects of cruciferous vegetables towards prostate cancer prevention through its 
degradation to highly-reactive intermediate products. 
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1.1 The Prostate Gland 
The prostate gland is an exocrine organ of the male genitourinary tract, located at 
the base of the bladder, anterior to the rectum and encompassing the urethra. The 
primary function of the prostate is to secrete prostatic fluid during ejaculation, which 
contributes 30% of the total volume to semen [1]. Enzymes, proteins and nutrients 
within this alkaline fluid provide support for the survival of spermatazoa in the acidic 
conditions of the vagina [2]. Prostate-specific antigen (PSA), a protease that 
liquefies semen by breaking down high molecular weight proteins, is a constituent of 
this fluid that facilitates free motility of sperm. PSA is also detectable in serum and is 
used as a common laboratory test to aid prostate cancer diagnosis [3, 4].  
The prostate is divided into three major zones; central, transitional and peripheral. 
The central zone surrounds the ejaculatory ducts, which run from the seminal 
vesicles to the prostatic urethra. The transitional zone surrounds the urethra as it 
descends from the bladder. It is the most common site for development of benign 
prostatic hyperplasia (BPH), a nodular enlargement of the prostate that compresses 
the urethra causing symptomatic impairment to urinary flow. The peripheral zone is 
the largest zone of the prostate and is the most easily palpable during digital rectal 
examination (DRE) [5]. 70-80% of all prostate cancers originate in the peripheral 
zone [6, 7]. 
1.1.1 Prostate Cancer 
Prostate cancer is the second most commonly diagnosed cancer in the UK. Men 
carry a lifetime risk of 1 in 8, with incidence being strongly linked to age (Figure 1-1) 
[8]. Worldwide, the highest incidences of prostate cancer are seen in Australia and 
New Zealand, and the lowest in South Central Asia [9]. The aetiology, however, 
remains relatively poorly understood. Geographical variation in the incidence of 
prostate cancer cannot be explained by known risk factors such as age, race and 
family history. This implicates environmental factors, including diet, in the risk of 
developing prostate cancer. There is also growing evidence to suggest that 
multifocal tumours arising within the same prostate gland have discrete mutational 
profiles with varying malignant potential [10]. Multifocal prostate cancer could, 
therefore, be susceptible to metabolic changes induced by dietary interventions that 
generate a hostile environment against the emergence and proliferation of 
cancerous clones. 
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Figure 1-1 Cancer Research UK statistics for prostate cancer incidence by age in UK males, 1993-
2014 [8]. 
 
1.1.2 Prostate Cancer Diagnosis 
There is no current screening programme for prostate cancer in the UK. Although 
men can request a PSA level to be checked by their General Practitioner, uptake 
between the ages of 45-89 is currently only 6%, with little change over the last 
decade [11]. Prostate cancer is predominantly diagnosed by trans-rectal ultrasound 
(TRUS) and needle biopsy once the findings of either an abnormal DRE or elevated 
serum PSA have been established. Standard practice for first biopsy is to take 10-
12 needle biopsy cores through the rectum, under local anaesthetic and with 
appropriate antibiotic prophylaxis. Magnetic Resonance Imaging (MRI) is not 
routinely used in screening for prostate cancer. However, it is recommended by the 
National Institute of Clinical Excellence (NICE) for staging the disease after 
diagnosis, or for additional information prior to a second prostate biopsy if the first 
was benign and clinical suspicion remains high [12]. 
Trans-perineal template biopsy of the prostate (TPB) is indicated to increase the 
diagnostic yield of a second biopsy following an initial negative or inconclusive 
TRUS biopsy. Sampling of the anterior prostate is improved by this technique, a 
larger number of cores are taken and in some cases suspicious lesions detected by 
MRI may be specifically targeted (Figure 1-2) [13]. All prostate tissue samples from 
participants in the human intervention studies described in this thesis (ESCAPE and 
SAP, Section 1.3 and Chapter 2 respectively) were obtained during TPB. 
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Figure 1-2 The procedure for trans-perineal template prostate biopsy. Image from the British 
Association of Urological Surgeons’ patient information sheet on trans-perineal prostate biopsies [14]. 
 
1.1.3 Prostate Cancer Grade and Stage 
The histopathological grade of prostate cancer is determined by the appearance of 
the tissue under a microscope. The most commonly used scoring system was 
developed by Donald Gleason and colleagues in the 1960s, categorizing the 
architectural patterns from 1 to 5. A well-differentiated appearance is scored 1 and 
the least differentiated is scored 5, with separate scores being assigned to both the 
primary and secondary patterns observed. Combining both primary and secondary 
patterns provides a Gleason Sum between 2 and 10 (e.g. Gleason 3+4=7), a higher 
score corresponding to progressive loss of differentiation and therefore worsening 
prognosis [15]. The system was revised in 2005, reallocating the groups to which 
certain morphologies were assigned and improving the overall performance [16]. As 
Gleason patterns 1-2 are considered normal, the minimum Gleason Sum to amount 
to cancer is 6 (Gleason 3+3). For this reason a simplified ‘Grade Group’ system was 
implemented by the World Health Organisation (WHO) in 2016, reclassifying 
cancers into groups from 1 to 5 according to prognostic risk and modified Gleason 
score (Figure 1-3) [17]. 
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Figure 1-3 The histological appearance, Gleason pattern, Gleason score and corresponding WHO 
Grade Group of prostate cancer described by Chen and Zhou, 2016 [18]. 
 
The TNM classification system, as described by the American Joint Committee on 
Cancer (AJCC), is used to describe the stage of the tumour according to the primary 
tumour (T), spread to regional lymph nodes (N) and distant metastases (M) [19]. 
The grade, stage and PSA are used to stratify the risk from prostate cancer and to 
inform decisions about how each patient is managed. 
1.1.4 The Metabolism of Prostate Cancer 
Normal cells utilise glucose via enzymatic breakdown in glycolysis to produce 
pyruvate. In aerobic conditions, pyruvate enters the mitochondria where it is 
converted to acetyl CoA by pyruvate dehydrogenase and subsequently to citrate to 
fuel the tricarboxylic acid (TCA) cycle [20]. Adenosine 5’-triphosphate (ATP) is 
produced by oxidative phosphorylation as a universal energy source [21]. Prostate 
epithelial cells have a characteristic metabolism that facilitates the import of zinc 
and excretion of citrate into prostatic fluid as an energy source for sperm [22]. The 
high concentration of zinc inhibits aconitase, preventing enzymatic conversion of 
citrate to iso-citrate in the TCA cycle. Citrate exits the mitochondria and is either 
excreted into prostatic fluid from the cytosol or converted back to acetyl CoA by ATP 
citrate lyase (ACLY) for lipid and cholesterol synthesis [23]. Thus, prostate cells are 
highly glycolytic, rely on aspartate and glutamine to replace intermediates of the 
TCA cycle and utilise more fatty acids through beta oxidation for energy production 
than other cell types [24]. 
Cancers at most tissue sites tend to adjust their metabolism in a process called the 
Warburg Effect; utilising glucose via glycolysis and producing lactate even when 
oxygen is abundant [25]. Prostate cancer, however, demonstrates a range of 
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relatively exclusive characteristics. High glucose dependency is not a typical 
feature, which accounts for the poor accumulation of 18F-fluorodeoxyglucose (FDG) 
[26]. The radio-labelled isotope is detectable by positron emission topography (PET) 
and commonly used in staging other cancer types, but has limited clinical value in 
prostate cancer [27]. Instead, prostate cancers reverse the usual excretion of citrate 
and rely heavily on fatty acid beta oxidation. Loss of zinc accumulation and 
downstream aconitase inhibition by cancerous cells redirects citrate back into the 
TCA cycle. Subsequent production of ATP via oxidative phosphorylation meets the 
high demands of the proliferating cancer [28]. Cytosolic citrate is also more readily 
converted to acetyl CoA by ACLY, an enzyme that is commonly upregulated in 
prostate cancer [29]. Acetyl CoA is a central substrate for cholesterol and fatty acid 
synthesis and histone acetylation, all of which have close links to prostate cancer. 
Increased de novo fatty acid synthesis is dependent on the catalytic activity of both 
acetyl CoA carboxylase (ACAC) and fatty acid synthase (FASN). Upregulation of 
the latter is so common in prostate cancer it is often referred to as an oncogene 
[30]. Fatty acids form building blocks for cell growth and proliferation. Alternatively, 
they can be used as an energy source by beta oxidation, which first requires 
transformation of branched chains by α-methylacyl-CoA racemase (AMACR). In 
prostate cancer AMACR overexpression is characteristic, making it a useful marker 
for immunohistochemistry staining of histopathology specimens, with a sensitivity of 
82-100% [31].  
Normal epithelial cells of the prostate therefore have metabolic characteristics that 
resemble a more cancerous than healthy phenotype of other body cells. This may 
predispose them to malignant transformation and contribute towards the high overall 
incidence of prostate cancer [32]. Dysregulation of both citrate and fatty acid 
metabolism is typical in prostate cancer, though multiple metabolic pathways are 
likely to be involved in both development and prevention of the disease. 
1.1.5 Prostate Exposure to Urinary Metabolites 
Under normal resting conditions the detrusor muscle of the bladder is relaxed and 
both the internal and external urethral sphincters are contracted, allowing the 
bladder to fill. During micturition (voiding) the opposite occurs; the detrusor muscle 
contracts and both sphincters relax to allow urine to be expelled from the bladder 
[33]. The prostate gland in men lies directly between the internal urethral sphincter, 
also known as the bladder neck, and the external urethral sphincter (Figure 1-4). 
The prostatic and ejaculatory ducts open into the prostatic urethra between these 
two sphincters, posing a risk of urinary reflux if flow is restricted at any point distal to 
the bladder neck.  
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Figure 1-4 Sphincter anatomy of the prostate. Image for patient information from the Prostate Cancer 
Foundation (Australia) [34]. 
 
Reflux of urine into the prostatic ducts was first proven in the 1980s [35]. Several 
days before undergoing a trans-urethral resection of the prostate (TURP), 10 men 
with chronic prostatitis received an intra-vesical instillation of carbon microspheres. 
70% of the resected prostate tissue was later found to contain microspheres, 
implicating urinary reflux in the aetiology of chronic inflammation [35]. Consistent 
with chemical irritation from urine exposure, the prostate secretions from men with 
abacterial prostatitis also contain higher concentrations of waste products urate and 
creatinine [36]. Other inflammatory conditions of the prostate include 
xanthogranulomatous prostatitis; a potential complication of intra-vesical bacillus 
Calmette-Guerin (BCG) used in the treatment of high-risk non-muscle invasive 
bladder cancer. The resultant granuloma formation is not limited to the tissue 
immediately adjacent to the urethra but occurs throughout all zones of the prostate 
gland, proving the extent to which urinary reflux occurs [37, 38].  
Although the role of urinary reflux has been largely studied in the context of 
pathological contact with irritants, urine may also provide a valuable route of 
exposure to highly-concentrated dietary metabolites. Modulation of inflammation by 
lycopene in the diet has previously been suggested by this route [39]. However, 
comparison of tissue concentrations of specific diet-derived metabolites at sites with 
and without exposure to urine has not previously been made. 
1.2 Cruciferous Vegetables and Prostate Cancer  
Cruciferous vegetables belong to the family of Brassicaceae, which include a wide 
range of cultivars, including the most commonly consumed green-leaf vegetables 
(Brassica oleracea) such as broccoli, cabbage, brussels sprouts and cauliflower. A 
meta-analysis of population-based case-control and cohort studies identified a 
negative correlation between intake of cruciferous vegetables and prostate cancer 
incidence [40]. This extended to an overall reduction in the risk of locally advanced 
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cancer (higher T stage). Habitual intake of cruciferous vegetables is especially high 
in Asia where the incidence of prostate cancer is the lowest worldwide [9]. 
Several mechanisms have been suggested by which these vegetables exert their 
potential anti-cancer effects. The biological activity is primarily attributed to 
isothiocyanates (ITCs) derived from glucosinolates. In vitro studies of ITCs have 
demonstrated their influence on multiple mechanisms associated with 
chemoprevention [41]. Glucoraphanin, the most abundant glucosinolate in broccoli, 
is broken down to the ITC sulforaphane (1-isothiocyanato-4-methylsulfinylbutane) 
by myrosinase. This enzyme, however, is commonly denatured during cooking, in 
which case glucoraphanin is broken down by thioglucosidase activity of gut 
microbiota (Figure 1-5) [42]. Sulforaphane has been shown in animal models and in 
vitro studies to modulate enzymes involved in activation and detoxification of 
carcinogens, induce apoptosis in prostate cancer cells, and inhibit both inflammation 
and angiogenesis [43, 44]. The major molecular target for these biological effects is 
nuclear factor erythroid 2-related factor 2 (Nrf-2), a regulator of phase I and phase II 
detoxification enzymes, antioxidant defence and nicotinamide adenine dinucleotide 
phosphate (NADPH) regeneration [45]. Sulforaphane prevents Kelch-like ECH-
associated protein (Keap)1 ubiquitination of Nrf-2, increasing both its nuclear 
abundance and activity. However, despite the multi-modal influence of sulforaphane 
on such a wide range of cell-signalling and metabolic pathways, human-intervention 
trials have so far been unable to confirm its role as either a preventive or therapeutic 
agent against prostate cancer [46, 47]. The significant effects of POMI-T, a 
polyphenol-rich dietary supplement that also included sulforaphane, on PSA rise in 
prostate cancer was a result of four phytochemicals in combination rather than 
individual ingredients [48]. 
 
 
Figure 1-5 Pathway for human metabolism of glucoraphanin. Enzymatic breakdown produces 
sulforaphane, which is readily absorbed by the gut and conjugated with glutathione. Sulforaphane may 
either be cleaved from glutathione or metabolised via the mercapturic acid pathway. Redrawn from[49]. 
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In addition to accumulation of ITCs, the unique sulphur metabolism of these 
vegetables allows them to deliver inorganic sulphate and S-methyl-L-cysteine 
sulfoxide (SMCSO), which may also offer significant biological activity [50, 51]. 
SMCSO is degraded by cysteine lyase to produce intermediates, including dimethyl 
disulphide sulfoxide (MMTSI) and dimethyl disulphide sulfone (MMTSO) 
(Figure 1-6). Both products provide in vivo protection against known carcinogens 
such as benzo[a]pyrene, Aflatoxin B1 and azoxymethane in animal models of skin, 
bone marrow and colon cancer respectively [52-54]. MMTSI also induces apoptosis 
in human prostate cancer cell lines via both caspase-dependent and independent 
mechanisms [55]. However, the most noteworthy characteristic in the metabolic fate 
of SMCSO is the high yield (up to 50%) of inorganic sulphate recovered in urine 
after consumption of radio-labelled [35S]-SMCSO [56]. The relevance of sulphate 
production to prostate cancer and the work conducted in this thesis are discussed 
below. 
 
Figure 1-6 Pathway for metabolism of SMCSO by cysteine lyase. Reactive intermediates include 
MMTSI, MMTSO and dimethyl disulfide. Adapted from [57] to include predominant end products in 
urine after consumption of radio-labelled SMCSO (right). 
 
1.2.1 Glutathione S-Transferase Mu 1 Genotype 
Systematic reviews and meta-analyses have identified associations between 
genetic polymorphisms in glutathione S-transferases (GSTs) and the development 
of prostate cancer [58, 59]. GSTs are part of a broad family of phase II detoxification 
enzymes which have roles in both inactivating carcinogens and utilising GSH to 
remove oxidative metabolites that could otherwise damage DNA. Therefore, those 
with deficiencies in GSTs are potentially at an increased risk of developing cancers 
at multiple sites. Of the 8 recognised classes of GSTs, three have been intensively 
studied in the context of prostate cancer; glutathione S-transferase Mu 1 (GSTM1), 
glutathione S-transferase theta-1 (GSTT1) and glutathione S-transferase pi 
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(GSTP1) [60]. The consistently reported finding is that the inherited GSTM1 
homozygous deletion polymorphism (GSTM1 null) genotype confers the greatest 
risk of developing prostate malignancy due to loss of enzyme function [58]. 
GSTM1 is among the many antioxidant genes regulated by Nrf-2, which 
accumulates in the nucleus after exposure to dietary ITCs such as sulforaphane 
from broccoli. Epidemiological studies have shown that the reduction in prostate 
cancer risk specifically due to cruciferous vegetable consumption is higher in those 
with a functioning GSTM1 allele [61]. The metabolism and glutathione conjugation 
of sulforaphane have been linked to GSTM1 genotype, and bioavailability studies 
show that sulforaphane and its biologically-active conjugates are more rapidly 
cleared (lost) from circulation in GSTM1 null individuals [62-64]. GSTM1 genotype 
is, therefore, considered an important explanatory variable when interpreting results 
from all broccoli-based dietary-intervention studies conducted at QIB. 
 
1.3 Human Studies Evidence from High-Glucosinolate Broccoli Trials at QIB 
Ongoing clinical trials at the Quadram Institute Bioscience (QIB) seek to explore the 
potential health benefits of high-glucosinolate broccoli. By selective breeding and 
introgression of a Myb28 allele from wild-type Brassica villosa, cultivars of broccoli 
have been developed on the Norwich Research Park to express three-fold 
(Beneforte®) and six-fold (Beneforte Extra) higher concentrations of glucoraphanin 
in their florets [65].  
The Effect of Sulforaphane on Prostate Cancer Prevention (ESCAPE) study (REC 
13/EE/0110; NCT01950143) is a 12-month dietary intervention study that first 
started recruiting in 2014. It was designed to test the effects of increasing 
sulforaphane concentrations on prostate metabolism by intervening with a single 
portion of glucoraphanin-enriched broccoli soup per week. The high-glucosinolate 
broccoli varieties, Beneforte® and Beneforte Extra, were therefore compared with a 
standard broccoli soup control. Men were recruited and randomised to one of the 
three broccoli soup diets after deciding on active surveillance for management of 
either low or intermediate-risk, organ-confined prostate cancer. The approach of 
active surveillance is to offer regular clinical follow up to monitor for any signs of 
disease progression, delaying or potentially avoiding the potential side effects of 
radical treatments such as radiotherapy or surgery [66]. In addition to regular PSA 
and DRE monitoring, men on the ESCAPE study underwent TPB both before and 
after 12 months of the dietary intervention. Prostate needle biopsy cores were taken 
separate to those required for histological analysis and used for dedicated research 
purposes; both global and targeted metabolite analysis, and next-generation RNA 
sequencing. 
In October 2015, an interim analysis was carried out on the prostate tissue from the 
first 15 volunteers to complete paired 0 and 12-month sample collections. Tissue 
extracts were sent to a metabolomics platform for global profiling (Metabolon®), 
which was successful in matching 381 detectable metabolites to their reference 
database. Statistically significant changes (paired t test, p<0.05) were identified in 
22 metabolites, highlighting distinct changes in several metabolic pathways 
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(unpublished data). Modification to tissue redox status, as could be expected after 
exposure to ITCs, was confirmed by significant increases in the glutathione 
metabolites glutathione-reduced (GSH), s-methyl glutathione and cysteine-
glutathione disulphide. The significant findings, however, occurred across all three 
arms of the study, indicating potential biological activity of the diet that was 
unrelated to the glucoraphanin content of the broccoli. 
The most statistically significant result from this interim analysis was an increase in 
levels of inorganic sulphate over the 12-month period (p=0.0006). The levels of both 
adenosine 5’-diphosphate (ADP) and phosphate also increased significantly 
(p=0.002 and p=0.005 respectively) suggesting depletion of ATP, the vital energy 
source. Most importantly, both changes in sulphate and ADP were significantly 
associated with a reduction in prostate cancer volume, defined by the percentage of 
biopsy cores affected (Figure 1-7) (unpublished data). These findings introduced the 
possibility of a novel link between sulphate accumulation and ATP depletion in 
prostate tissue. As there was no significant difference between study diets, the 
outcome may have been due to alternative sources of sulphate in the broccoli. 
SMCSO, for example, represents a major pool of sulphur metabolism and degrades 
in humans to provide a rich source of inorganic sulphate, as previously described in 
Figure 1-6.  
To test the hypothesis that sulphate delivered by broccoli consumption, and 
SMCSO degradation, was accumulating in prostate tissue, an independent study 
was required. The design of this study has introduced a non-intervention control arm 
(Chapter 2). The potential mechanistic links between sulphate, ATP and prostate 
cancer prevention are discussed below. 
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Figure 1-7 Graphs from unpublished doctoral thesis (Al Kadhi, O. 2017) showing the significant 
negative associations between change in cancer volume over 12 months and tissue levels of (A) 
sulphate (p<0.05) and (B) ADP (p<0.01) in the ESCAPE subgroup analysis (n=15) [67]. 
 
1.4 Sulphate and Cancer 
A direct link between tissue levels of inorganic sulphate and cancer has not 
previously been established. Increasing the level of sulphate is likely to drive 
synthesis of 3’-phosphoadenosine 5’-phosphosulphate (PAPS), a universal sulphate 
donor for sulphonation reactions [68]. The process of sulphonation via PAPS 
provides a vital metabolic pathway for detoxification of a wide range of xenobiotics, 
drugs and endogenous compounds [69, 70]. However, some dietary and 
environmental agents have the opposite characteristic, depending on sulphonation 
for activation to highly-reactive, toxic intermediates with implications towards 
carcinogenesis [71]. 
Synthesis of PAPS is limited by the intra-cellular availability of inorganic sulphate 
[68, 72]. Each of the two PAPS synthase enzymes (PAPSS-1 and PAPSS-2) has 
dual enzymatic activity, acting as both an ATP-sulfurylase and adenosine 
phosphosulphate (APS) kinase. A molecule of ATP is used at each step, thereby 
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depleting two mol ATP for each mol of inorganic sulphate that is converted to PAPS 
(Figure 1-8). Deficiencies in PAPS synthase have been linked to a range of disease 
states, although none have shown a causative relationship with cancer [73]. 
Although it may not translate to loss of function of PAPSS-2, copy number losses in 
established prostate cancer specimens have been linked to PSA recurrence after 
prostatectomy [74]. Interestingly, upregulation of PAPSS-1 has also been shown to 
protect against proliferation in other hormone-sensitive cancer models, such as 
breast cancer, due to increased sulphonation of oestrogens [75]. A clinically 
relevant approach to prostate cancer through regulation of androgens by 
sulphonation, however, is yet to be investigated [76].  
 
 
Figure 1-8 Synthesis of PAPS from inorganic sulphate. The two-step process is catalysed at both 
stages by PAPS synthases (PAPSS-1 and PAPSS-2), which have dual enzymatic functions. 
Availability of sulphate is rate limiting, so increased concentrations are likely to drive PAPS synthesis, 
consuming ATP as both substrate and energy source. 
 
Animal studies of diets deficient in the sulphur-containing amino acids cysteine and 
methionine have demonstrated a reduction in levels of inorganic sulphate both 
circulating in plasma and excreted in urine. This led to reduction in tissue levels of 
“biologically active sulphate” (PAPS), as well as levels of the antioxidant glutathione 
[77]. Conversely, the unique sulphur metabolism of broccoli offers a rich source of 
both methionine and cysteine, in addition to the glucoraphanin, inorganic sulphate 
and SMCSO content [78].  
 
1.5 ATP Depletion and Cancer 
Cancerous cells have high energy requirements and are unable to adjust their 
metabolism according to fluctuations in ATP [79]. The response in non-cancerous 
cells to a rise in the adenosine monophosphate (AMP)/ATP and adenosine 
diphosphate (ADP)/ATP ratios is through activation of the AMP protein kinase 
(AMPK) pathway by LKB1. Activated AMPK restores cellular energy levels by 
reducing protein synthesis, increasing glycolysis and fatty acid oxidation, and 
inducing cell cycle arrest in proliferating cells [80, 81]. Cancerous cells have a 
characteristic metabolism that exhibits some of these traits under normal conditions; 
increased glycolysis and greater turnover of fatty acids. However, cancerous cells 
favour lactate production by aerobic glycolysis (the Warburg Effect), which is 
   Chapter 1 
14 
 
relatively inefficient at producing ATP (2mol ATP/ mol glucose) compared to 
oxidative phosphorylation via the TCA cycle (~36mol ATP/ mol glucose) [25]. The 
role of activated AMPK is also complex because it is upregulated in several prostate 
cancer cell lines, but excess stimulation inhibits proliferation and induces apoptosis 
[82]. Thus, novel therapeutic agents targeting AMPK activation are under ongoing 
investigation in the treatment of prostate cancer [83]. The same mechanism is also 
proposed to account for the cancer-preventing properties of the anti-diabetic drug 
metformin [84]. 
ATP suppression by dietary intervention therefore offers a potentially attractive 
mechanism for cancer prevention. Global metabolomics analyses have recently 
been used to investigate the use of a large number of diet-derived bioactive 
compounds in reducing ATP levels in prostate cancer models [85]. Although 
SMCSO was not included, the most interesting results were observed in 
combinatorial treatments compared to individual compounds. This supports the use 
of diet intervention with food (broccoli soups) in trials undertaken at QIB because of 
the combined content of glucosinolates, SMCSO and other constituents of broccoli 
that may confer health benefit. 
 
1.6 Thesis Objectives 
This thesis describes the impact of broccoli-derived sulforaphane and SMCSO on 
prostate metabolism in both humans and prostate cells in vitro. The primary 
hypothesis is that the multi-modal effects of broccoli-derived bioactives induce an 
energy-deplete prostate microenvironment with an increased capacity to resist 
oxidative stress and inhibit prostate carcinogenesis. The approach includes: 
- Carrying out a randomised, parallel-unblinded, high-dose broccoli 
intervention study in men awaiting TPB 
 
- Investigating untargeted global metabolomic differences in tissue 
samples of men recruited to a high-dose broccoli intervention study  
 
- Development and application of targeted analytical methods to quantify 
sulphate, ATP and SMCSO in human samples 
 
- Investigating the effects of sulforaphane and SMCSO on real-time 
bioenergetics in prostate cell lines 
 
- Testing the antioxidant capacity of sulforaphane and SMCSO in 
protecting the phosphatase and tensin homologue (PTEN) tumour 
suppressor against oxidative stress. 
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2  A Pre-Biopsy Window-of-
Opportunity Study to Measure 
Sulphate Levels in Human Prostate 
After Broccoli Consumption 
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Summary 
The chemopreventive effects of cruciferous vegetables are largely attributed to their 
ability to deliver ITCs, including sulforaphane from broccoli. This chapter describes 
the background, study design and working hypotheses of a high-dose, broccoli-
enriched dietary-intervention study during the pre-biopsy ‘window of opportunity’ for 
men under investigation for prostate cancer. The metabolism of the prostate is 
uniquely adapted to support the exocrine secretion of nutrients in seminal fluid. It 
may also be exposed to the highly-concentrated mix of metabolites from urine as it 
refluxes via the prostatic ducts during voiding. The Sulphate Accumulation in 
Prostate (SAP) study aims to clarify the relationship between sulphur-containing 
compounds from broccoli and prostate metabolism. Utilising both global and 
targeted analytical platforms, potential mechanistic links to prostate cancer 
prevention will be sought, primarily via an accumulation of inorganic sulphate. 
 
2.1 Introduction 
Sulphur metabolism in cruciferous vegetables accounts for their characteristic 
flavour and is central to production of biologically active metabolites, including 
glucosinolates (sulphur-containing glycosides) [50, 78]. Major pools of sulphur also 
exist in Brassicaceae in the forms of SMCSO, and to lesser extents amino acids 
(cysteine and methionine), glutathione and sulphate [51]. Degradation products of 
sulphur metabolites include the putative anti-cancer agent sulforaphane, volatile 
intermediates and inorganic sulphate [43, 56].  
2.1.1 Emerging Evidence for Sulphate Accumulation in Prostate 
Interim results from a 12-month dietary intervention with broccoli soup (ESCAPE 
study) identified changes in several metabolic pathways. The most significant was 
an increase in inorganic sulphate levels in prostate tissue (unpublished data). 
Sulphate availability is the rate-limiting substrate for synthesis of PAPS, the 
universal sulphate donor for sulphonation reactions [72]. Consistent with an 
increased drive to synthesise PAPS, a significant increase in both ADP and 
phosphate was also detected in the ESCAPE subgroup analysis, suggesting 
depletion of ATP stores to fuel the reaction. Furthermore, the change in ADP was 
negatively correlated to change in number of prostate cores affected by cancer after 
12 months (unpublished data). Potential depletion of ATP in human prostate tissue 
by dietary intervention represents a novel mechanistic link between the sulphur 
metabolism of cruciferous vegetables and prostate cancer prevention; cancerous 
clones have high energy demands and are unable to adapt to restricted availability 
of ATP, making them more susceptible to elimination [79, 86]. 
The ESCAPE study seeks to investigate the effects of varying the glucosinolate 
content in broccoli soups on prostate metabolism. A major advantage of 
upregulating the glucosinolate content within broccoli varieties, and consumption as 
food rather than isolated sulforaphane, is maintaining the contribution of other 
phytochemicals. No statistically significant differences have emerged between study 
diets, which could suggest a contribution of other constituents to sulphate 
accumulation, though the subgroup has relatively limited power (n=15). To 
independently test the effects of a glucoraphanin-enriched broccoli soup on 
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sulphate metabolism in the prostate, an additional human intervention study was 
required to compare those receiving the intervention to a control group continuing 
their normal diet. The study hypothesis was that metabolism of SMCSO in the 
broccoli soup, which yields high proportions of inorganic sulphate (~50%), drives 
PAPS synthesis and depletes ATP in prostate tissue (Figure 2-1).  
 
 
Figure 2-1 Pathway hypothesis for SAP study. Degradation of SMCSO from broccoli soup produces 
sulphate, driving synthesis of PAPS and depleting ATP. Modified from Figure 1-7. 
 
2.1.2 Route of Exposure to Broccoli Metabolites 
The Bioavailability of Broccoli Soups (BOBS) study (REC 14/EE/1121; 
NCT02300324) at QIB detected both SMCSO and glucoraphanin in urine after 
broccoli soup consumption in healthy subjects. Reflux of urine into the prostatic 
ducts during voiding may, therefore, provide an additional route of exposure to 
systemic circulation for the accumulation of broccoli-derived sulphur-containing 
metabolites in the prostate [35]. To date there is no evidence that urinary reflux into 
the prostate provides an additional route of exposure to dietary agents. Hence, 
further investigation is needed to elucidate the process. Biopsies of pelvic adipose 
tissue can be obtained at the same time as prostate biopsies during TPB, without 
extending the surgical field beyond the template grid. Utilising the same extraction 
and analytical methods for both prostate and adipose tissue provides a method for 
comparing metabolic profiles with and without urine exposure. This could represent 
a useful experimental tool for investigating in vivo whether exposure to urinary 
compounds drives unique metabolic changes in the prostate. 
2.1.3 Modulation of Redox Status by Dietary Intervention 
Increased levels of antioxidant glutathione metabolites in the ESCAPE subgroup 
analysis was one of the most significant metabolic pathway changes after 12 
months of broccoli soups (unpublished data). The consequence of increasing 
capacity to resist oxidative stress could be to maintain the function of proteins 
regulating metabolism, such as the phosphatase and tensin homologue (PTEN). 
The importance of the PTEN tumour suppressor in prostate cancer is widely 
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recognised and will be described in greater depth in Chapter 6. In essence, the 
PTEN protein inhibits activation of the phosphoinositide 3-kinase (PI3k)/Akt 
pathway, which would otherwise promote the rapid cell growth and proliferation 
required for cancer progression [87]. Mutations and deletions in one or both PTEN 
alleles are common in prostate cancer and provide prognostic information on the 
likelihood of disease recurrence after radical treatment [88, 89]. However, the ability 
of PTEN to dephosphorylate phosphatidylinositol 3,4,5 triphosphate (PIP3) is further 
reduced at the protein level due to reversible inactivation by oxidative stress [90]. 
Upregulating the antioxidant capacity of prostate tissue by dietary intervention could 
restrict cancer growth by maintaining PTEN in its reduced (active) state.  
 
2.2 SAP Study Aims 
The aims of the SAP study, as specified in the original protocol (Annex 1), are 
detailed below. As the control diet of the ESCAPE study includes standard broccoli 
soup, the primary role of SAP was to compare levels of sulphate in the prostates of 
men on a high-dose broccoli intervention to those of men continuing their normal 
diets. Additional outcome measures, including an increase in ADP and phosphate, 
aimed to further test the hypothesis that sulphate accumulation was driving down 
ATP via PAPS synthesis. Comparing metabolite profiles in prostate, adipose and 
urine sought to establish whether diet-induced changes in the prostate were related 
to systemic circulation or exposure to urine refluxing via the prostatic ducts. Further 
mechanistic links to prostate cancer prevention were outlined through plans to 
assess the redox status of the PTEN tumour-suppressor protein. The impact of 
GSTM1 genotype on both prostate cancer risk and the bioavailability of broccoli 
bioactives is well established [58, 63]. The GSTM1 status of participants, therefore, 
remains an important explanatory variable when interpreting the results of this 
study. The results from all study outcomes were also interpreted in the context of 
habitual cruciferous vegetable intake assessed by a validated food frequency 
questionnaire. 
2.2.1 Primary aim 
- To determine whether a diet rich in broccoli will result in a difference in 
sulphate levels in tissue samples obtained from men scheduled for prostate biopsy. 
2.2.2 Secondary aims 
 - To determine whether a diet rich in broccoli will result in metabolic 
differences such as increased ADP in prostate tissue of men scheduled for prostate 
biopsy 
- To determine whether differences in sulphate and ADP levels induced by 
diet are specific to prostate tissue. 
- To determine whether the metabolite differences induced by diet will affect 
the redox status of phosphatase proteins such as PTEN in prostate tissue. 
- To determine whether the differences in metabolites induced by diet in 
prostate tissue are associated with metabolite differences in urine. 
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- To demonstrate if the differences in metabolites induced by diet are 
modulated by glutathione S-transferase Mu 1 (GSTM1) genotype or other relevant 
genotypes.  
 
2.3 Materials and Methods 
2.3.1 SAP Study Design 
Figure 2-2 outlines the design of a two-arm, parallel un-blinded, dietary-intervention 
study, delivering a short, high-dose broccoli diet intervention to men in the pre-
biopsy window before their TPB (SAP study). Eighteen men were randomised to 
either continue their normal diet (non-intervention controls) or receive three portions 
of Beneforte® (glucoraphanin-enriched) broccoli and stilton soup (300g) per week 
for a minimum of 4 weeks. The soup content from sulphur analysis at QIB is 
included in Table 2-1. Recruited participants completed a health questionnaire and 
Cruciferous Vegetable Food Frequency Questionnaire (CVFFQ). On the study day 
samples of whole blood, post-DRE urine, prostate and adipose tissue were 
collected. The routine TPB was performed to meet the patients’ clinical 
requirements and their follow-up care was continued by the urology consultants at 
the Norfolk and Norwich University Hospital (NNUH). A further supply of soup was 
offered to all participants after completing the study for their own consumption.  
 
Figure 2-2 Flow diagram of the SAP study outline 
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Table 2-1 Results from content analysis for the batch of Beneforte® broccoli and stilton soup used in 
the SAP study 
Beneforte 
Broccoli 
Soup 
Glucoiberin 
(µmol/G) 
Glucoraphanin 
(µmol/G) 
SMCSO 
(µmol/G) 
Sulphate 
(µmol/G) 
Polyphenols 
(µmol/G) 
Batch 1C 0.527 4.077 20.05 ± 
1.36 
10.43 ± 
0.14 
15.01 ±   
0.46 
 
2.3.2 Study Management 
The SAP study was funded by the Biotechnology and Biological Sciences Research 
Council (BBSRC, UK) and the Prostate Cancer Foundation (PCF, USA). It was 
carried out in collaboration with QIB (formerly the Institute of Food Research (IFR)), 
the Urology and Histopathology departments at NNUH and co-investigators from the 
University of East Anglia (UEA). The named scientists were Professor Richard 
Mithen (Chief Investigator), myself and Dr Antonietta Melchini (QIB Investigators), 
and Mr Robert Mills (NHS Investigator). The protocol was approved by the Human 
Research Governance Committee (HRGC IFR 01/2016) at QIB in January 2016 for 
submission to the National Research Ethics Services (NRES). The East of England 
– Cambridge East Research Ethics Committee (REC) gave full ethical approval in 
February 2016 (ref: 16/EE/0054) and, in compliance with Health Research Authority 
(HRA) requirements, the trial was registered on a publicly-accessible database 
(ClinicalTrials.gov, NCT02821728). 
2.3.3 Study Population 
Men who were on the waiting list for TPB at NNUH as part of their routine clinical 
care were targeted for enrolment if they were between the ages of 18 and 80 years 
and had a body mass index (BMI) of between 19.5 and 35 kg/m2. This included 
those with either a previous negative TRUS-guided prostate biopsy or those with a 
histologically-confirmed abnormality, including diagnosis of prostate cancer, that 
required further investigation or surveillance. A list of inclusion and exclusion criteria 
is included in Table 2-2. Importantly, it remained essential to exclude participants 
whose biopsy was scheduled within the 4-week dietary intervention period to avoid 
creating a delay in any individual’s routine clinical care. 
  
   Chapter 2 
21 
 
Table 2-2 Inclusion and exclusion criteria for participation in the SAP study 
Basic Inclusion Criteria Basic Exclusion criteria 
Males Those regularly taking 5α-reductase 
inhibitors or testosterone replacement 
medicines 
Scheduled for TPB as part of routine 
investigation or staging for prostate 
cancer 
Those on warfarin treatment 
Aged 18–80 years Those with a diagnosis of diabetes 
BMI between 19.5 and 35 kg/m2 Those diagnosed with or suspected to 
be high risk for human 
immunodeficiency virus (HIV) and/or 
hepatitis 
Smokers and non-smokers Those allergic to any of the ingredients 
of the broccoli and stilton soups 
 Those taking dietary supplements or 
herbal remedies that may affect the 
study outcome 
 Those that are unable to understand 
English or provide informed consent 
 Parallel participation in another 
research project that involves dietary 
intervention 
 Any person related to or living with any 
member of the study team 
 
2.3.4 Study Recruitment and Randomization 
Recruitment was carried out by myself and Mr Mills (Urology Consultant) through 
close communication with the administrative team at NNUH. As soon as potentially 
eligible patients were added to the waiting list for TPB they were sent an information 
pack containing an invitation letter (Annex 2), participant information sheet (PIS) 
(Annex 3) and soup information sheet (Annex 10). After one week, or if they 
expressed their interest by response slip sooner, patients were contacted by 
telephone to ensure they had obtained all relevant information. Those who wished 
to take part were given a 3-day consideration period before being randomised to 
either arm of the study. Formal written consent was obtained before receiving the 
study diet during a visit to the Human Nutrition Unit (HNU) at QIB for participants in 
the intervention arm, or on the day of their hospital visit for TPB in the non-
intervention arm. The process for recruitment and study participation is described in 
Figure 2-3. 
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Randomisation was performed by a third party with use of an online randomisation 
generator (www.randomization.com). The method of ‘block randomisation’ ensured 
that participants were evenly distributed between both study arms. 
 
Figure 2-3 Flow diagram detailing the involvement of participants within the SAP study 
 
2.3.5 Study Day Procedure 
To participate in the study volunteers were required to complete 3 separate consent 
forms; trial consent (Annex 4), clinical consent for the biopsy (Annex 6) and 
consent for tissue banking at the Norwich Biorepository (Annex 5). The banking of 
biological samples at the Biorepository also ensures their availability for future 
research purposes. The sample of whole blood for genotyping was obtained via the 
intravenous cannula inserted for use by the anaesthetist, thus avoiding additional 
venepuncture. After prostatic massage, a first-pass urine sample was collected for 
both metabolomic and targeted analyses.  
TPB is performed under general or spinal anaesthesia with appropriate antibiotic 
prophylaxis. Once anaesthetised the patient is positioned supine with their legs 
elevated in stirrups. A template grid is placed on the skin of the perineum and the 
prostate is visualised by trans-rectal ultrasound scan. After measuring the volume of 
the prostate, the whole gland is systematically sampled through the template grid, 
which has holes spaced at 5mm intervals. For the SAP study eight biopsy cores of 
prostate tissue were taken from a region of the prostate not known or suspected to 
contain cancer; one placed in methanol for metabolomics analysis, two in RNAlater 
for next-generation RNA sequencing and five snap frozen for targeted analyses. 
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An additional two cores were taken from the peri-prostatic adipose tissue outside of 
the prostate gland but within the scope of the template grid. One was placed in 
methanol and the other snap frozen. 
Samples in methanol were incubated at room temperature for 24 hours as per 
MetabolonÒ’s protocol. Tissue samples that were snap frozen were immediately 
placed on dry ice and subsequently transferred for storage at -80o C. 
2.3.6 PSA Testing and Histopathology 
The most recent PSA level was recorded for each participant from the clinical 
records held at NNUH. PSA density was calculated by dividing PSA (ng/ml) by the 
prostate volume (cm3) measured by trans-rectal ultrasound at the start of TPB. 
To minimise variation in prostate tissue sampling, all biopsies were carried out 
following the same procedural technique by Mr Mills at NNUH. Biopsies taken for 
clinical evaluation were fixed in formalin and later paraffin-embedded. Sections were 
stained for haematoxylin and eosin, with additional processing steps such as 
immunohistochemical staining performed if necessary. The tissue was analysed by 
a single consultant histopathologist, Professor Richard Ball, to prevent inter-
observer error; a potential hazard in diagnosing and grading prostate cancer [91]. In 
addition to providing a Gleason score for WHO grading, the volume of cancer was 
reported as a percentage involvement of each tissue core affected. The prostate 
tissue samples that had been incubated in methanol for metabolite extraction were 
also sent to histopathology for analysis by Professor Ball. 
2.3.7 Cruciferous Vegetable Food Frequency Questionnaire 
To evaluate the habitual intake of cruciferous vegetables of all volunteers, a 
CVFFQ, developed by the University of Arizona, was completed during the study 
day. The questionnaire has been validated against other standard food frequency 
questionnaires and improves accuracy in correlation with urinary dithiocarbamate 
excretion, a marker of cruciferous vegetable consumption [92]. Data were adjusted 
according to both portion size and cooking method. Results are shown in grams per 
day and portions per day for cruciferous vegetables, and as total glucosinolate 
intake (mg/day) according to data from the US Department of Agriculture (USDA) 
Nutrient Database [93].  
2.3.8 Quantification of Urinary Isothiocyanates by Liquid Chromatography-
Tandem Mass Spectrometry 
Sulforaphane and its conjugates sulforaphane-cysteine (SF-Cys), sulforaphane-
glutathione (SF-GSH) and sulforaphane-N-acetyl cysteine (SF-NAC), as well as 
erucin-N-acetyl cysteine (ER-NAC), were measured in urine using a validated LC-
MS/MS method [94]. A 10-point, matrix-matched calibration curve was generated by 
serial 2-fold dilution of standards (SF, SF-Cys, SF-GSH, SF-NAC and ER-NAC) in 
blank (non-intervention group) urine from 8µg/ml to 0. 100µl aliquots of study 
sample urine were diluted in 900µl of 0.1% ammonium acetate buffer containing 
mixed internal standards (B-ITC). The sample was centrifuged at 14,000g for 10 
minutes at 4o C and the supernatant transferred to an HPLC vial for analysis by LC 
MS/MS. 
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Sulforaphane and its metabolites were quantified using an Agilent 6490 triple-quad 
LC MS mass spectrometer (Agilent technologies) with HPLC Phenomenex® Luna 
3u C18 (2) (100A, 100 x 2.1 mm) column with a Phenomenex® C18 (2) 100A 
column guard. The system comprised a degasser, binary pump, column oven, 
cooled autosampler, diode array detector and 6490 mass spectrometer. The LC-
MS/MS was set on a flow rate of 0.3 ml/min. The column temperature and 
autosampler were maintained at 40° C and 4° C respectively. Samples were 
injected at 5μl, ‘system suitability’ was injected at 1μl, and blank was injected at 
20µl. Separation of metabolites was carried out with 0.1% ammonium acetate in 
Milli Q water plus 0.1% acetic acid (mobile phase A, pH 4) and 0.1% acetic acid in 
acetonitrile (mobile phase B). The LC eluent flow was sprayed into the mass 
spectrometer interface without splitting. Sulforaphane and conjugates were 
monitored using mass spectrometry Multiple Reaction Monitoring (MRM) mode in 
positive polarity with electrospray ionisation (ESI) source. The source parameters 
were: gas temperature 200o C with a gas flow of 12 l/minute, a sheath gas 
temperature of 400o C with a sheath gas flow of 12 l/minute, a nebuliser pressure of 
60 psi and capillary voltage of 4000 V. 
2.3.9 GSTM1 Genotyping 
DNA was extracted from whole blood samples using the QIAamp DNA minikit 
following the manufacturer’s instructions (Qiagen Inc.). Both the DNA and 260:280 
ratio were quantified on a Nanodrop™ spectrophotometer (ThermoFisher). 
Genotype was determined with 20ng genomic DNA in a StepOnePlus real-time 
PCR system (Applied Biosystems), with GSTM1 primer (ThermoFisher) and 
Taqman™ universal master mix II (Applied Biosystems). A 10-minute activation 
period was carried out at 95oC, followed by 40 PCR cycles at 92oC for 15 seconds 
and 60oC for 90 seconds. Allelic discrimination of GSTM1 genotype was determined 
using StepOne™ v2.3 software (Applied Biosystems). 
2.3.10 Statistical analysis 
There are no data reporting the effect of a diet rich in broccoli on sulphate levels 
within prostate or at the systemic level. The sample size for the SAP study was 
calculated taking into consideration the preliminary data obtained from the interim 
analysis of the ESCAPE study. The metabolite profiling of prostate tissue from 
patients (n=15) randomised to a 12-month broccoli intervention has shown a 
significant accumulation of sulphate in prostate tissue after the intervention period 
compared to baseline. To detect a difference of 1.735 (normalised ion count) at a 
5% significance level with 90% power and assuming a within-group standard 
deviation of 1.056 (normalised ion count) required a sample size of 9 individuals in 
each group (total 18). These sample sizes were calculated for a two-group study 
design (broccoli intervention vs no intervention) assuming a two-sided comparison 
(i.e. to detect a difference rather than a higher level). 
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2.4 Results 
2.4.1 Recruitment 
Data from the coding office at NNUH confirmed that a total of 190 TPBs were 
performed in 2015. Based on experience with ESCAPE, and an expected 
recruitment rate of 20%, a timeline was set for completion within six months. The 
first information packs were sent on 19th April 2016 with a target deadline for the last 
biopsy to be completed on 31st October 2016 to allow time for the intervention. As 
can be seen in Figure 2-4, recruitment completed early and the last biopsy was 
performed on 9th September 2016. 
 
Figure 2-4 SAP study recruitment timeline. All participants had agreed to participate by August 2016. 
The last biopsy was performed on 9th September 2016, 7 weeks ahead of schedule. 
During the recruitment period, 92 information packs were sent to patients on the 
waiting list for TPB (Figure 2-5). 24 potential participants returned response letters, 
another 27 were contacted by telephone and no response by either method was 
received from the remaining 41. The conversion rate to full participation was high 
(62.5%) amongst those who returned the response slip, primarily limited by a 
scheduled biopsy date that was too soon for the intervention. Those that were first 
contacted by telephone were less likely to meet the inclusion criteria and only three 
(11%) subsequently decided to enrol on the study. One volunteer in the non-
intervention arm dropped out from further participation due to illness on the study 
day. 
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Figure 2-5 Flow chart of pathway to recruitment  
 
2.4.2 Participant Demographics 
Block randomisation distributed participants equally to both study arms, with no 
statistically significant difference (unpaired t-test) in age, BMI, PSA or PSA density 
(Table 2-3). The mean BMI for men in both arms fell into the overweight category, 
and as anticipated for men recommended to undergo TPB the PSA in both groups 
was above the age-adjusted normal range. 
Table 2-3 Distribution of participants across both study arms. Data expressed as mean ± SD. 
 Non-Intervention 
(n=9) 
Intervention 
(n=9) 
Age (years) 64.67 ± 5.385 68.56 ± 6.464 
BMI (kg/m2) 26.84 ± 3.288 (n=8) 28.05 ± 2.575 (n=8) 
PSA (ng/ml) 7.789 ± 4.165 8.667 ± 2.644 
PSA Density (ng/ml/cm3) 0.1426 ± 0.1012 0.1216 ± 0.04817 
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2.4.3 Participant Cancer Grade and Volume 
Despite clinical suspicion of prostate cancer indicating the need for TPB, histology 
reports provided by Professor Ball revealed 11 of the 18 participants had benign 
diagnoses. There were no significant differences in the overall distribution of cancer 
diagnoses between the two groups (Figure 2-6). Study biopsies were taken from the 
right anterior quadrant of the prostate or the most remote region from any focal 
areas of clinical suspicion. Three volunteers were diagnosed with cancer in the 
quadrant sampled (2 in the intervention group and one in the non-intervention 
group). However, the volume of tissue affected was small (<15%) so further 
histological analysis of samples used for metabolite extraction is awaited from 
Professor Ball before any additional normalisation is performed. 
 
Figure 2-6 Graphs of histological findings in both study arms. A) Percentage of all tissue received for 
histological analysis affected by cancer (mean + SEM, p=0.618 by unpaired Student’s t-test). B) Grade 
of cancer by WHO grade group.  
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2.4.4 Cruciferous Vegetable Intake 
Only one volunteer failed to fully complete and return the Arizona CVFFQ. The data 
revealed a wide range in consumption between individuals. However, there was no 
statistically significant difference between groups for either cruciferous vegetable or 
glucosinolate consumption (Table 2-4, Figure 2-7). 
Table 2-4 Data from the CVFFQ on daily intake of cruciferous vegetables across both study arms. 
Presented as mean ± SD. Additional column with supplemental content of study diet (right). 
 Non-Intervention 
(n=8) 
Intervention 
(n=9) 
Additional 
Content in 
Study Diet 
Cruciferous vegetable 
intake (g/day) 
72.12 ± 54.47 66.63 ± 52.96 36 
Cruciferous vegetable 
intake (servings/day) 
1.094 ± 0.9241 1.098 ± 0. 0.9067 0.45 
Glucosinolate intake 
(mg/day) 
83.52 ± 101.3 54.90 ± 52.07 38.82 
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Figure 2-7 Cruciferous vegetable consumption data calculated from the Arizona CVFFQs comparing 
intake of cruciferous vegetables as g/day (A), servings/day (B) and glucosinolates (C). Data shown as 
mean + individual values to demonstrate the range in consumption. No significant difference detected 
between study groups (p values from unpaired Student’s t tests). 
 
2.4.5 Urinary Isothiocyanates 
Sulforaphane was detectable in the urine samples of all participants in the SAP 
study. The conjugates SF-Cys and SF-NAC, as well as ER-NAC, were detectable in 
all participants in the intervention group and most of those in the non-intervention 
group. Similar to the findings of the CVFFQ, there was a wide range between 
individuals but no significant differences overall between groups (Figure 2-8). There 
was also a significant positive correlation between urinary ITCs and habitual intake 
of cruciferous vegetables and glucosinolates (data not shown). 
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Figure 2-8 Graphs of urinary isothiocyanate concentrations between SAP study arms. Data for 
sulphoraphane (A) and its conjugates sulforaphane-cysteine (B) and sulforaphane-N-acetyl cysteine 
(C), and erucin-N-acetyl cysteine (D) shown as mean and individual concentrations. No statistically 
significant (p < 0.05) differences detected. 
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2.4.6 GSTM1 Genotype 
Genomic DNA was extracted from all participants’ blood samples with a mean 
260:280 ratio of 1.54 (range 1.39 to 1.78). GSTM1 genotyping was successfully 
performed for all participants, revealing an overall incidence of 50% GSTM1 null, 
which is in line with European population studies [60]. There was no significant 
difference between study arms (Figure 2-9). 
 
Figure 2-9 Graph of individuals within both study arms with either GSTM1 null or GSTM1 positive 
phenotypes. 
 
2.5 Discussion 
Recruitment to the SAP study exceeded expectations by completing ahead of 
schedule. Failure to recruit sufficient numbers to clinical trials represents a major 
problem in health research, commonly resulting in delays, inconclusive results and 
financial loss [95]. Only 55% of trials successfully recruit their target number, with 
further challenges for those working with seriously ill or cancer patients [96]. 
Although a typical window-of-opportunity study is carried out in the interval between 
cancer diagnosis and radical treatment, the pre-biopsy design offered an effective 
and successful model for a short-term dietary intervention [97]. Participation was 
readily taken up by men who were both eligible and whose biopsy date was 
scheduled beyond the minimum period for intervention. A single participant dropped 
out for reasons unrelated to the study and there were no reported complications 
from taking part.  
Comparing age, BMI, PSA and PSA density did not reveal any significant 
differences between study arms (Table 2-3). Both groups were also homogenous in 
terms of cruciferous vegetable intake, GSTM1 genotype and histology. The fact that 
over 60% of study participants received a benign diagnosis is consistent with known 
cancer detection rates in men who proceed to TPB after an initial negative TRUS 
biopsy [98]. The increasing number of patients considered for TPB at NNUH during 
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the SAP study period reflects the rising demand for the procedure. As 
multiparametric MRI increases in sensitivity for detecting small target lesions, and 
centralisation of services means more men are being referred to tertiary cancer 
centres, this trend is likely to continue [99, 100].  
The range of cruciferous vegetable intake was broad in both groups, replicating 
results of variation in habitual diet from previous dietary studies in the Norfolk 
population [51]. The correlation between the CVFFQ and presence of ITCs in urine 
is probably representative of consumption the night before the study. Bioavailability 
studies have shown that ITCs reach peak concentrations in urine within 6-8 hours of 
consumption and are almost completely cleared within 48 hours [101]. No significant 
difference between groups was expected as those receiving the study diet 
consumed their last portion of soup a minimum of 48 hours before the study 
samples were collected. Thus, any metabolic changes resulting from the study diet 
could be considered cumulative effects of the high-dose 4-week intervention.  
 
2.6 Conclusion 
The SAP study successfully employed a window-of-opportunity design, with full 
ethical approval, to recruit the target 18 participants on the waiting list for TPB. The 
men randomised to either the non-intervention group or the broccoli-enriched 
dietary intervention were homogenous in their baseline demographics, histology, 
cruciferous vegetable consumption and GSTM1 genotype. Prostate tissue, adipose 
and urine were obtained for global and targeted analysis and no adverse events 
were reported as a result of participation in the study.
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3 Global Metabolomic Profiles of Men 
Enrolled on a Broccoli Intervention 
(SAP) Study  
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Summary 
Global metabolomics have broadened our understanding of common changes that 
occur in prostate carcinogenesis and of the unique characteristics of the normal 
prostate that might predispose it to malignant transformation. Manipulating the 
prostate microenvironment by dietary intervention is complicated by the milieu of 
micronutrients in food and their influence on multiple metabolic pathways. In this 
chapter the use of global metabolite profiling is applied to prostate, adipose and 
urine samples of men recruited to the SAP study (Chapter 2). Combining univariate 
and multivariate pathway-enrichment analyses allows us to identify common 
metabolites and metabolic pathways that characterise differences in both habitual 
diet and a broccoli-enriched dietary intervention.  
 
3.1 Introduction 
The prostate gland is known to have a unique metabolite profile [102]. The evolution 
of technology with the power to investigate systems biology across multiple cellular 
pathways have created growing interest in the scientific ‘omics’ networks that relate 
to the development of disease. The prostate gland is no exception, with cancer 
research embracing the tools to study genomics, transcriptomics, proteomics and 
metabolomics [103]. Metabolomics is the study of small molecules and end products 
spanning a wide range of biological reactions. The output is a cumulative effect of 
upstream gene and protein expression changes, and may characterise the most 
relevant phenotypic changes related to disease or intervention. The use of global 
metabolomics in prostate tissue has already identified specific metabolites, such as 
sarcosine, which are associated with prostate cancer progression [104]. More 
recently, serum metabolites have been identified that correlate with aggressiveness 
of prostate cancer at diagnosis up to 20 years later [105]. Thus, targets continue to 
emerge with the potential for cancer prevention and treatment by lifestyle 
(diet/exercise) or other therapeutic interventions. 
US company Metabolon® has built up a library of over 4500 chemicals against 
reference standards of known metabolite structure. Combined with the Discovery 
HD4™ Platform, which employs ultra-high performance LC-MS and tandem mass 
spectroscopy (MS/MS), this offers some of the widest commercially-available 
coverage of global metabolite profiling [106].  
Data utilising the Metabolon® platform from ongoing clinical trials at QIB suggest 
that a broccoli-enriched diet leads to accumulation of sulphate and ADP in the 
prostate, as well as upregulating capacity for antioxidant defence (ESCAPE study) 
(unpublished data). These findings appeared unrelated to the glucosinolate content 
of the broccoli, bringing into question the role of other biologically-active broccoli 
metabolites; no difference was seen between the three study diets, which included 
standard broccoli and two varieties of glucoraphanin-enriched broccoli (Beneforté® 
and Beneforte Extra). The SAP study design was described in detail in Chapter 2. 
Men on the waiting list for TPB were randomised to either continue their normal diet 
or receive a short-term, high-dose broccoli intervention before providing samples of 
prostate tissue, pelvic adipose tissue and urine. All three tissue types were 
subsequently analysed by Metabolon®. 
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3.2 Aims 
In addition to taking a global analytical approach to detecting diet-induced 
metabolomic change, the overall aims are consistent with those of the SAP study: 
- To determine whether a diet rich in broccoli will result in a difference in 
sulphate levels in tissue samples obtained from men scheduled for prostate biopsy. 
 - To determine whether a diet rich in broccoli will result in metabolic 
differences such as increased ADP in prostate tissue of men scheduled for prostate 
biopsy. 
-	To determine whether differences in sulphate and ADP levels induced by 
diet are specific to prostate tissue. 
 
3.3 Material and Methods 
3.3.1 Sample Collection and Processing 
As described in Chapter 2, ethical approval for the use of prostate, adipose and 
urine from SAP study volunteers was granted by the East of England - Cambridge 
East REC (ref: 16/EE/0054) in January 2016. Written informed consent was 
obtained for study participation, clinical consent for the biopsies and tissue banking 
consent at the Norwich Biorepository. Following DRE, a first-pass urine sample was 
collected, divided into 1ml aliquots and snap frozen on dry ice. Biopsy cores of both 
prostate and adipose were taken through the template grid during TPB. Metabolites 
were extracted according to the Metabolon® protocol for concurrent histopathologic 
and metabolomic analysis of tissue biopsies (PREF™: Preservation by Extraction 
and Fixation) based on the study carried out by Brown and colleagues (Figure 3-1) 
[107]. One tissue core of prostate and one of adipose from each participant was 
incubated in 80% methanol (HPLC grade)/20% water at room temperature for 24 
hours. The tissue core was then removed and placed in formalin to be sent for 
histological analysis at the NNUH Histo and Cellular Pathology department (Cotman 
centre, Norwich). The residual extraction solvent was dried down using a centrifugal 
vacuum concentrator (SpeedVac®, Thermo Fisher Scientific) and stored at -80o C 
before shipping to the US on dry ice. Details of the subsequent sample preparation, 
processing and quality control are derived from the Metabolon® analysis report 
below. 
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Figure 3-1 Flow diagram for metabolite extraction from needle-biopsy tissue cores. Structural integrity 
of tissue retained for histological assessment as previously demonstrated by Brown [107]. 
 
3.3.2 Sample Preparation 
Once received by Metabolon®, samples were prepared using the automated 
MicroLab STAR® system from Hamilton Company. Several recovery standards were 
added prior to the first step in the extraction process for quality control (QC) 
purposes. Proteins were precipitated with methanol under vigorous shaking for 2 
min (Glen Mills GenoGrinder 2000) followed by centrifugation. The resulting extract 
was divided into five fractions: two for analysis by two separate reverse phase (RP)/ 
ultra-performance liquid chromatography (UPLC)-MS/MS methods with positive ion 
mode electrospray ionization (ESI), one for analysis by RP/UPLC-MS/MS with 
negative ion mode ESI, one for analysis by hydrophilic interaction liquid 
chromatography (HILIC) /UPLC-MS/MS with negative ion mode ESI, and one 
sample was reserved for backup. Samples were placed briefly on a TurboVap® 
(Zymark) to remove the organic solvent. The sample extracts were stored overnight 
under nitrogen before preparation for analysis.   
3.3.3 Quality Assurance and Control 
A pooled matrix was generated by mixing small volumes of each experimental 
sample for analysis as technical replicates throughout. A selection of QC standards 
was added to every sample being analysed, avoiding interference with endogenous 
compounds and allowing both instrument performance monitoring and 
chromatographic alignment. Experimental samples were randomized across the 
platform run with QC samples spaced evenly among the injections. 
3.3.4 Ultra-high Performance Liquid Chromatography-Tandem Mass 
Spectroscopy  
All methods utilised a Waters ACQUITY UPLC and a Thermo Scientific Q-Exactive 
high resolution/accurate mass spectrometer interfaced with a heated electrospray 
ionization (HESI-II) source and Orbitrap mass analyser operated at 35,000 mass 
resolution. The sample extract was dried then reconstituted in solvents compatible 
to each of the four methods. One aliquot was analysed using acidic positive ion 
conditions, chromatographically optimised for more hydrophilic compounds. Another 
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aliquot was also analysed using acidic positive ion conditions, however it was 
chromatographically optimised for more hydrophobic compounds. Another aliquot 
was analysed using basic negative ion optimised conditions using a separate 
dedicated C18 column. The fourth aliquot was analysed via negative ionisation 
following elution from a HILIC column (Waters UPLC BEH Amide 2.1x150 mm, 1.7 
µm). The MS analysis alternated between MS and data-dependent MSn scans using 
dynamic exclusion. The scan range varied slightly between methods but covered 
70-1000 m/z.  
3.3.5 Bioinformatics 
The informatics system consisted of four major components, the Laboratory 
Information Management System (LIMS), the data extraction and peak-identification 
software, data processing tools for QC and compound identification, and a collection 
of information interpretation and visualisation tools for use by data analysts. The 
hardware and software foundations for these informatics components were the LAN 
backbone, and a database server running Oracle 10.2.0.1 Enterprise Edition. 
3.3.6 Data Extraction and Compound Identification 
Raw data was extracted, peak-identified and QC processed using Metabolon®’s 
hardware and software. Compounds were identified by comparison to library entries 
of purified standards or recurrent unknown entities. Metabolon® maintains a library 
based on authenticated standards that contains the retention time/index (RI), mass 
to charge ratio (m/z), and chromatographic data (including MS/MS spectral data) on 
all molecules present in the library. Furthermore, biochemical identifications are 
based on three criteria: retention index within a narrow RI window of the proposed 
identification; accurate mass match to the library +/- 10 ppm; and the MS/MS 
forward and reverse scores between the experimental data and authentic 
standards. The MS/MS scores are based on a comparison of the ions present in the 
experimental spectrum to the ions present in the library spectrum. While there may 
be similarities between these molecules based on one of these factors, the use of 
all three data points can be utilised to distinguish and differentiate biochemicals. 
More than 3300 commercially available purified standard compounds have been 
acquired and registered into LIMS for analysis on all platforms for determination of 
their analytical characteristics.  
 
3.4 Results 
3.4.1 Global Metabolomics Analysis Achieved Quality Control Criteria 
The total number of metabolites detectable in each sample type are detailed in 
Table 3-1. Instrument and process variability checks fell within the acceptance 
criteria for Metabolon® (Table 3-2). Instrument variability was determined by 
calculating mean relative standard deviation (RSD) against internal standards 
added to each sample before injection into the mass spectrometers. Process 
variability was determined by calculating mean RSD of all detectable endogenous 
compounds in pooled samples for multiple technical replicates. 
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Table 3-1 Number of compounds detected in each sample type by Metabolon® 
Matrix	 Named	Biochemicals	
Prostate	 482	
Adipose	 372	
Urine	 719	
 
Table 3-2 Instrument and process variability data for sample analysis by Metabolon® 
 
 
 
3.4.2 Univariate Analysis Identified Common Metabolites in Prostate, 
Adipose and Urine 
Unpaired Student’s t-tests were performed on the full data set for each tissue type 
(prostate, adipose and urine) to identify differences between study arms. The top 20 
metabolites for each tissue were ranked by p-value (Table 3-3). Corresponding 
differences were seen throughout in tryptophan betaine, a metabolite marker of 
peanut consumption, and both trigonelline and quinate, which are linked to coffee 
consumption. All three of these metabolites were significantly higher in the non-
intervention group (p<0.05) (Figure 3-2).  
 
QC	Sample	 Measurement	 Median	RSD	
	 	 Prostate	 Adipose	 Urine	
Internal	
Standards	
Instrument	
Variability	
3	%	 2	%	 5	%	
Endogenous	
Biochemicals	
Total	Process	
Variability	
7	%	 7	%	 7	%	
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Table 3-3 Top 20 metabolites ranked by p-value between dietary arms from global metabolomic 
analysis of prostate, adipose and urine. Significant results from unpaired t-tests are listed above a 
threshold of p<0.05, and common differences shown for coffee (*) and peanut (**) metabolites. 
Prostate Adipose Urine 
Metabolite p 
value 
Metabolite p 
value 
Metabolite p 
value 
1-(1-enyl-palmitoyl)-2-
linoleoyl-GPC  
0.006 Tryptophan 
betaine** 
0.009 S-methylcysteine 
sulfoxide 
0.004 
Adenosine 5'-
diphosphate (ADP) 
0.019 Quinate* 0.017 1,3,7-trimethylurate 0.007 
Trigonelline*            
(N'-methylnicotinate) 
0.025 Choline phosphate 0.018 1,7-dimethylurate 0.015 
Xanthine 0.026 Theophylline 0.021 Acesulfame 0.017 
Palmitoyl 
ethanolamide 
0.028 Significance threshold  
(p<0.05) 
Ectoine 0.022 
2-hydroxy-
acetaminophen 
sulfate 
0.029 Trigonelline*        
(N'-
methylnicotinate) 
0.071 Vanillate 0.023 
Tryptophan betaine** 0.029 Sphingadienine 0.077 Quinate* 0.023 
Uridine 5'-
diphosphate (UDP) 
0.034 Androstenediol 
(3beta,17beta) 
disulfate (1) 
0.079 2-ketogluconate 0.031 
Quinate* 0.036 4-guanidino-
butanoate 
0.081 2-ketogulonate 0.031 
1-(1-enyl-palmitoyl)-2-
oleoyl-GPC  
0.038 3-hydroxyhippurate 0.082 Malonylcarnitine 0.032 
1-stearoyl-2-linoleoyl-
GPE  
0.040 Pyroglutamine* 0.088 N-acetyl-S-allyl-L-
cysteine 
0.034 
Palmitoyl 
dihydrosphingomyelin  
0.040 2-
hydroxydecanoate 
0.090 N-acetyl-aspartyl-
glutamate (NAAG) 
0.036 
1-stearoyl-2-
arachidonoyl-GPE  
0.043 Hippurate 0.118 Tryptophan betaine** 0.037 
Glycocheno-
deoxycholate 
0.045 Argininosuccinate 0.137 5-acetylamino-6-
amino-3-methyluracil 
0.038 
p-cresol sulfate 0.046 2,3-dihydroxy-
isovalerate 
0.138 3-methylglutaryl-
carnitine (2) 
0.039 
Inosine 0.050 Anserine 0.138 5-hydroxyhexanoate 0.041 
Significance threshold       
(p<0.05) 
7-methylguanine 0.141 Tartarate 0.042 
Sphingomyelin  0.051 4-acetamidophenol 0.142 Allantoin 0.043 
3-hydroxyhippurate 0.051 Pimelate 
(heptanedioate) 
0.145 Fucose 0.043 
4-methylcatechol 
sulfate 
0.055 5-oxoproline 0.152 Trigonelline*              
(N'-methylnicotinate) 
0.047 
Nicotinamide adenine 
dinucleotide reduced 
(NADH) 
0.056 4-methylcatechol 
sulfate 
0.155 Significance threshold        
(p<0.05) 
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Figure 3-2 Graphs of individual metabolite differences between study arms for (A, B) dietary coffee 
metabolites (trigonelline and quinate respectively) and (C) peanut (tryptophan betaine) intake. Data are 
expressed as ScaledImpData (rescaled values to set the median equal to 1) ± SD; unpaired Student’s 
t-tests, *=p<0.05, ** = p<0.01. 
 
3.4.3 Univariate Analysis Showed Significant Differences in Levels of 
SMCSO in Urine and ADP in Prostate 
Although the Metabolon® platform was unable to detect SMCSO in either prostate or 
adipose tissue extracts, the increased concentration of SMCSO in urine in the 
dietary-intervention group represented the highest ranking metabolic difference by 
p-value (Figure 3-3). There was no difference in levels of inorganic sulphate in 
either prostate or adipose tissue because of the study diet. ADP, however, was 
significantly higher in prostate tissue in the intervention group, consistent with 
previous findings in the ESCAPE subgroup analysis (Figure 3-4). 
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Figure 3-3 SMCSO in urine of SAP study arms. Concentrations significantly higher in the intervention 
group by unpaired Student’s t-test, representing the most significant metabolite change in urine 
(p<0.01). Data are expressed as OsmoNormImpData (values normalised by sample osmolality) ± SD. 
 
 
Figure 3-4 Individual metabolite data for sulphate (A) and ADP (B) in prostate tissue. No significant 
difference was seen by unpaired Student’s t-test in sulphate levels between intervention arms 
(p=0.26). ADP, however, was significantly higher (p<0.05) in the intervention group. Data are 
expressed as ScaledImpData ± SD. 
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3.4.4 Multiple Correction Testing 
Multiple correction testing was performed using the Benjamini and Hochberg 
method [108]. Once corrected, none of the p-values for individual metabolites within 
separate tissue compartments remained significant. Ranking metabolites, however, 
provided useful insight into potential influences of the dietary intervention despite 
the relatively small study population. Comparing parallel findings in different tissue 
types and performing integrated pathway analyses were therefore justified to further 
investigate biological activity and dietary influence on prostate metabolism. 
3.4.5 Integrated Pathway Analysis 
All metabolomics data were uploaded by HMDB code to the Metaboanalyst 3.0 web 
tool [109]. Integrated pathway enrichment and topology analyses were performed 
on all metabolites recognised by the software; 382 in prostate, 299 in adipose and 
494 in urine. No filters were applied, the data were log transformed for normalisation 
and underwent global testing with relative-betweeness centrality. 
3.4.5.1 Prostate Tissue Pathway Analysis Showed Significant Differences in 
Steroid Hormone and Caffeine Metabolism 
Prostate tissue pathway analysis revealed statistically significant differences in both 
steroid hormone biosynthesis and caffeine metabolism pathways (Table 3-4, 
Figure 3-5). The difference in caffeine metabolism corresponds to previously 
suggested differences in individual coffee metabolites identified by univariate 
analysis between groups (Figure 3-2). The difference in steroid hormone 
biosynthesis is due to consistent trends toward lower levels of both androst-5-ene 
diol and dehydroepiandrosterone sulphate (DHEA-S) in the intervention group, 
which were not significant individually. Purine metabolism, to which ADP is central, 
was the third highest-ranked pathway but did not reach statistical significance 
overall (p=0.235). 
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Table 3-4 Table of metabolic pathway differences in prostate tissue. Pathways are ranked by FDR-
adjusted p-value with a significance threshold of p<0.05. The 20 highest-ranked pathways are shown. 
Metabolic Pathway 
 
Match 
Status 
p FDR Impact 
Steroid hormone biosynthesis 3/99 0.025 0.958 0.015 
Caffeine metabolism 5/21 0.037 0.958 0.344 
Significance threshold (p<0.05) 
Purine metabolism 20/92 0.235 0.958 0.340 
Primary bile acid biosynthesis 4/47 0.243 0.958 0.081 
Linoleic acid metabolism 3/15 0.244 0.958 0.656 
Pyrimidine metabolism 18/60 0.257 0.958 0.403 
Vitamin B6 metabolism 2/32 0.258 0.958 0.019 
Arachidonic acid metabolism 2/62 0.272 0.958 0.216 
Riboflavin metabolism 1/21 0.278 0.958 0.000 
alpha-Linolenic acid metabolism 1/29 0.290 0.958 0.000 
Phenylalanine metabolism 8/45 0.305 0.958 0.150 
Glycosylphosphatidylinositol(GPI)-anchor 
biosynthesis 
1/14 0.320 0.958 0.043 
Starch and sucrose metabolism 4/50 0.352 0.958 0.257 
Sphingolipid metabolism 7/25 0.355 0.958 0.547 
Sulfur metabolism 4/18 0.360 0.958 0.040 
beta-Alanine metabolism 11/28 0.380 0.958 0.156 
Histidine metabolism 12/44 0.400 0.958 0.274 
Nicotinate and nicotinamide metabolism 12/44 0.412 0.958 0.096 
Pantothenate and CoA biosynthesis 8/27 0.425 0.958 0.292 
Glycerophospholipid metabolism 15/39 0.448 0.958 0.581 
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Figure 3-5 The “metabolome view” from prostate tissue pathway analysis using the Metaboanalyst 
software. Y-axis values are presented as -log(p) for graphical separation and X-axis values for 
pathway impact according to topology analysis. The match status and centrality within pathways confer 
higher pathway impact. Steroid hormone biosynthesis and caffeine metabolism are both significantly 
different (p<0.05) between study arms. 
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3.4.5.2 Adipose Tissue Pathway Analysis Exhibited Similar Characteristics to 
Prostate  
Similar to prostate tissue, pathway analysis for adipose identified steroid hormone 
biosynthesis and caffeine metabolism to be the highest-ranked pathways by p-
value, although no pathway reached statistical significance in adipose by FDR-
corrected p-value (Table 3-5, Figure 3-6). 
Table 3-5 Table of metabolic pathway differences in adipose tissue. The 20 highest-ranked pathways 
by FDR-adjusted p-value are shown. 
Pathway Name Match Status p FDR Impact 
Steroid hormone biosynthesis 3/99 0.129 0.921 0.015 
Caffeine metabolism 3/21 0.133 0.921 0.160 
Nicotinate and nicotinamide metabolism 11/44 0.178 0.921 0.072 
beta-Alanine metabolism 10/28 0.229 0.921 0.145 
Sulphur metabolism 3/18 0.295 0.921 0.040 
Arginine and proline metabolism 21/77 0.303 0.921 0.568 
Valine, leucine and isoleucine biosynthesis 6/27 0.313 0.921 0.146 
Selenoamino acid metabolism 1/22 0.329 0.921 0.000 
Cyanoamino acid metabolism 4/16 0.334 0.921 0.000 
Ether lipid metabolism 2/23 0.338 0.921 0.000 
Ubiquinone and other terpenoid-quinone biosynthesis 2/36 0.351 0.921 0.036 
Glutathione metabolism 9/38 0.355 0.921 0.338 
Valine, leucine and isoleucine degradation 4/40 0.367 0.921 0.022 
Synthesis and degradation of ketone bodies 1/6 0.393 0.921 0.000 
Aminoacyl-tRNA biosynthesis 19/75 0.411 0.921 0.225 
Alanine, aspartate and glutamate metabolism 11/24 0.437 0.921 0.754 
Nitrogen metabolism 11/39 0.452 0.921 0.008 
Tyrosine metabolism 5/76 0.478 0.921 0.047 
D-Arginine and D-ornithine metabolism 2/8 0.485 0.921 0.500 
Histidine metabolism 12/44 0.489 0.921 0.274 
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Figure 3-6 The “metabolome view” from adipose pathway analysis using the Metaboanalyst software. 
Y-axis values are presented as -log(p) for graphical separation and X-axis values represent pathway 
impact according to topology analysis. The match status and centrality within pathways confer higher 
pathway impact. Steroid hormone biosynthesis and caffeine metabolism are the highest-ranking 
pathways affected but do not reach statistical significance (p<0.05). 
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3.4.5.3 Urine Pathway Analysis Reveals a Discrete Profile to Solid Tissues 
In urine, the only pathway that reached statistical significance was glyoxylate and 
dicarboxylate metabolism (Table 3-6). Tartarate, glycerate and succinate appeared 
lower in the intervention group, although tartarate was the only metabolite to reach 
statistical significance (p=0.04).  
Despite falling below the threshold for significance, differences in caffeine 
metabolism seen in the prostate may also be present in urine as this was the fifth 
highest-ranked pathway. In addition to ascorbate and fatty acid metabolism, 
glutathione metabolism also featured just outside the significance threshold due to a 
non-significant reduction in cysteinylglycine and an increase in ascorbic acid  
(Figure 3-7).  
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Table 3-6 Metabolic pathway differences in urine. Pathways are ranked by FDR-adjusted p-value with 
a significance threshold of p<0.05. The 20 highest-ranked pathways are shown. 
Pathway Name Match Status p FDR Impact 
Glyoxylate and dicarboxylate metabolism 11/50 0.038 0.825 0.229 
Significance threshold 
(p<0.05) 
Ascorbate and aldarate metabolism 9/45 0.068 0.825 0.247 
Fatty acid metabolism 1/50 0.082 0.825 0.000 
Glutathione metabolism 10/38 0.086 0.825 0.108 
Caffeine metabolism 11/21 0.105 0.825 0.637 
Folate biosynthesis 2/42 0.108 0.825 0.131 
Phenylalanine metabolism 17/45 0.112 0.825 0.244 
Propanoate metabolism 5/35 0.114 0.825 0.003 
D-Arginine and D-ornithine metabolism 3/8 0.141 0.825 0.500 
Butanoate metabolism 7/40 0.144 0.825 0.145 
Nicotinate and nicotinamide metabolism 11/44 0.158 0.825 0.087 
beta-Alanine metabolism 11/28 0.172 0.825 0.239 
Amino sugar and nucleotide sugar metabolism 6/88 0.192 0.825 0.011 
Glycolysis or Gluconeogenesis 3/31 0.208 0.825 0.095 
Pentose phosphate pathway 4/32 0.213 0.825 0.108 
Histidine metabolism 16/44 0.247 0.825 0.345 
Ether lipid metabolism 2/23 0.252 0.825 0.000 
Valine, leucine and isoleucine biosynthesis 9/27 0.261 0.825 0.323 
Synthesis and degradation of ketone bodies 1/6 0.267 0.825 0.000 
Fructose and mannose metabolism 2/48 0.288 0.825 0.040 
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Figure 3-7 The “metabolome view” from urine pathway analysis using the Metaboanalyst software. Y-
axis values are presented as -log(p) for graphical separation and X-axis values represent pathway 
impact according to topology analysis. The match status and centrality within pathways confer higher 
pathway impact. Glyoxylate and dicarboxylate metabolism is the only pathway to be significantly 
affected by intervention (p=0.038).   
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3.4.6 Steroid Hormone Analysis Demonstrates Common Trends Across 
Sample Types 
The prominence of steroid hormone biosynthesis in the pathway analyses for both 
prostate and adipose tissue was further evaluated by comparison of the detectable 
hormone levels in all 3 tissue types (Figure 3-8). None reached statistical 
significance individually but a trend towards reduction in the intervention group 
explains the overall pathway impact. In prostate tissue, the levels of trigonelline 
(coffee metabolite) and androsterone sulphate are positively correlated, indicating a 
potential link between the highest ranked pathways (Figure 3-9). 
 
Figure 3-8 Graphs of steroid hormone levels detected by Metabolon® in all 3 tissue types. No 
statistically significant differences detected by unpaired student’s t-test, but the trend towards lower 
levels in the intervention group accounts for impact on previous pathway analyses. Data are expressed 
as ScaledImpData ±SD 
 
 
Figure 3-9 Correlation between trigonelline (coffee metabolite) and androsterone sulphate in prostate 
tissue. Weak but statistically significant (p<0.05) positive correlation detected by Pearson correlation 
analysis. Data are expressed as ScaledImpData. 
Trigonelline
ScaledImpData
An
dr
os
te
ro
ne
 S
ul
ph
at
e
Sc
al
ed
Im
pD
at
a
0 2 4 6
0
2
4
6
8 r = 0.5194
p =  0.027
   Chapter 3 
51 
 
3.5 Discussion 
3.5.1 Sulphate Levels in Prostate Tissue 
No significant difference was seen in the sulphate levels of prostate tissue for men 
in either study arm (Figure 3-4). The range of levels in both study arms was much 
higher than those observed in the ESCAPE subgroup analysis (unpublished data). 
The SAP study was also powered for a difference between groups instead of a 
change from pre- to post-intervention, increasing potential sensitivity to distortion by 
individuals with much higher baseline sulphate levels. On review of individual health 
questionnaires, no participant was found to regularly take medications or 
supplements formulated to contain high levels of sulphate. The concentration of 
sulphate in tap water is known to vary nationally but will have been limited by 
recruiting participants from a single hospital site [110]. Other sources of dietary 
sulphate, in addition to the influence of colonic microbiota (sulphate-reducing 
bacteria) on sulphur metabolism were not controlled during the study [111]. 
Independent quantification of sulphate levels in the SAP study tissue will be 
discussed in Chapter 4, utilising an optimised protocol for targeted analysis. 
3.5.2 ADP in Prostate Tissue 
Ranking by p-value found higher levels of ADP in the prostate of men recruited to 
the intervention arm to be the second most significant metabolite difference 
(Table 3-3). Verification of one of the key ESCAPE study interim findings is 
therefore provided in an independent study delivering a broccoli-enriched dietary 
intervention. The link to change in cancer volume in ESCAPE, whether this is via 
sulphate-driven PAPS synthesis or otherwise, continues to represent a promising 
mechanism for cancer prevention by ATP depletion. As the Metabolon® platform 
was unable to detect ATP directly, targeted analytical methods are required to 
measure ATP, ADP and AMP in prostate tissue. Similarly, SMCSO could not be 
detected in the prostate or adipose tissue by global metabolomics. The difference in 
urine concentration of SMCSO between groups suggests the diet intervention is 
increasing its biological availability, but presence in tissue and links to cancer 
prevention are yet to be confirmed. Both purine and SMCSO quantification will also 
be described in full in Chapter 4. 
3.5.3 Metabolic Pathway Differences Between Study Groups 
Common to prostate, adipose and urine were higher levels of tryptophan betaine, 
trigonelline and quinate in the non-intervention groups (Figure 3-2, Table 3-3). In 
epidemiological studies, these metabolites all have specific dietary associations 
[112, 113]. Global metabolite profiling of participants in the Prostate, Lung, 
Colorectal and Ovarian (PLCO) Cancer Screening Trial and comparison with diet 
information from the National Cancer Institute’s food frequency questionnaire linked 
tryptophan betaine to peanuts and both trigonelline and quinate to coffee 
consumption [113]. Habitual intake of these dietary components was beyond the 
scope of the CVFFQ used in the SAP study. However, it appears likely that 
participants in the non-intervention arm of the study were higher consumers of both 
coffee and peanuts in their habitual diet. 
The two metabolic pathways in the prostate that were both significantly different 
between study arms were steroid hormone biosynthesis and caffeine metabolism. 
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Despite the small number of participants in the SAP study, a significant positive 
correlation between trigonelline and androsterone sulphate in prostate tissue could 
support a link between the two pathways in vivo (Figure 3-9). Increased coffee intake 
is associated with higher free and bound testosterone and sex hormone binding 
globulin (SHBG) levels, possibly due to stress axis stimulation by caffeine causing 
an increase in cortisol [114, 115]. 
Overall incidence of prostate cancer is considered unlikely to be affected by coffee 
consumption [116, 117]. The reduced risk of lethal prostate cancer reported in men 
who drank more than 6 cups of coffee per day in the Health Professionals Follow-
Up Study was unrelated to caffeine content, suggesting a role for other bioactive 
constituents [118]. In contrast, a recent metabolomics study evaluated serum 
xanthine levels as a surrogate for coffee/caffeine consumption and found 
significantly higher levels in men who later developed T4-staged prostate cancer 
[105]. 
As cortisol levels were no different between arms of the SAP study it remains 
unclear whether coffee intake influenced hormone levels by this or another, 
caffeine-independent mechanism. The sample size is relatively small and these 
findings may be due to chance. The higher levels of tryptophan betaine from 
peanuts in the non-intervention group are also further suggestive of differences in 
habitual diet between groups. However, alternative hypotheses remain possible, 
including induction of detoxification pathways in response to the broccoli-enriched 
diet. Specific phase I cytochrome p450 enzymes are known to increase in broccoli 
consumption, with implications for metabolism of both caffeine and androgenic 
hormones [119, 120]. Combining RNA sequencing data from the SAP study with the 
full diet diary and tissue analysis of ESCAPE participants will hopefully provide 
further clarity on the influence of study versus habitual diet on these two pathways. 
 
3.6 Conclusion 
Global metabolomic analysis of prostate, adipose and urine from SAP study 
participants was technically successful and has highlighted several metabolite 
changes relevant to the study objectives. Although there was no significant 
difference in inorganic sulphate, participants in the intervention arm had higher 
levels of both SMCSO in urine and ADP in prostate tissue. To establish whether 
broccoli-derived metabolites are biologically available in tissue and driving ATP 
depletion, further targeted analysis is required (Chapter 4). Investigating whether 
sulforaphane or SMCSO could reduce ATP by inhibiting its production will also be 
considered with in vitro studies of their effects on prostate energy metabolism 
(Chapter 5). Glutathione metabolism pathways were not significantly different in any 
tissue analysed but ongoing work on PTEN redox status will also be described 
(Chapter 6). 
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4 Targeted Quantification of Sulphate, 
SMCSO and ATP Levels After 
Consuming a Broccoli-Enriched Diet 
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Summary 
The beneficial effects of cruciferous vegetables on health are likely to extend 
beyond their content of glucosinolates to other specialised sulphur-containing 
metabolites, such as SMCSO. Some of the key findings from global metabolomic 
analysis of prostate, adipose and urine samples from participants of the SAP study 
were significant increases in SMCSO in urine and ADP in prostate following a 
broccoli-enriched diet. To test the hypothesis that these findings were linked by 
sulphate (derived from SMCSO) driving synthesis of PAPS and depleting ATP, 
increased analytical sensitivity was required to quantify the relevant metabolites in a 
range of biological matrices. This chapter describes the analyses of key 
metabolites, including ATP and SMCSO, in tissue and urine samples of men 
recruited into the SAP study. Extensive profiling of the metabolic changes induced 
by diet within the prostate gland, and at the systemic level, may prove influential in 
the future management and prevention of prostate cancer. 
 
4.1 Introduction 
Epidemiological studies support an inverse association between cruciferous 
vegetable consumption and both cancer and cardiovascular disease risk [40, 121]. 
The unique sulphur metabolism of cruciferous vegetables confers potential health 
benefits that include accumulation of glucosinolates, the hydrolysis breakdown 
products of which have proven biological activity in cell and animal models of 
prostate cancer [122]. Like many health foods, however, cruciferous vegetables are 
a rich source of other minerals and compounds which may contribute to their health-
promoting properties. SMCSO, another sulphur-containing metabolite from broccoli, 
was the single highest-ranking difference in urine by global metabolomic profiling of 
men receiving a high-broccoli diet during the SAP study (Chapter 2). 
By comparison to glucosinolate breakdown products, experimental evidence for the 
biological activity of SMCSO is sparse [57]. Human metabolism of SMCSO 
predominantly yields inorganic sulphate [123]. Availability of sulphate is the rate-
limiting step in synthesis of PAPS, the universal sulphate donor, a process that 
consumes ATP [69]. SMCSO was, therefore, hypothesised to be responsible for the 
significant accumulation of both sulphate and ADP in the prostates of men receiving 
a broccoli-enriched diet for 12 months (ESCAPE study). Global metabolomic 
analysis of tissue obtained from the SAP study revealed no significant difference in 
sulphate levels between those in the intervention arm and those receiving their 
normal diet (Chapter 3). ADP, however, was significantly higher in the intervention 
arm (p < 0.05), suggesting loss of ATP either by (i) depletion (dephosphorylation) to 
ADP and AMP, or (ii) restricted production. 
A validated LC-MS/MS method for targeted sulphate and SMCSO analysis in 
freeze-dried powder of plant material had previously been developed at QIB [124]. 
However, taking into consideration the limitations of quantitative analysis by LC-MS 
in terms of matrix effects [125], further work was required to optimise not only 
extraction conditions in human tissue and urine samples but also chromatography 
and detection parameters. Furthermore, a novel analytical method was developed 
for ATP quantification in different biological matrices, which is likely to provide a 
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useful tool for a wider range of applications in the future. Commercially-available 
bioluminescence assays for ATP are restricted by their ability to only measure one 
metabolite, and risk co-precipitation of ATP during extraction from protein-rich 
biological samples [126]. 
ATP is considered the “energy currency” of organisms, as well as playing vital roles 
in signal transduction, coenzyme function and as a precursor for RNA synthesis. 
The reactions that dephosphorylate ATP to ADP, and subsequently AMP, provide 
the energy to fuel most cellular functions [127]. The levels of ATP relative to ADP 
and AMP therefore provide a useful insight into the metabolic status of the cell [21]; 
a rise in AMPK resulting in a cascade of metabolic changes to conserve ATP [128].  
The availability of ATP also has important implications for cancer cells, which 
establish metabolic characteristics that support rapid growth and proliferation but 
are unable to adapt their metabolism according to changes in ATP levels [79]. 
Therapeutic agents that drive ATP depletion or inhibit production in prostate cancer 
cells are currently under investigation, making accurate quantification of ATP, ADP 
and AMP a critical analytical process [129]. 
 
4.2 Aims 
 - To develop highly-accurate LC-MS/MS methods for quantification of 
sulphate, SMCSO and ATP in human tissues and urine 
 - To quantify sulphate, SMCSO and ATP levels in human tissues and urine 
from men enrolled on the SAP study   
 
4.3 Materials and Methods 
All LC-MS/MS methods applied after extraction of metabolites were optimised by Dr 
Shikha Saha (QIB Senior Analytical Chemist). Urine sample preparation followed 
the protocol developed by Dr Tharsini Sivapalan for the analysis of samples 
collected as part of The Bioavailability Of Sulforaphane From Broccoli Soups Study 
(BOBS, NCT02300324) (unpublished doctoral thesis). 
4.3.1 Sample Collection and Processing 
4.3.1.1 Ex Vivo Prostate Tissue 
Prostate tissue was accessed via the Norwich Biorepository with ethical approval 
issued by the Faculty of Medical and Health Sciences Research Ethics Committee 
at the University of East Anglia in November 2015 (ref: 20152016 – 30HT). Men 
undergoing radical prostatectomy for confirmed prostate cancer consented to tissue 
banking with the Norwich Biorepository Adult Information Sheet for Patients and 
Consent Form (version 15, 21 February 2014). Immediately following extraction of 
the prostate, needle-biopsy tissue cores were taken from regions remote from the 
known cancer. Tissue cores were snap frozen on dry ice and stored at -80o C until 
required for analysis. No impact was made on the histological assessment of the 
remaining specimen, as confirmed by Professor Ball (NNUH histopathology 
consultant). 
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4.3.1.2 In Vivo Prostate, Adipose and Urine Samples from the SAP Study 
As described in Chapter 2, ethical approval for the use of prostate, adipose and 
urine from SAP study participants was granted by the East of England - Cambridge 
East REC (ref: 16/EE/0054) in January 2016. Written informed consent was 
obtained for study participation, clinical consent for the biopsies and tissue banking 
consent at the Norwich Biorepository. Following DRE, a first-pass urine sample was 
collected, divided into 1ml aliquots and snap frozen on dry ice. Biopsy cores of both 
prostate and adipose were taken through the template grid during TPB. Those to be 
used for targeted analysis were immediately snap frozen on dry ice to minimise 
ischaemia time. All samples were stored at -80o C until required for analysis.  
4.3.2 Sulphate and SMCSO Extraction from Tissue 
Snap-frozen tissue cores were individually weighed on a Cubis® high-sensitivity 
balance (Sartorius) and transferred to screw-top tubes. 200µl of cold Milli- Q® water 
and 300µg of autoclaved, acid-washed 710 to 1180µm glass beads (Sigma®) were 
added to each tube. The tissue was completely homogenised using a DNA Fast-
Prep® (MP Biomedicals) at 4.0m/s for 3 cycles of 60 seconds each. The samples 
were then placed on a revolving shaker for 15 minutes at 4o C. The tubes were 
centrifuged at 17,000g for 10 minutes at 4o C and 50µl of supernatant transferred to 
a new Eppendorf. 10µl of 50% trichloroacetic acid (TCA) were added to each 
sample to precipitate proteins. The centrifugation step was repeated and 50µl of 
supernatant transferred to HPLC insert vials for analysis by LC MS/MS. 
4.3.3 Sulphate and SMCSO Extraction from Urine   
Aliquots of urine were thawed on ice, vortexed briefly and 100µl was transferred to a 
new Eppendorf tube. A 10-fold dilution in 5% TCA was performed, the sample was 
vortexed again and then incubated on ice for 10 minutes to precipitate proteins. The 
sample was centrifuged at 14,000g for 10 minutes at 4o C and the supernatant 
transferred to an HPLC vial for analysis by LC-MS/MS. 
4.3.4 Quantification of Sulphate and SMCSO by LC-MS/MS 
Quantification was performed by matrix-matched calibration curve. Matrix matching 
was achieved by pooling samples from participants in the non-intervention arm of 
the SAP study. Stock solutions of 1mg/ml sulphate (Sigma®) and SMCSO (LKT 
laboratories Inc) were generated by dilution of weighed powder into Milli- Q® water. 
Serial 5-fold dilutions were performed in the relevant matrix to produce 6-point 
calibration curves from 10µg/ml to 0 on the day of analysis. 
Sulphate was quantified using an Agilent 6490 triple-quad LC MS mass 
spectrometer (Agilent technologies) with Thermo Scientific Hypercarb, Porous 
Graphitic Carbon (PGC) (3 x 50mm, 3 µm) column. The system comprised a 
degasser, binary pump, column oven, cooled autosampler (4o C), diode array 
detector and 6490 mass spectrometer. 2µl were injected from each sample, with 
separation by 1% formic acid in Milli- Q® water (mobile phase A) and 1% formic acid 
in methanol (mobile phase B). The gradient started at 8% mobile phase B, 
increasing to 70% over 5.5 minutes and returning to 8% mobile phase B for re-
equilibration over the last 9.5 minutes. The column temperature was maintained at 
60º C and the flow rate at 0.3ml/min. The LC eluent flow was sprayed into the mass 
spectrometer interface without splitting. Inorganic sulphate was monitored using 
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mass spectrometry in MRM mode (m/z = 97/80 transition) with electrospray 
ionisation in the negative polarity. The mass spectroscopy source parameters were: 
gas temperature 200º C, gas flow 16 l/min, sheath gas temperature 400º C, sheath 
gas flow 12 l/min, capillary voltage 3000 V and nozzle voltage 1000 V. 
Quantification of sulphate was performed by peak area against the matrix-matched 
standard curve, and identification by retention time and product ions. Table 4-1 
summarises the optimal parameters for sulphate detection. 
Table 4-1 The optimised LC MS/MS parameters for detection of the sulphate anion 
Analyte Retention 
time 
(mins) 
Precursor 
ion (m/z) 
Product 
ion (m/z) 
Collision 
energy 
Cell 
accelerator 
energy 
Polarity 
 
Sulphate 
 
 
2.0 
 
96.99 
 
80.0 
 
24 
 
           4 
 
Negative 
 
SMCSO was quantified with the same Agilent system described above. Samples 
were injected at 2 µl eluted at a flow rate of 0.3 ml/min on an Agilent SB-AQ 1.8µM 
(100 x 21mm) C18 column. Separation was carried out using 10mM ammonium 
acetate + 0.05% hetafluorobutyric acid in Milli- Q® water (mobile phase A) and 
10mM ammonium acetate + 0.05% hetafluorobutyric acid in 90% methanol (mobile 
phase B). The gradient started at 2% mobile phase B, increasing over 2 minutes to 
5% B and returning to 2% mobile phase B for re-equilibration over the last 2 
minutes. The column was set at 20º C due to the instability of SMCSO at high 
temperatures. The LC eluent flow was sprayed into the mass spectrometer interface 
without splitting. SMCSO ion was monitored by mass spectrometry in MRM mode 
(m/z = 87.9) in positive polarity with electrospray ionisation. The source parameters 
were: gas temperature 200o C, gas flow 16 l/minute, sheath gas temperature 300o C 
with a sheath gas flow of 11 l/minute, a nebuliser pressure of 50 psi and capillary 
voltage 3500 V. Quantification was performed by peak area against the matrix-
matched standard curve, and identification by retention time and product ions. 
Table 4-2 summarises the optimal parameters for SMCSO detection. 
Table 4-2 The optimised parameters for detection of SMCSO ions by LC-MS/MS 
Analyte Retention 
time 
(mins) 
Precursor 
ion (m/z) 
Product 
ion (m/z) 
Collision 
energy 
Cell 
accelerator 
energy 
Polarity 
SMCSO 
 
0.98 152.19 87.9 4 4 Positive 
SMCSO 
 
0.98 152.19 69.9 16 4 Positive 
SMCSO 
 
0.98 152.19 42.1 20 4 Positive 
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4.3.5 ATP, ADP and AMP Extraction from Prostate Tissue 
Labelled (15N) internal standards for ATP (purity 95%), ADP (purity 90%) and AMP 
(purity 90%) were purchased from Sigma®. 1mg/ml stock solutions were generated 
from dried powder in Milli- Q® water and stored at -20o C. On the day of analysis 
stock solutions were serial diluted in Phenol-TE (Sigma®) to a final concentration of 
mixed standards of 1µg/ml. Snap-frozen tissue cores were individually weighed on a 
high-sensitivity balance and transferred to screw-top tubes. 200µl of cold Phenol-TE 
containing internal standards and 300µg of autoclaved, acid-washed 710 to 1180µm 
glass beads (Sigma®) were added to each tube. The tissue was completely 
homogenised using a DNA Fast-Prep® (MP Biomedicals) at 4.0m/s for 3 cycles of 
60 seconds each. The samples were then placed on a revolving shaker for 15 
minutes at 4o C. The tubes were centrifuged at 17,000g for 10 minutes at 4o C. The 
supernatant was serial diluted to 1000-fold in Milli- Q® water before being 
transferred to an HPLC vial for analysis by LC-MS/MS. 
Due to the highly labile nature of ATP, meticulous care was taken to ensure 
samples were maintained below 4o C at all stages of extraction and analysis [130]. 
4.3.6 Quantification of ATP, ADP and AMP by LC-MS/MS 
ATP, ADP and AMP were quantified with the same Agilent system described above. 
Samples were injected at 2µl eluted at a flow rate of 0.3 ml/minute on an Agilent SB-
AQ 1.8 uM (100 x 2.1mm) C18 column. Separation was carried out using 50mM 
ammonium acetate in Milli- Q® water (mobile phase A) and 50mM ammonium 
acetate in methanol (mobile phase B). The gradient started at 2% mobile phase B, 
increasing over 5 minutes to 20% mobile phase B and finally re-equilibrated to 2% 
mobile phase B for 2 minutes. The column temperature was set at 40º C. The LC 
eluent flow was sprayed into the mass spectrometer interface without splitting. ATP, 
ADP and AMP ions were monitored using mass spectrometry in MRM mode, in 
positive polarity with electrospray ionization. The source parameters were kept the 
same as described for SMCSO. Quantification was performed by peak area against 
matrix-matched calibration curve.  Identification was achieved based on retention 
time and product ions. Table 4-3 summarises the monitored ions and the optimised 
MS operating parameters of the analytes.  
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Table 4-3 The optimised parameters for detection of ATP, ADP and AMP ions by LC-MS/MS 
  
 
4.4 Results 
4.4.1 Sulphate Quantification in Prostate Tissue Required Strict 
Experimental Controls 
Baseline population levels of inorganic sulphate in the prostate were quantified 
during optimisation of the analytical technique. Tissue cores obtained from 
prostatectomy specimens were of comparable size and weight (2-5mg per core) to 
those obtained during TPB, depending on the size of the prostate gland. The 
method for sulphate extraction previously included a 95o C heating step after the 
tissue had been homogenised (data not shown). However, further optimisation 
revealed that the most reliable results were achieved with cold extraction and 
deproteinisation, which allowed preservation of the same sample for further 
analysis.  
A total of 11 prostatectomy specimens were analysed to establish variability 
between individuals, which were quantified in 2 batches. Analysis of variance testing 
revealed no significant difference in the first 8 prostatectomy specimens (p = 0.178, 
F = 1.975) (Figure 4-1), which were run as a single batch of 4 biopsy tissue cores 
per patient. Analysis of a further 3 prostatectomy samples, which were extracted 
and run as a second batch revealed significant variability from the first (p < 0.0001, 
F = 25.14) (Figure 4-2). Interestingly, we observed inter-day variability in inorganic 
sulphate concentrations in the Milli-Q® water used for the LC-MS/MS analysis. 
Therefore, normalisation of samples analysed in separate batches was not possible 
due to the varying sulphate content of the water used as both extraction solvent and 
in generating standard curves. All SAP study samples were later analysed in a 
Compound 
Name 
Retention 
Time 
(mins) 
Precursor 
ion (m/z) 
Product 
ion (m/z) 
Collision 
energy 
Cell 
accelerator 
energy 
Polarity 
15N5 ATP 1.34 513.16 141.2 40 4 Positive 
ATP1 
 
1.34 508.15 136.1 48 4 Positive 
ATP1 
 
1.34 508.15 39.2 80 4 Positive 
15N5 ADP 
 
1.586 433.18 141 28 4 Positive 
ADP1 
 
1.586 428.2 136.2 24 4 Positive 
ADP1 
 
1.586 428.2 119 80 4 Positive 
15N5 AMP 
 
2.339 353.13 141 12 4 Positive 
AMP 
 
2.339 348.13 136 16 4 Positive 
AMP 
 
2.339 348.13 119.2 68 4 Positive 
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single batch using the same original stock of Milli- Q® water as the first 8 
prostatectomy specimens. 
 
 
Figure 4-1 Sulphate levels (µmol/g tissue) analysed as a single batch from 4 prostate biopsy cores per 
patient in men undergoing radical prostatectomy. Mean range 0.173 to 0.363 µmol/g frozen tissue 
weight. Data shown as mean ± SD. No significant difference between individuals by one-way ANOVA 
(p = 0.178, F = 1.975). 
 
 
Figure 4-2 Sulphate levels (µmol/g tissue) in prostate biopsy cores, indicating significant variability 
between batches due to inter-day variability of sulphate content in the Milli- Q® water used for sulphate 
extraction and generation of standard curves. Data shown as mean ± SD. Significant difference 
between batches by one-way ANOVA (p < 0.0001, F = 25.14). 
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4.4.2 Sulphate Levels in the Prostate Did Not Significantly Increase 
Following a Broccoli-enriched Diet 
A single snap-frozen prostate biopsy core was analysed per participant enrolled in 
the SAP study. All samples were extracted and analysed in parallel as a single 
batch with a single stock of Milli-Q® water used for both extraction and generation of 
calibration curves. Two participants in the non-intervention group were found to 
have very high levels of sulphate, which were out of keeping with the rest of the 
cohort, as well as previous results from prostatectomy samples (Figure 4-3). 
Grubbs’ test, also called extreme studentised deviate test, was performed on both 
results and they were found to be significant outliers (p < 0.05). The two outliers 
were removed from further analysis. Although there was no statistically significant 
difference between groups, an apparent bi-modal separation emerged in individuals 
receiving the dietary intervention as part of the SAP study (Figure 4-4). 
Quantification of sulphate in the adipose tissue of SAP study participants revealed 
no significant difference between groups (Figure 4-5). 
 
 
Figure 4-3 Graph of sulphate levels (µmol/g) in prostate tissue comparing both study arms of the SAP 
study to previous results from prostatectomy specimens. Data are shown as mean + individual 
concentrations for visual separation. By carrying out a Grubb’s test, two outliers were identified in the 
non-intervention group and subsequently removed from further analysis. 
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Figure 4-4 Graph of sulphate levels (µmol/g) in prostate tissue comparing both study arms of the SAP 
study to previous results from prostatectomy specimens (outliers removed). Data are shown as means 
+ individual concentrations for visual separation. No statistically significant difference was observed by 
unpaired Student’s t-test between groups, but there is a trend towards clear separation of the 
individuals in the intervention arm of the SAP study. 
 
       
Figure 4-5 Graph of sulphate levels (µmol/g) in adipose tissue of SAP study participants. Data shown 
as mean + individual concentrations. No statistically significant difference between groups. 
  
Su
lp
ha
te
 C
on
c.
( µ
m
ol
/g
 ti
ss
ue
)
No
n-I
nte
rve
nti
on
Int
erv
en
tio
n
Pr
os
tat
ec
tom
y
0.0
0.2
0.4
0.6
0.8
1.0
p = 0.0756
Su
lp
ha
te
 C
on
c.
( µ
m
ol
/g
 ti
ss
ue
)
No
n-I
nte
rve
nti
on
Int
erv
en
tio
n
0.0
0.5
1.0
1.5 p = 0.202
   Chapter 4 
63 
 
Comparing global metabolomic analysis by Metabolon® with targeted analysis at 
QIB did not reveal statistically significant correlations in sulphate quantification in 
either the adipose or prostate tissues (Figure 4-6). While this may represent 
metabolic differences between separate tissue biopsy samples, this would be 
especially unlikely in adipose tissue as it is known to be highly homogenous [130]. 
Another possibility could be the standard method of metabolite extraction and 
processing in global metabolomics, which is not optimised for highly water-soluble 
metabolites such as inorganic sulphate. Tissue extraction was carried out in 80% 
methanol/20% water, and a further substantial increase in the requirement for 
organic solvents is encountered with other methods on the Metabolon® platform, 
such as HILIC. Furthermore, the most likely limitation is that the reverse phase LC-
MS Negative platform used by Metabolon® for sulphate analysis is too polar for 
accurate detection of inorganic anions, a problem that was overcome at QIB by 
using the Hypercarb column. 
 
 
Figure 4-6 Graphs showing quantification of inorganic sulphate on a global metabolomics platform 
compared to targeted analysis at QIB in human prostate (A) and adipose (B) tissue samples collected 
from the SAP study. No significant correlation seen in either prostate or adipose tissue by Pearson 
correlation coefficient analysis. 
 
4.4.3 A Broccoli-Enriched Diet Led to a Significant Accumulation of SMCSO 
in Urine and Prostate 
Results obtained by carrying out a targeted analysis of SMCSO in samples 
collected from the SAP study revealed significantly higher levels of SMCSO 
following the broccoli intervention (Figure 4-7) in accordance with global 
metabolomics data reported in 0. The results positively correlate with strong 
statistical significance (p < 0.001, r2 = 0.536), validating the method of SMCSO 
quantification in urine used by Metabolon® (Figure 4-8). 
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Figure 4-7 Graph of SMCSO quantification in the urine of SAP study participants by targeted LC-
MS/MS analysis. The line in the middle of the box-and-whiskers plots is plotted at the median. 
Significantly higher concentrations by unpaired Student’s t-test in the intervention group confirm 
previous findings from global metabolomics analysis reported in Figure 3-3.  
 
 
Figure 4-8 Graph showing strongly significant positive correlation between SMCSO detected in SAP 
study urine by global metabolomics and targeted analysis at QIB by Pearson correlation coefficient 
analysis. 
 
Whereas SMCSO had been below the limit of detection for global metabolomics in 
prostate and adipose tissue, the aqueous extracts from both tissue types were 
found to have detectable levels by targeted LC-MS/MS analysis. The concentrations 
were higher in adipose tissue than prostate, and Grubbs’ test was used again to 
determine outliers in the adipose data set; two in the non-intervention and one in the 
No
n-i
nte
rve
nti
on
Int
erv
en
tio
n
0
50
100
150
SM
C
SO
(µ
M
)
p=0.004
**
QIB SMCSO (µM)
M
et
ab
ol
on
 S
M
C
SO
(O
sm
oN
or
m
Im
pD
at
a)
0 50 100 150
0.0
0.5
1.0
1.5
2.0
r2 = 0.536
p < 0.001
Non-Intervention
Intervention
   Chapter 4 
65 
 
intervention group. Both tissue types appeared to contain higher concentrations of 
SMCSO in the intervention group, although statistical significance was only reached 
in prostate tissue (p = 0.005, Figure 4-9). This was possibly due to a reduction in 
statistical power once the outliers were removed from the adipose data set. 
 
 
Figure 4-9 Graph of SMCSO concentrations in prostate and adipose tissue of SAP study participants. 
Data shown as means ± SD. Significantly higher levels by unpaired Student’s t-test were seen in the 
prostate of men randomised to the intervention arm (** = p < 0.01). The increase in adipose tissue did 
not reach statistical significance, possibly due to a reduction in power following removal of 3 outliers. 
 
4.4.4 Isothiocyanates Were Not Detectable in Adipose or Prostate Tissue 
Using the LC-MS/MS method described for quantification of urinary ITCs 
(Section 2.3.8), the aqueous extracts from both prostate and adipose tissue were 
also analysed. No detectable peaks were identified for sulforaphane, SF-Cys, SF-
NAC or ER-NAC. This may reflect either an absence of accumulation in the tissue, 
or a transient increase after broccoli consumption that had cleared by the time the 
samples were collected. 
4.4.5 A Broccoli-Enriched Diet Did Not Reduce ATP levels in the Prostate 
Developing a novel method for quantifying ATP, ADP and AMP in prostate tissue 
required optimisation at several stages of the analysis. A range of extraction 
solvents have previously been reported for quantifying ATP in both plant and animal 
tissues, including water, TCA, perchloric acid, ethylene glycol, 50% methanol and 
Phenol-TE [126, 131, 132]. As the highest recovery rates of ATP in human and 
animal tissues have been with methanol and Phenol-TE, these were compared both 
with each other and against a simple aqueous extract (data not shown). Consistent 
with findings in visceral tissues obtained from mice, Phenol-TE yielded the highest 
and most reproducible results [126]. 
ATP supplies are rapidly depleted in ischaemic tissue, so comparison was made 
between samples that had been obtained by TPB in vivo and immediately snap 
frozen, and those that were obtained from ex vivo prostatectomy specimens 
(Figure 4-10). The total levels of ATP did not reach a statistically significant 
difference between groups and were low relative to both ADP and AMP throughout. 
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ADP and AMP were both significantly higher (p < 0.01 and p < 0.05 respectively) in 
the ex vivo prostatectomy tissue, as was the AMP:ATP ratio (p < 0.01), confirming 
the effects of ischaemia on energy balance. 
 
 
Figure 4-10 Graphs showing (A) concentrations of ATP, ADP and AMP (µmol/g) in 8 perfused ‘in vivo’ 
biopsy tissue samples and 3 ischaemic ‘ex vivo’ prostatectomy tissue samples and (B) the proportion 
of AMP to ATP. Data shown as means ± SD. Statistical analysis by unpaired Student’s t-test (* = p < 
0.05, ** = p < 0.01). 
 
Analysing the prostate tissue from SAP study volunteers revealed no significant 
difference in levels of ATP, ADP or AMP, or in the AMP:ATP ratio between study 
arms (Figure 4-11). The results previously obtained for levels of ADP by global 
metabolomics analysis (Chapter 2) suggested a significant increase (p = 0.03) 
because of the dietary intervention. The results obtained by targeted analysis at QIB 
did not detect similar results despite having a statistically significant (p < 0.05) but 
not strong correlation (r2 = 0.252) to the data from Metabolon® (Figure 4-12). We 
have shown that ischaemia time has an impact on ADP levels, thus the 24-hour 
period at room temperature and subsequent drying down of extraction solvent in the 
Metabolon® protocol may account for these conflicting results. 
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Figure 4-11 Graphs showing (A) concentrations of ATP, ADP and AMP (µmol/g) in the prostate tissue 
of SAP study participants and (B) the proportion of AMP to ATP. Data shown as means ± SD. No 
statistically significant differences detected by unpaired Student’s t-tests. 
 
 
Figure 4-12 Graph showing correlation between ADP detected in SAP study prostate tissue by global 
metabolomics carried out by Metabolon® and targeted analysis at QIB. Weak but statistically significant 
positive correlation detected by Pearson correlation coefficient analysis (r2 = 0.252, p < 0.05). 
   Chapter 4 
68 
 
4.4.6 Sulphate, SMCSO and ATP Levels in the Prostate Were Not Influenced 
by Other Explanatory Variables in the SAP Study 
The baseline characteristics of the SAP study participants were evaluated as 
explanatory variables in the results of targeted metabolite quantification. Multi-linear 
regression analysis was performed with sulphate, SMCSO and ATP as the 
dependent variables and study arm, GSTM1 genotype, cruciferous vegetable intake 
and histological findings as the explanatory variables. The only variable to account 
for a significant metabolite change was the intervention arm of the SAP study and 
higher levels of SMCSO in both urine and prostate. 
 
4.5 Discussion 
Despite the wealth of information provided by global metabolite profiling across a 
range of biological samples, independent analysis of target metabolites is crucial to 
confirm specific findings.  
The method for quantifying inorganic sulphate described in this chapter utilises an 
extraction protocol that has been optimised for biological samples of human origin 
(prostate/adipose tissue). The LC-MS/MS method used also offers a robust method 
for retention of highly polarised metabolites. Not only is inorganic sulphate widely 
abundant, posing risks for sample contamination, but the content in purified water is 
also variable [110]. The importance of highly-controlled experimental conditions and 
same-day analysis were highlighted by the differences in batched samples during 
the earlier analysis of prostatectomy specimens. Findings obtained from the method 
validation process will be extremely valuable for future studies. The results of 
targeted sulphate analysis provided no evidence to support the SAP study 
hypothesis that a broccoli-enriched diet leads to accumulation of sulphate in the 
prostate. The apparent bimodal separation of sulphate levels in the prostate of men 
in the intervention arm (Figure 4-4) suggests that a few individuals may have 
characteristics that make them susceptible to an effect. However, these were not 
attributable to any of the explanatory variables accounted for in the study. 
SMCSO represents an under-investigated phytochemical with potential biological 
activity supporting anti-cancer, anti-diabetic and cardiovascular health benefits [57]. 
A wide range of analytical techniques have been applied for the analysis of SMCSO 
in plant materials [133-135], but few reports exist for analysis of samples of human 
origin [136, 137]. Results obtained from optimising a LC-MS/MS method in urine 
and different tissue types (prostate and adipose) will help further work not only for 
assessing SMCSO bioavailability and biodistribution in vivo but also for investigating 
its biological activity in ex vivo models. Targeted quantification of SMCSO in this 
chapter independently confirms the higher levels seen in the urine of men in the 
intervention arm of the SAP study, with close correlation to the previous global 
metabolomic results (Figure 4-8). It also reveals for the first time an accumulation of 
intact SMCSO in adipose and prostate tissues, with a significant increase in the 
prostate after just 4 weeks of intervention with a broccoli-enriched diet. The 
degradation of SMCSO, which is known to ultimately yield a high proportion of 
sulphate, includes a number of reactive intermediate products [123]. In cell and 
animal models, used at higher levels than those of SMCSO detected in prostate and 
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adipose tissue, these products have been proven to induce apoptosis in cancerous 
cell lines, including prostate cancers, and protect against a number of pro 
carcinogens [55]. Both caspase-dependent and -independent mechanisms have 
been suggested, leaving extensive scope for further investigation [52]. 
The emergence of therapeutic ATP depletion to target lung and breast cancers, and 
the recent finding that ATP synthase is overexpressed in aggressive prostate 
cancer, mark the need for accurate methods to quantify ATP in tissue and assess 
response to treatment [138, 139]. The novel method of quantification described in 
this Chapter surpasses commercially-available fluorescence-based assay kits by 
simultaneously measuring ATP, ADP and AMP against labelled internal standards. 
It also offers preparation and extraction techniques specific to small-volume prostate 
tissue biopsies, which have not previously been described. As the changes in tissue 
after a period of ischaemia were also quantified, the method was validated against a 
positive control for detection of a significant change in energy state. 
No significant differences were detected in ATP or its dephosphorylation products in 
the prostate tissue of SAP study participants. The broccoli-enriched diet at the dose 
administered (3 x 300g portions per week) did not, therefore affect ATP levels in the 
tissue. As the results of global metabolomic profiling had initially suggested an 
increase in ADP, further in vitro studies were carried out to investigate the effects of 
sulforaphane and SMCSO on mitochondrial energy metabolism; ATP production 
rather than the hypothesised mechanism for depletion. Results obtained from in 
vitro models are reported in Chapter 4. 
 
4.6 Conclusion 
Highly-sensitive LC MS/MS techniques have been developed to quantify sulphate, 
SMCSO and ATP in biological samples. These methods represent valuable 
analytical tools for carrying out targeted analyses in future dietary-intervention 
studies. The broccoli-enriched diet of the SAP study intervention led to one 
consistent and significant metabolic change; an accumulation of SMCSO in urine 
and prostate tissue that was unrelated to any of the other explanatory variables. The 
mechanisms of biological and potential anti-cancer activity of SMCSO require 
further investigation, but do not appear to be linked to either an accumulation of 
sulphate or a resultant depletion of ATP. The absence of detectable ITCs in prostate 
tissue, despite their presence in urine, may signify greater importance to the finding 
of SMCSO accumulation in the prostate. 
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5 In Vitro Effects of Sulforaphane and 
SMCSO on Prostate Mitochondrial 
Energy Metabolism 
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Summary 
Dysregulation of mitochondrial metabolism is characteristic of cancer in the prostate 
and other body sites. The role for regulating or reversing these changes by diet is 
increasing, as is our understanding of the mechanisms that link specific 
phytochemicals to cancer prevention. In Chapter 3 a global metabolomics approach 
was taken to analyse the effects of broccoli consumption on prostate tissue in vivo. 
A key finding was a significant increase in ADP, which was suggestive of ATP 
depletion because of the study diet. Targeted LC MS/MS analysis revealed no 
significant difference in net ATP levels (Chapter 4), so an in vitro approach was 
taken to test the dynamic effects of broccoli-derived sulforaphane and SMCSO on 
real-time prostate bioenergetics.  
 
5.1 Introduction 
The role of dietary ITCs, including sulforaphane, has yielded promising results in 
both in vitro and animal models of prostate cancer [43, 44]. Multiple chemo-
preventive mechanisms have been suggested that involve pathways targeting 
inflammation, anti-oxidant defence, phase I enzyme modulation, and induction of 
phase II enzymes and apoptosis [140]. The overall effects are, therefore, likely to 
interact with mitochondrial metabolism in numerous directions. Recent studies in 
breast cancer have revealed additional roles for diet-derived ITCs in restricting 
mitochondrial bioenergetics [141, 142]. ATP depletion is also a common finding 
following a range of in vivo interventions with natural compounds that inhibit 
prostate cancer growth, such as ursolic acid, curcumin and resveratrol [85]. At high 
doses, sulforaphane induces reactive oxygen species (ROS) production in the 
cancerous PC3 prostate cell line, inducing apoptosis by interaction with the 
mitochondrial electron transport chain (ETC) [143]. Although not tested in prostate 
cells, high-dose sulforaphane is a known inhibitor of complex III of the ETC, with 
similar properties to antimycin (discussed below) [144, 145]. However, Nrf-2 
activation by sulforaphane maintains mitochondrial homeostasis, preventing 
oxidative stress from affecting rate-limiting enzymes [146, 147]. Thus, metabolic 
reprogramming, which is inherent in prostate cancer, represents another potential 
target among the multi-modal effects of broccoli-derived bioactive compounds.   
Global metabolomic analysis of prostate tissue from men enrolled in two broccoli-
enriched dietary intervention studies undertaken at QIB have independently 
revealed an increase in ADP. In the ESCAPE study (REC 13/EE/0110; 
NCT01950143), paired samples were taken before and after 12 months of broccoli 
soup, investigating the effects of increasing glucosinolate content compared to a 
standard broccoli control. Participants in the SAP study (Chapter 2) were 
randomised to either a non-intervention arm or a high-dose broccoli-enriched diet 
for four weeks prior to prostate biopsy. The significant increase in ADP suggested a 
reduction of ATP, either through increased utilisation or reduced production. No 
difference in ADP levels was seen between intervention arms of the ESCAPE study 
(unpublished doctoral thesis), and increasing concentrations of SMCSO (another 
broccoli-derived metabolite) in urine of SAP study participants was the most 
significant metabolite change (Table 3-3). The biological activity on energy 
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metabolism of both sulforaphane and SMCSO therefore required separate 
investigation.  
The Seahorse XFp Bioanalyser (Agilent®) was selected to simultaneously measure 
oxygen consumption rate (OCR) and extra-cellular acidification rate (ECAR) in 
cultured cells, indicating the rates of oxidative phosphorylation and glycolysis 
respectively [148]. Assays are run in real time with the capacity for acute injections 
of up to four test compounds. The dynamic response of cells to stressed conditions 
elicits their capacity to adapt various parameters of mitochondrial function. 
However, individual cell lines and assay conditions require careful optimisation 
before tightly-controlled and reproducible results can be obtained. In this chapter the 
application of the Agilent Mitochondrial (Mito) Stress Test, the Glycolysis Stress 
Test and the Mito Fuel Flex Fatty Acid Oxidation Capacity Test will be fully 
described [149-151].  
The substrates of respiration, NADH and FADH2, donate electrons to the 
mitochondrial ETC [152]. NADH donates directly to complex I, initiating a series of 
redox reactions that release energy and pump protons out of the matrix and into the 
intermembrane space [152]. FADH2 releases electrons less readily and is 
dependent on complex II, which does not span the membrane or transport protons 
[152]. Electrons from both complex I and II are transported by the mobile electron 
carrier ubiquinone (Q) to complex III, at which point more protons are pumped out 
and the electrons continue via another carrier (cytochrome C) to complex IV. In 
addition to pumping out further protons, complex IV is the site of oxygen 
consumption; O2 dissociates and then binds with protons from the matrix to form 
water. The flow of protons back down their electrochemical gradient via ATP 
synthase provides the energy for ATP production from ADP and phosphate [153]. 
The Mito Stress Test allows quantification of ATP production, maximal respiration 
and non-mitochondrial respiration by manipulation of the mitochondrial electron 
transport chain. Figure 5-1 shows the sites of action of the compounds injected 
during the assay. OCR is measured before and after sequential injections of 
oligomycin (ATP synthase inhibitor), carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (FCCP, mitochondrial membrane uncoupler) and 
rotenone/antimycin A (complex I and III inhibitors). The OCR response at each 
stage can be used to determine the separate characteristics of mitochondrial 
function (Figure 5-2A).  
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Figure 5-1 The mitochondrial electron transport chain and the sites of action of the compounds injected 
during the Mito Stress Test assay. 
 
OCR can also be used to determine the capacity and dependency on specific 
substrates fuelling oxidative phosphorylation. Inhibition of individual pathways 
relative to combined inhibition of others can be applied to glucose, glutamine and 
fatty acids with the respective injections of a mitochondrial pyruvate transporter 
inhibitor (UK5099), a glutaminase inhibitor (Bis-2-(5-phenylacetamido-1,3,4-
thiadiazol-2-yl)ethyl sulphide, BPTES) and an irreversible O-carnitine 
palmitoyltransferase-1 (CPT-1) inhibitor (etomoxir). 
The Glycolysis Stress Test allows quantification of glycolysis and glycolytic capacity 
by measuring ECAR (Figure 5-2B). Pyruvate produced by metabolism of glucose in 
glycolysis can either enter the mitochondrial TCA cycle or be converted to lactate in 
the cytoplasm [154]. The result of lactate production is extrusion of protons into the 
extracellular space, which in cultured cells results in acidification of the media [155]. 
Measuring ECAR under glucose-starved conditions and after a saturating dose of 
glucose determines the rate of glycolysis under basal conditions. Adding oligomycin 
blocks mitochondrial ATP synthesis, forcing cells to their maximal glycolytic capacity 
to maintain ATP. A final injection of 2-deoxyglucose (2-DG) completely inhibits 
glycolysis, confirming the basal levels of ECAR that were unrelated to glycolysis.  
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Figure 5-2 Examples of stress test parameters (source: Agilent®). (A) Parameters of mitochondrial 
function derived from injections of Mito Stress Test compounds. (B) Parameters of glycolytic function 
derived from Glycolysis Stress Test injections after basal measurements under glucose-starved 
conditions. Oligomycin (ATP synthase inhibitor), FCCP: carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (mitochondrial membrane uncoupler); Rotenone/antimycin A 
(complex I and III inhibitors). 2-DG: 2-deoxyglucose (inhibitor of glucose-6-phosphate production). 
 
5.2 Aims 
 - To characterise normal and cancerous prostate cell lines of human origin 
and optimise assay conditions for use with the Seahorse XFp Bioanalyser 
 - To investigate the effects of sulforaphane and SMCSO on mitochondrial 
function in normal and cancerous prostate cells 
 - To perform preliminary analyses on other metabolic pathways such as 
glycolysis and fatty acid oxidation 
 - To test whether sulforaphane protects against ROS-induced mitochondrial 
dysfunction 
 
5.3 Materials and Methods 
5.3.1 Cell Culture 
All in vitro work was carried out with immortalised human Caucasian prostate cell 
lines. Human normal prostate epithelial cells (PNT1A) (Cat. 95012614) were 
purchased from the European Collection of Authenticated Cell Cultures (ECACC) 
and routinely cultured in RPMI-1640 (Sigma-Aldrich®) medium. Cancerous cell lines 
of human prostate adenocarcinoma, VCaP (Cat. CRL-2876) and DU145 (Cat. HTB-
81), were purchased from the American Type Culture Collection (ATCC®). VCaP 
and DU145 were cultured in DMEM and EMEM media respectively. For all three cell 
lines, the media was supplemented with 10% fetal calf serum (FCS) (Sigma®) and 
1% penicillin/streptomycin (Gibco®). Cells were grown as adherent monolayers 
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(semi-adherent for VCaP) at 37o C, in humidified conditions supplemented with 5% 
CO2. 
5.3.2 Cell Seeding and Sensor Cartridge Hydration 
Optimisation of assay conditions (characterisation) was performed on each cell line 
as per the manufacturer’s protocol for the Seahorse XFp Bioanalyser (Agilent®). 
Cells were grown to 70% confluent and seeded in a total volume of 180µl in the 
central 6 wells of an XFp cell culture miniplate (2.5 to 6 x 104 cells/well) (Figure 5-3). 
The outer wells were filled with culture media and the surrounding moats filled with 
400µl of sterile phosphate-buffered saline (PBS). An additional step was required 
for immobilisation of VCaP cells, which are semi-adherent; Cell-Tak™ (Corning®) 
was applied with 1M sodium hydroxide and 0.1M sodium bicarbonate to wells A-H in 
accordance with the manufacturer’s Basic Adsorption Protocol. Following 
application, excess Cell-Tak™ solution was removed and the wells were washed 
twice with 200µl of sterile water before cells were seeded. All cells were seeded and 
relevant pre-treatments applied in the usual growth media for that cell line. 
48 hours prior to the assay run an XFp Sensor Cartridge was hydrated with 200µl 
XF Calibrant solution per well and 400µl in each of the surrounding moats. The 
cartridge was placed in a 37o C non-CO2 incubator until required for the assay. 
 
Figure 5-3 XFp cell culture miniplate (A) and sensor cartridge with compound injection ports (B). The 
inner 6 wells (B-G) are seeded with cells in normal growth medium. The outer wells (A and H) contain 
sterile media without cells and the moats are filled with sterile PBS. Source: Agilent®. 
 
5.3.3 Assay Optimisation 
A target basal OCR is specified by Agilent® at 50–200 pmol/min. Cells were seeded 
in triplicate at multiple densities (from 2.5 to 6 x104 cells/well). On the day of the 
assay, cells were washed twice and incubated in 180µl of warmed assay medium 
(Agilent® XF base DMEM, pH 7.4, supplemented with L-glutamine 2mM, pyruvate 
2mM and glucose 2g/L) for 1 hour in a 37o C non-CO2 incubator. Blank assay 
conditions were specified on the Seahorse XFp and optimal cell numbers 
determined by microscope appearance (viability and confluence) and OCR. 
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FCCP optimisation was carried out using components of the Mito Stress Test Kit 
(Agilent®) on the pre-determined cell number. Injection port A was loaded with 20µl 
of 10mM oligomycin A for a final well concentration of 1.0mM. PNT1A were known 
to require low dose FCCP, so injection ports B were loaded in duplicate with 22µl of 
1.25, 2.5 or 5µM FCCP for a 10-fold dilution into the well (0.125, 0.25 and 0.5 µM) 
as part of a complete mitochondrial stress test (e.g. Figure 5-2 A). Serial FCCP 
dose titration was carried out for both DU145 and VCaP (Table 5-1). The 
concentration that achieved the highest peak OCR was considered optimal. 
	
Table 5-1 Template for loading injection ports of sensor cartridge for FCCP optimisation. 
Port 
Designation 
Volume 
per port 
Port 
Conc. 
Wells A-D 
(Low dose) 
Port 
Conc. 
Wells E-H 
(High dose) 
Final Well 
Conc. 
Wells A-D 
(Low dose) 
Final Well 
Conc. 
Wells E-H 
(High dose) 
A 
(oligomycin) 
20μL 10μM 10μM 1μM 1μM 
B (FCCP) 22μL 1.25μM 5μM 0.125μM 0.5μM 
C (FCCP) 28μL 1.25μM 5μM 0.25μM 1.0μM 
D (FCCP) 30μL 2.5μM 10μM 0.5μM 2.0μM 
 
5.3.4 Treatment with Sulforaphane or SMCSO 
24 hours after seeding into the cell culture miniplate, an appropriate treatment or 
vehicle control was applied in triplicate in growth medium for a further 24-hour 
incubation. R, S-Sulforaphane ((4-(methylsulfinyl) butyl isothiocyanate) (CAS 4478-
93-7) (purity > 98%) was purchased from LKT Laboratories (St. Paul, USA) and 
used in parallel with a dimethyl sulfoxide (DMSO) vehicle control. S-methyl L-
cysteine sulfoxide (CAS 6858-87-8) (purity >98%) was also purchased from LKT 
and used in parallel with a water control. 
5.3.5 Mitochondrial Stress Test 
Assays were initially carried out with components of the Mito Stress Test Kit 
(Agilent®). Once the procedural technique was established, oligomycin A, FCCP, 
rotenone and antimycin A were purchased separately from Sigma® and diluted in 
DMSO to generate 10mM stock solutions, which were stored at -20o C. On the day 
of the assay working solutions were generated by dilution in warm assay media. 
FCCP concentration was determined by cell type, while concentrations of 
oligomycin and combined rotenone/antimycin A remained constant (Table 5-2). 
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Table 5-2 Template for loading injection ports of sensor cartridge for mitochondrial stress test. 
Port Designation 
 
Volume per Port Port Conc. Final Well Conc. 
A- 
Oligomycin 
 
20µl 10µM 1.0µM 
B - 
FCCP 
22µl 5.0µM 
(PNT1A, DU145) 
0.5µM 
 
  20µM 
(VCaP) 
 
2.0µM 
C – 
Rotenone/ 
Antimycin A 
25µl 5.0µM 0.5µM 
 
5.3.6 Glycolysis Stress Test 
Growth medium was removed from cells and glucose starvation medium (XF base 
DMEM + 2mM L-glutamine) applied for 1 hour in a 37o C non-CO2 incubator prior to 
the assay. Working injection-port solutions of 100mM glucose (Fisher®) and 10µM 
oligomycin A (Sigma®) were diluted in warm glucose starvation (assay) media, and 
2-DG (Sigma®) was loaded direct from a 500mM stock solution. 
Table 5-3 Template for loading injection ports of sensor cartridge for glycolysis stress test. 
Port Designation 
 
Volume per Port Port Conc. Final Well Conc. 
A- 
Oligomycin 
 
20µl 10µM 1.0µM 
B - 
Glucose 
22µl 100mM 10mM 
 
 
C – 
2-DG 
 
25µl 500mM 50mM 
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5.3.7 Exposure to Hydrogen Peroxide 
Hydrogen peroxide (H2O2) was purchased from Sigma® (Cat. 16911) and diluted in 
sterile Milli-Q® water to generate a stock solution of 20mM on the day of use. H2O2 
solutions were protected from light. Working port solutions were generated by 
dilution in warm assay medium to concentrations of 1.25mM, 2.5mM and 5.0mM. 
Injection ports A and B were loaded with 1.25mM, port C with 2.5mM and port D 
with 5.0mM H2O2, achieving serial 2-fold increases in final well concentrations of 
H2O2 from 125µM to 1.0mM (Table 5-4). 
Table 5-4 Template for loading injection ports with hydrogen peroxide at increasing concentrations. 
Port Designation 
 
Volume per Port Port Conc. Of H2O2 Cumulative Well 
Conc. 
Port A 
 
20µl 1.25mM 125µM 
Port B 
 
22µl 1.25mM 250µM 
 
Port C  25µl 2.5mM 500µM 
    
Port D 28µl 5.0mM 1.0mM 
 
 
5.3.8 Mito Fuel Flex Fatty Acid Oxidation Capacity Test 
Growth medium was removed from cells and flex test assay medium (XF base 
DMEM, pH 7.4, + 1mM pyruvate + 2mM L-glutamine + 10mM glucose) was applied 
for 1 hour in a 37o C non-CO2 incubator prior to the assay. Injection port A was 
loaded with UK5099 (20µM) and BPTES (30µM) from the Mito Fuel Flex Test Kit 
(Agilent®) and port B was loaded with etomoxir (40µM). Fatty acid oxidation capacity 
was calculated by the following formula: 
 
Equation 1. The formula for calculating fatty acid oxidation capacity of cells as part of the Agilent® Mito 
Fuel Flex Test [151]. 
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5.4 Results 
5.4.1 Oxygen Consumption was Higher in Cancerous VCaP and DU145 than 
Benign PNT1A Cells 
Cells were seeded 48 hours before the Seahorse assay, allowing 24 hours for 
normal adherence and growth and a further 24 hours for application of pre-
treatment. The optimal seeding density was determined by appearance and OCR at 
the end of this period. To achieve a basal OCR of around 100 pmol/min, PNT1A 
required a seeding density of 6x104 cells per well. At the time of the assay, cells 
were 100% confluent but appeared viable and yielded a more desirable OCR than 
lower cell numbers (Figure 5-4 A). Both VCaP and DU145 achieved basal OCR 
levels of around 120 pmol/min with 2.5x104 cells per well, less than half the number 
for PNT1A. Increasing the cell numbers further resulted in either an OCR outside 
the target range (VCaP) or significant over confluence affecting cell viability 
(DU145) (Figure 5-4 B, C).
  
 
Figure 5-4 Basal oxygen consumption rates (OCR, pmol/min) for prostate cell lines at varying seeding densities. Optimal seeding density (*) determined for (A) PNT1A, (B) 
VCaP and (C) DU145 by satisfactory confluence and OCR in the target range of 50-200 pmol/minute. Data are expressed as mean ± SD of wells in triplicate 
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5.4.2 VCaP Cells Required Higher Concentrations of FCCP than PNT1A and 
DU145 for Maximal Respiration 
FCCP dose optimisation was performed after 48 hours incubation and at the 
seeding densities described above. Maximal OCR response was seen for both 
PNT1A (Figure 5-5) and DU145 (Figure 5-6 B) at 0.5µM FCCP, consistent with 
other studies on mitochondrial function in the prostate [156]. VCaP cells 
demonstrated a dose-dependent increase in OCR up to the maximal concentration 
of FCCP (2.0µM), with no evidence of toxicity (Figure 5-6 A). No previous studies on 
VCaP were available for comparison on the Agilent Seahorse Cell Reference 
Database [157]. 
 
  
 
 
 
 
Figure 5-5 FCCP dose optimisation for PNT1A (6 x 104 cells/well). Mitochondrial stress test with no pre-treatment and a range of FCCP (0.125, 0.25 and 0.5 µM) at injection 2. 
Greatest response seen at 0.5µM. Data are expressed as mean ± SEM of wells in duplicate.   
  
 
Figure 5-6 FCCP dose optimisation for (A) VCaP and (B) DU145, both at seeding densities of 2.5 x 104 cells/well. 1.0 µM oligomycin given at injection 1, followed by serial 
injections of FCCP to achieve both low (0.125, 0.25 and 0.5 µM) and high (0.5, 1.0 and 2.0 µM) dose ranges. Maximal response in VCaP seen at 2.0µM. Maximal response in 
DU145 seen at 0.5µM, with toxicity at 1.0µM and above. Data are expressed as mean ± SEM of wells in triplicate.
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5.4.3 Sulforaphane Exposure Did Not Alter Mitochondrial Metabolism in 
Normal or Cancerous Prostate Cells 
PNT1A, VCaP and DU145 were all incubated for 24 hours with 5µM sulforaphane 
prior to mitochondrial stress test under optimised conditions.  
Experiments were duplicated for each cell line and data extracted from the assay of 
highest technical quality; a representative experiment for each cell line is presented 
in Figure 5-7. Compared to baseline, the spare respiratory capacity of VCaP cells 
was significantly higher than both PNT1A and DU145 (p <0.0001). However, no 
significant differences were detected in either basal ATP production or spare 
respiratory capacity as a result of sulforaphane treatment versus controls 
(Figure 5-8). 
  
 
Figure 5-7 Mitochondrial stress test graphs performed under optimised conditions, after a 24-hour pre-treatment with 5µM sulforaphane (SF) in normal and cancerous prostate 
cell lines; (A) PNT1A, (B) VCaP and (C) DU145. Data shown as mean % of third basal OCR measurement ± SEM for each time point.
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Figure 5-8 Graphs showing (A) ATP production and (B) spare respiratory capacity as percentages of 
basal OCR in prostate cells in response to sulforaphane (SF).  Results derived from mitochondrial 
stress tests under optimised conditions for three prostate cell lines (PNT1A, VCaP and DU145) after 
24 hour pre-treatments with 5µM sulforaphane. Data are shown as means ± SD. No significant 
differences by unpaired Student’s t-test were detected due to sulforaphane exposure. 
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5.4.4 SMCSO Exposure Did Not Alter Mitochondrial Metabolism in Normal or 
Cancerous Prostate Cells 
Mitochondrial stress tests were repeated under the same optimised conditions for 
the three cell lines (PNT1A, VCaP and DU145) after incubation for 24 hours with 
200µM SMCSO. Similar to sulforaphane, no statistically significant differences were 
detected in either basal ATP production or spare respiratory capacity after SMCSO 
treatment versus control (Figure 5-9). 
 
Figure 5-9 Graphs showing (A) ATP production and (B) spare respiratory capacity as percentages of 
basal OCR in prostate cells. Results derived from mitochondrial stress tests under optimised 
conditions for three prostate cell lines (PNT1A, VCaP and DU145) after 24-hour pre-treatment with 
200µM SMCSO. Data are shown as means ± SD. No significant differences by unpaired Student’s t-
test (p < 0.05) due to SMCSO exposure were detected. 
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5.4.5 Sulforaphane Treatment Did Not Affect the Outcome of Glycolysis 
Stress Testing in PNT1A Cells 
PNT1A cells were treated for 24 hours with either 5µM or 10µM sulforaphane before 
glycolysis stress test assay (Figure 5-10). No statistically significant differences 
were detected at either treatment concentration for either basal glycolysis or forced 
glycolytic capacity (Figure 5-12). This was consistent with ECAR results from 
previous mitochondrial stress tests, which had shown no significant differences 
either before or after oligomycin injection (Figure 5-11). Expansion of the glycolysis 
stress test to other cell lines and treatment applications was not, therefore, 
considered relevant. 
  
 
 
Figure 5-10 Graph of typical glycolysis stress test assay with PNT1A cells after a 24-hour pre-treatment with sulforaphane (SF). Data shown as mean ± SEM at each time 
point. No significant difference seen by unpaired Student’s t-test between treatment conditions at any stage or sulforaphane dose.  
 
Figure 5-11 Graph of ECAR (mpH/min) during Mito Stress Test of PNT1A treated for 24 hours with sulforaphane (SF) (Figure 5-7A). Data shown as mean ± SEM as 
percentage of basal ECAR. No significant differences detected by unpaired Student’s t-test after sulforaphane exposure.
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Figure 5-12 Graphs of glycolytic function expressed as ECAR (mpH/min) in PNT1A cells treated for 
24hours with 5µM or 10µM sulforaphane (SF) before glycolysis stress testing: (A) glycolysis and (B) 
forced glycolytic capacity after oligomycin injection. Data are expressed as mean ± SD. No significant 
differences detected by unpaired Student’s t-test following sulforaphane exposure.  
 
5.4.6 Combined Treatment with Sulforaphane and SMCSO Did Not Protect 
Mitochondrial Metabolism Against Oxidative Stress in PNT1A 
PNT1A cells were treated with a combination of sulforaphane (5µM) and SMCSO 
(200µM) for 24 hours before assay with progressive two-fold higher injections of 
H2O2 (0-1mM). The OCR declined compared to baseline in response to each 
injection of H2O2, with the most significant impact seen above 500µM. The 
interaction of ROS is known to cause inhibition of TCA cycle enzymes, including 
aconitase and α-ketoglutarate dehydrogenase, which accounts for the change in 
OCR [158, 159]. Treatment with sulforaphane and SMCSO for 24 hours did not 
induce a sufficient change in antioxidant defence to protect PNT1A cells against 
these effects (Figure 5-13).
  
 
 
 
 
Figure 5-13 Graph of effect on OCR (% baseline) with increasing concentrations of H2O2. PNT1A cells pre-treated with combination of sulforaphane (5µM) and SMCSO 
(200µM) for 24 hours. Two-fold increases in H2O2 concentration in well after each injection; 125µM (injection 1), 250µM (injection 2), 500µM (injection 3) and 1mM (injection 4). 
Data shown as mean ± SEM percentage of baseline OCR at each time point. No significant differences by unpaired Student’s t-test or protective effects seen after treatment.
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5.4.7 DU145 Cells Had Greater Capacity for Fatty Acid Oxidation than PNT1A  
Blockade of pathways involved in the metabolism of glucose and glutamine 
(UK5099 and BPTES, respectively) increases the dependency of cells on fatty acid 
oxidation. Establishing the level of OCR before and after subsequent blockade of 
fatty acid oxidation with etomoxir reveals the contribution of this pathway to 
oxidative phosphorylation via acetyl CoA production. Fatty acid metabolism, both in 
synthesis and beta oxidation, is known to be upregulated in prostate cancer [30, 
160]. These assays revealed a fatty acid beta oxidation capacity of 44.6% in benign 
PNT1A cells. The cancerous cell line, DU145, had a significantly higher capacity of 
68.4%. However, no effect was seen in either cell line after 24-hour treatment with 
sulforaphane (Figure 5-14).
  
 
Figure 5-14 Graphs of mito fuel flex fatty acid oxidation capacity tests. (A) PNT1A and (B) DU145 were pretreated with sulforaphane for 24 hours before acute injection of 
BPTES+UK5099 (injection 1) and etomoxir (injection 2). Data shown as means ± SEM of third basal OCR (%) measurement. No significant differences detected by unpaired 
student’s t-test due to sulforaphane treatment.
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5.5 Discussion 
The Seahorse Bioanalyser provides a useful tool for studying the interaction 
between dietary components and real-time metabolism in prostate cells. As ATP 
regulation becomes an increasingly popular target for therapeutics, this will also be 
a useful adjunct to the novel LC MS/MS method of ATP quantification (developed in 
Chapter 4) for comparison of in vitro and in vivo outcomes. A major limitation of the 
Seahorse XFp is the limited number of wells in the culture miniplate, which allows 
for comparison of only one treatment concentration and controls in triplicate. 
The significant findings of this chapter are primarily limited to fundamental 
differences between prostate cell lines. Normal PNT1A cells required a seeding 
density more than two-fold higher than both cancerous cell lines (VCaP and DU145) 
to achieve comparable OCR at 48 hours. The results are similar to those of other 
studies defined by OCR, supporting the higher energy turnover of cancerous cells 
[156]. Although growth rate will ultimately influence OCR, this does not account for 
the lower levels in PNT1A; population doubling time for VCaP for example is known 
to be especially slow [161]. During mitochondrial stress testing, VCaP cells were 
found to have a significantly higher spare respiratory capacity than both PNT1A and 
DU145 (p<0.0001) (Figure 5-8). This may be due to either a dose-dependent 
response to FCCP (2.0µM vs 0.5µM), to which VCaP were less susceptible to 
toxicity, or reflect the metabolic adaptations of VCaP as an aggressive, malignant 
and androgen-insensitive cell line [162]. Another metabolic trait of prostate cancer 
cells was confirmed by the differences in fatty acid oxidation capacity between 
PNT1A and DU145 (Figure 5-14). 
Existing research on the biological activity of SMCSO and energy metabolism has 
only been concerned with antidiabetic and hypolipidaemic effects in rats, and not 
specific to the prostate or prostate cancer [163, 164]. The hypothesis of the SAP 
study described in Chapter 4 was that degradation of SMCSO to sulphate was 
depleting ATP as both substrate and energy source for synthesis of PAPS. It was 
therefore unknown whether ATP synthesis would also be affected. The 200µM dose 
of SMCSO was selected according to levels in SAP study urine over 48 hours post 
broccoli consumption, and peaks in the first 24 hours of the Bioavailability of 
Broccoli Soup (BOBS) study undertaken at QIB, but had no significant effect on 
oxidative phosphorylation (Figure 5-9). 
Sulforaphane, among other ITCs, has received more focused research in the 
context of prostate cancer metabolism. A recent, high-throughput study screened 
levels of ATP in a mouse cell line after exposure to naturally-occurring compounds, 
including sulforaphane, known to be efficacious against prostate cancer [85]. 
Treatment with a wide range of sulforaphane doses (0-20µM) did not exert any 
effect on ATP levels. For this reason, no further investigation was carried out in 
samples obtained from the dietary intervention studies described in this thesis. In 
studies with human prostate cancer cell lines (PC3 and DU145), mitochondrial 
dysfunction due to ROS production was only achieved at non-physiological doses of 
sulforaphane (up to 40µM) [143]. Most recently, phenethyl isothiocyanate (PEITC), 
which is also present in broccoli, was shown to induce down-regulation of a range of 
fatty-acid metabolism enzymes and reduce serum ATP levels in the transgenic 
adenocarcinoma of the mouse prostate (TRAMP) model. Physiological 
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concentrations of PEITC (2.5-5µM) were equally effective in an androgen 
dependent human prostate cancer cell line (LnCaP) [165]. A physiologically relevant 
concentration of sulforaphane (5µM) was selected for use throughout the 
experiments carried out using the Seahorse XFp [166]. No effect was seen on any 
of the parameters of oxidative phosphorylation, glycolysis or fatty acid oxidation 
capacity in the cell lines tested. The Nrf-2 regulated induction of anti-oxidant 
defence by sulforaphane will be discussed in greater detail in Chapter 6. In the 
presence of an exogenous source of ROS (H2O2), no protective effects on oxidative 
phosphorylation were seen in PNT1A cells after sulforaphane and SMCSO 
treatments.  
Interestingly, data obtained from investigating broccoli-derived compounds in the in 
vitro models of the human prostate described in this chapter confirmed the findings 
of the broccoli-enriched dietary-intervention study (SAP). The initial global 
metabolomics results from the SAP study detected a significant increase in ADP, 
suggesting reduced tissue levels of ATP (Chapter 3). However, targeted 
quantification by LC-MS/MS later revealed no significant difference in the net ATP 
levels within prostate tissue (Chapter 4). Accordingly, exposure to physiological 
concentrations of sulforaphane and SMCSO during the Seahorse experiments has 
not demonstrated any evidence of a dynamic shift in metabolism in prostate cells.  
Future work with the Seahorse Bioanalyser could extend to a range of higher 
treatment concentrations, ranging from those achievable by diet to those that may 
require purified compound supplements in humans. The bioenergetics of individual 
prostate cell lines can be clearly characterised on the Seahorse platform, so 
ongoing investigation is required to test compounds with the potential to prevent or 
reverse the malignant metabolism of prostate cancer. The observed accumulation of 
SMCSO in the prostate following dietary intervention (Chapter 4) brings into 
question whether it is intact SMCSO or its degradation products that have the 
highest potential to influence metabolism. Testing these compounds either in 
isolation or combination, as they would naturally be delivered in food, will provide 
useful information on their potential effects and dose thresholds. 
 
5.6 Conclusion 
Three human prostate cell lines of both benign and cancerous origin have been 
optimised for analysis on the Seahorse XFp Bioanalyser. Whilst individual cell lines 
demonstrated significant heterogeneity in mitochondrial metabolism, sulforaphane 
(5µM) and SMCSO (200µM) did not disrupt their homeostasis after a 24-hour 
treatment. Further work is required to investigate whether these dietary bioactives 
are able to protect cells from exogenous stressors known to influence cellular 
metabolism. These compounds exert their anti-cancer potential via a number of 
recognised mechanisms, though the effects of combinatorial treatment, rising 
concentrations and degradation to more reactive intermediates on bioenergetics are 
yet to be investigated. 
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6 Effect of Sulforaphane and SMCSO 
on Redox Status of a Key Tumour 
Suppressor Protein in the Prostate 
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Summary 
The PTEN gene is a tumour suppressor responsible for inhibition of the PI3K 
pathway, which drives signalling cascades via AKT, required to promote the rapid 
growth and proliferation of cancerous cells. Although PTEN allelic deletions and 
mutations are common in prostate cancer, PTEN protein is also susceptible to post-
translational modification, such as inactivation by oxidative stress. This chapter 
describes the use of laboratory techniques to quantify both reduced and oxidised 
forms of PTEN following exposure to an exogenous inducer of oxidative stress. To 
investigate potential links between diet-induced, anti-oxidant defence and PTEN 
redox status, the effects of both sulforaphane, a potent inducer of Nrf-2, and 
SMCSO from broccoli were investigated.  
 
6.1 Introduction 
The PTEN gene, also known as MMAC1 (mutated in multiple advanced cancers), is 
an important tumour suppressor that belongs to the family of protein tyrosine 
phosphatases [167]. PTEN acts as the only known inhibitor of the phosphoinositide 
3-kinase (PI3K) pathway, one of the most studied cancer promoting pathways [168]. 
In response to extracellular stimuli such as insulin, growth factors and chemokines, 
PI3Ks are recruited to the membrane by G-protein coupled receptors or activated 
receptor tyrosine kinases (RTKs). Here they catalyse the phosphorylation of 
phosphatidylinositol-4,5 bisphosphate (PIP2) to the active second messenger 
phosphatidylinositol-3,4,5 trisphosphate (PIP3). In cancer it is class IA PI3Ks that 
have the most central role, responding to upregulated growth-factor activation of 
RTKs [169]. The potent lipid phosphatase activity of PTEN antagonises this action 
by dephosphorylating PIP3 to PIP2 [87, 170]. If unregulated, PIP3 recruits a range 
of proteins to the membrane, including AKT and 3-phosphoinositide dependent 
kinase 1 (PDK1). AKT is activated upon phosphorylation by PDK1, influencing 
multiple pathways related to growth, proliferation and apoptosis, including loss of 
downstream inhibition of the mammalian target of rapamycin complex 1 (mTORC1) 
(Figure 6-1) [171].  
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Figure 6-1 The PI3K/AKT signalling pathway and inhibition by PTEN. Abbreviations: GPCR, G-protein 
coupled receptor; RTK, receptor tyrosine kinase; PI3K, phosphoinositide 3-kinase; PIP2, 
phosphatidylinositol-4,5 bisphosphate: PIP3, phosphatidylinositol-3,4,5 trisphosphate; pAKT, 
phosphorylated AKT; TSC1/2, tuberous sclerosis complex 1/2; AMPK, AMP-activated protein kinase; 
mTORC1, mammalian target of rapamycin complex 1.  
 
Abnormalities in the PTEN gene, either as mutations or deletions, occur in both 
prostate adenocarcinoma and the presumed pre-malignant condition known as 
high-grade prostatic intra-epithelial neoplasia (HG-PIN) [10, 172, 173]. Tissue from 
primary human prostate cancer lesions have identified a frequency of bi-allelic 
homozygous deletions occurring in 10-15% and monoallelic deletions in up to 70% 
[88, 89]. However, the reported loss of PTEN activity at the protein level is greater 
than expected from the latter loss of heterozygosity, suggesting other non-genomic 
influences on overall function [174]. The implication of PTEN deletion is an 
association with worse clinical outcomes from prostate cancer; integrated genomics 
analyses of metastatic prostate cancer deposits revealed an incidence of bi-allelic 
deletions up to 45% [173]. Decreasing PTEN protein expression in primary tumours 
is also associated with a higher Gleason score (grade) and stage of tumour at the 
time of diagnosis, and a significant increase in early biochemical (PSA) recurrence 
and progression to metastatic disease after radical prostatectomy [175, 176]. 
As well as other post-transcriptional (mi-RNA) and post-translational 
(phosphorylation and ubiquitination) regulatory mechanisms, PTEN exhibits similar 
sensitivity to oxidative stress as other phosphatases [177]. The formation of 
disulphide bonds between cysteines Cys71 and Cys124 occurs with exposure to 
ROS and renders the PTEN protein inactive (Figure 6-2). This method of oxidation 
of PTEN has been shown in an in vitro model, but it is unclear whether this occurs in 
prostate tissue of men with localised prostate cancer [90]. If demonstrated, it may 
well represent a post-translational mode of modification in prostate carcinogenesis. 
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Figure 6-2 Activity of PTEN protein dependent on reversible redox status. Phase II antioxidants 
function both to detoxify ROS, preventing oxidation of PTEN, and reduce PTEN to its active form. 
 
Research into the negative epidemiological association between cruciferous 
vegetable intake and prostate cancer risk has focused on the effects of dietary ITCs 
and antioxidant defence [178]. Sulforaphane, which is derived from glucoraphanin, 
is the most intensively studied bioactive compound to be delivered by broccoli 
consumption. Sulforaphane exerts its influence on cellular redox status in a dose-
dependent manner, ranging from protective to cytotoxic effects [179]. At low 
(physiological) concentrations, exposure to sulforaphane prevents KEAP-1 
ubiquitination of Nrf-2, increasing its localisation to the nucleus and binding to the 
antioxidant response element (ARE) [180]. Downstream induction occurs for a 
range of genes responsible for phase II detoxification and antioxidant defence [181]. 
However, at higher (pharmacological) concentrations, conjugation with sulforaphane 
depletes stores of the antioxidant glutathione, and direct inhibition of complex III of 
the mitochondrial electron transport chain generates higher levels of ROS [144, 
182]. Increased sensitivity and production of ROS following exposure to 
sulforaphane are thought to induce apoptosis in cancerous cells, while normal cells 
benefit from an increase in Nrf-2-regulated antioxidant defence [145].  
SMCSO, another bioactive compound in broccoli, has also been shown to 
demonstrate antioxidant properties in animal studies by induction of both superoxide 
dismutase and catalase [163]. Although the mechanism for this is less well 
understood, SMCSO protects against pro-carcinogens and readily accumulates in 
human prostate tissue after broccoli consumption (Chapter 4) [183]. 
Considering the key role of dietary agents in preventing cancer development and 
modulation of cellular redox homeostasis, this chapter describes the development of 
highly-sensitive techniques to monitor the redox status of non-cancerous prostate 
cells in response to exogenous factors. The redox status of PTEN protein could 
represent a quantifiable and highly-relevant biological outcome to test the capacity 
for sulforaphane and SMCSO to induce antioxidant defence and protect against 
prostate carcinogenesis. 
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6.2 Aim 
 - To investigate the influence of sulforaphane and SMCSO on the redox 
status of PTEN after H2O2 exposure  
- To investigate the ability of sulforaphane and SMCSO to protect prostate 
cells against H2O2 and generation of ROS 
   
6.3 Methods 
6.3.1 Cell culture 
PNT1A (95012614), a benign epithelial prostate cell line, was purchased from 
ECACC and cultured in RPMI-1640 (Sigma-Aldrich) medium supplemented with 
10% FCS (SigmaÒ) and 1% penicillin/streptomycin (GibcoÒ). Cells were grown as 
an adherent monolayer at 37o C in humidified conditions, supplemented with 5% 
CO2. 
6.3.2 Treatment with Sulforaphane, SMCSO and H2O2 
PNT1A cells were incubated at 70% confluence for 24 hours with an appropriate 
treatment or vehicle control. R, S-Sulforaphane ((4-(methylsulfinyl) butyl 
isothiocyanate) (CAS 4478-93-7) (purity > 98%) was purchased from LKT 
Laboratories (St. Paul, USA) and used in parallel to a DMSO control. SMCSO (CAS 
6858-87-8) (purity >98%) was also purchased from LKT and used in parallel with a 
water control. 
H2O2 was purchased from Sigma (Cat. 16911) and diluted in sterile Milli-QÒ water to 
generate a stock solution of 20mM on the day of use. Prior to protein extraction, 
appropriate concentrations of H2O2 were achieved by dilution in growth medium and 
applied to cells for a 10-minute incubation period. For fluorescence assays, H2O2 
stock solution was diluted in Hank’s balanced salt solution (HBSS) supplemented 
with 10% FCS. 
6.3.3 Protein Extraction and Quantification 
All reagents for protein extraction and subsequent quantification were purchased 
from SigmaÒ. After treatment with H2O2, cells were treated with catalase 1µg/ml and 
washed using ice cold PBS. Cells were then incubated for 5 minutes on ice with 
lysis buffer (20mM Tris pH 7.4, 150mM NaCl, 5% glycerol, 0.1% NP40, 100mM 
phenylmethanesulfonyl fluoride (PMSF), 50mM indole acetic acid (IAA) and 0.1% 
sodium dodecyl sulfate, scraped into Eppendorf tubes with 1µl benzonase added to 
each tube. Samples were sonicated in a cold-water bath for 30 seconds and cell 
debris spun off by centrifugation at 14,000g, 4o C for 10 minutes. The supernatants 
were transferred to new Eppendorf tubes and protein quantification performed by 
bicinchoninic acid (BCA) assay as per manufacturer’s protocol. Fluorescence was 
measured from 96-well plates using a FLUOstar-Optima plate reader (BMG 
technologies) at 565nm. 
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6.3.4 Western Blot for PTEN Redox Status 
The application of western blot analysis to PTEN redox status in PNT1A was a 
continuation of previous method development work carried out by Dr Karen 
Chambers (QIB research scientist). Briefly, protein lysates were run by sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) on 10% Bis-Tris 
gels with NuPAGE® MOPS running buffer (Invitrogen®) under non-reducing 
conditions. Semi-dry transfer of proteins was carried out using the i-Blot 2® system 
and polyvinyl difluoride (PVDF) membrane transfer stacks (Invitrogen®). Membranes 
were initially blocked by 1-hour incubation at room temperature with 5% bovine 
serum albumin (BSA), and incubated overnight in 5% BSA at 4o C with addition of 
primary antibody; anti-PTEN rabbit monoclonal antibody (9188L, Cell Signaling 
Technology) at a concentration of 1:1000. After washing steps, membranes were 
incubated for a further 1 hour at room temperature with secondary antibody in 5% 
BSA; HRP-linked anti-rabbit IgG (7074S, Cell Signalling Technology) at a 
concentration of 1:5000. Following further washing, membranes were developed by 
chemiluminescence with the Clarity™ ECL Western Blotting Substrate kit (Bio-
Rad®) and fluorescence intensity measured using Bio-Rad Fluor-STM Multilmager 
Quantity One software. 
6.3.5 Developing a Highly-Sensitive Quantitative Method for PTEN Redox 
Status 
For the purpose of this study, a novel LC-MS/MS method to quantify the redox 
status of PTEN was under development by Dr Shikha Saha (Senior Analytical 
Scientist, QIB). PTEN peptides were identified with the same Agilent® system 
described in Chapter 3. Samples were injected at 2 µl and eluted at a flow rate of 
0.4 ml/min on an Aeris 1.7 µm Peptide (100 x 2.1mm) XB-C18 column. Separation 
was carried out using 0.1% formic acid in Milli-Q® water (mobile phase A) and 0.1 % 
formic acid in methanol (mobile phase B). The gradient started at 5% mobile phase 
B increasing over 3.9 min to 35% mobile phase B and finally re-equilibrated to 5% 
mobile phase B for 2.4 min. The column temperature was set at 40 ºC. The LC 
eluent flow was sprayed into the mass spectrometer interface without splitting. 
PTEN peptide ions were monitored using mass spectrometry in MRM mode in 
positive polarity with ESI source. The source parameters were: gas temperature 
was 200 ˚C with a gas flow of 16 l/minute; sheath gas temperature was 400 ˚C with 
a sheath gas flow of 11 l/minute; nebuliser pressure was 50 psi and capillary voltage 
was 4000 °C. Identification was achieved based on retention time and product ions. 
The retention time and fragments were determined by comparison with synthetic 
peptide standards, which were made and authenticated by JPT in Germany. The 
Agilent optimiser software was used to obtain fragment ions and collision energy, 
and a fragments calculator was used to verify the fragment ions. 
6.3.6 Quantification of Intra-Cellular Reactive Oxygen Species Levels by 
Fluorescence Assay 
PNT1A cells were seeded into clear-bottom, black, 96-well plates at a density of 25 
x 103 cells per well, and incubated in growth medium for 24 hours. Pre-treatment or 
appropriate controls were subsequently applied for a further 24 hours. After washing 
with PBS, cells were incubated with a 20µM concentration of 2’,7’-dichlorofluorescin 
diacetate (DCFH-DA), a cell-permeant reagent that is oxidised by ROS to 
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fluorescent dichlorofluorescin, for 45 minutes in the dark. Cells were washed and 
incubated in HBSS with 10% FCS throughout the assay detection period. H2O2 was 
added to specific wells as either a positive control or to assess the protective effects 
of pre-treatment with sulforaphane or SMCSO. Fluorescence was measured with a 
FLUO-star Optima plate reader at excitation and emission spectra of 485nm and 
530nm respectively. 
6.3.7 Statistical Analysis 
Analysis of variance (ANOVA) and Bonferroni multiple post-comparison tests were 
used to analyse ROS assay data. 
 
6.4 Results 
6.4.1 Hydrogen Peroxide Caused Oxidation of PTEN in PNT1A Cells 
Western blot and LC-MS/MS analysis were used to confirm the effects on PTEN of 
exposure to extrinsically applied oxidative stress (H2O2) in benign prostate epithelial 
cells (PNT1A). Western blot analysis demonstrated that PTEN protein is maintained 
entirely in its reduced (active) form in PNT1A control cells. However, in the 
presence of H2O2 at concentrations ≥ 250µM there is a separate oxidised band for 
PTEN that becomes increasingly prominent as H2O2 concentration increases 
(Figure 6-3). High-performance LC-MS/MS also confirms that only the reduced 
peptides of PTEN are detectable in control samples, but that oxidised PTEN 
peptides become apparent after H2O2 exposure.  However, the developed LC- 
MS/MS method requires further optimisation due to poor reproducibility. 
 
Figure 6-3  Western blot analysis of PTEN under non-reducing conditions in PNT1A cells treated 
with increasing concentrations of H2O2 for 10 minutes. The oxidised (lower) band is first 
seen at 250µM and increases in proportion to reduced PTEN (upper band) up to 1000µM.  
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6.4.2 Sulforaphane Did Not Protect PTEN Redox Status in PNT1A Against 
Oxidative Stress 
Pre-treating PNT1A cells with physiological concentrations of sulforaphane (0-5µM) 
for 24 hours did not show a protective effect on the redox status of PTEN when 
incubated for 10 minutes with H2O2 (250µM) (Figure 6-4).  
 
Figure 6-4 Western blot analysis of PTEN under non-reducing conditions in PNT1A cells pre-treated 
with sulforaphane (SF, 2-5µM) or DMSO control before 10-minute exposure to H2O2 at the final 
concentration of 250µM. The oxidised (lower) band is present in all cell samples exposed to H2O2 with 
no significant evidence of a protective effect from sulforaphane. 
 
6.4.3 SMCSO Did Not Protect PTEN Redox Status in PNT1A Against 
Oxidative Stress 
Western blot analysis showed that pre-treating PNT1A cells with a range of 
concentrations of SMCSO (0-100µM) for 24 hours did not have a protective effect 
on the redox status of PTEN when incubated for 10 minutes with H2O2 at the final 
concentration of 250µM (Figure 6-5). To further investigate the influence of SMCSO 
on oxidative stress, a separate experimental approach was taken by performing 
fluorescence assays for ROS in PNT1A cells (Figure 6-6). 
 
 
Figure 6-5 Western blot analysis of PTEN under non-reducing conditions for PNT1A cells pre-treated 
with SMCSO (0µM to 100µM) or water control before 10-minute exposure to H2O2 (250µM). The 
oxidised (lower) band is present in all cell samples exposed to H2O2 with no significant evidence of a 
protective effect from SMCSO.  
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6.4.4 SMCSO Exposure Did Not Induce Oxidative Stress in PNT1A  
Exposing PNT1A cells to varying concentrations of SMCSO (0-100µM) did not 
induce any significant change in mitochondrial ROS production as measured by 
DCFH-DA fluorescence assay (Figure 6-6). Results obtained were independently 
confirmed by additional experiments carried out with SMCSO at concentrations as 
high as 3mM, which did not result in significant generation of ROS or impact on cell 
viability (unpublished data from Andrew Jones, masters student). 
 
 
Figure 6-6 ROS levels in PNT1A cells after 24 hour pretreatment with increasing concentrations of 
SMCSO (0-100µM). Data are expressed as means of blank-corrected fluorescence units of 8 biological 
replicates ± SD. 
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6.4.5 Sulforaphane and SMCSO Did Not Reduce Oxidative Stress in H2O2-
treated PNT1A Cells 
Pre-treatment for 24 hours with either sulforaphane (0-5µM) or SMCSO (0-100µM) 
did not significantly reduce the levels of ROS measured by DCFH-DA assay when 
H2O2 (125µM) was applied to PNT1A cells (Figure 6-7). A significant difference (p < 
0.05) in detectable levels of ROS occurred at lower concentrations of H2O2 by 
fluorescence assay than Western blot analysis of PTEN redox status (125µM vs 
250µM). Therefore, the lower concentration was used. 
 
Figure 6-7 ROS level measurements in PNT1A cells after 24-hour pre-treatment with SMCSO (A) or 
sulforaphane (B) and application of H2O2 at start of assay. Data are expressed in blank-corrected 
fluorescence units from 8 technical replicates as means ± SD (*** = p<0.001, by Bonferroni post-test). 
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6.5 Discussion 
6.5.1 Role of Oxidative Stress in Prostate Carcinogenesis 
ROS are generated during normal mitochondrial metabolism and kept in balance by 
detoxification systems targeting their removal. Excessive ROS, termed ‘oxidative 
stress,’ occurs due to either an increase in ROS production or inadequacy of the 
cell’s antioxidant defence [184]. Oxidative stress is associated with tissue injury and 
damage to DNA, as well as interaction with signalling pathways responsible for 
inflammation, proliferation, apoptosis and senescence. These factors have all been 
implicated in the development of cancers [185]. Prostate cancer is further 
susceptible because of the link between ROS and androgen receptor activation; 
higher levels increasing the risk of androgen insensitivity and likelihood of 
metastatic disease [186]. 
The potential for cruciferous vegetables to protect against prostate cancer has been 
largely attributed to their delivery of glucosinolates, which are hydrolysed to 
biologically active ITCs, including sulforaphane [44]. Central to the multimodal 
action of sulforaphane is its potent induction of Nrf-2 regulated antioxidant genes, 
protecting cells against oxidative stress [41]. Reduced levels of Nrf-2 and 
downstream genes are common findings in both human prostate cancer specimens 
and TRAMP mice [187, 188]. The latter is reversed in vivo by supplementation with 
sulforaphane [189]. The unique sulphur metabolism of cruciferous vegetables 
extends beyond glucosinolate content to other specialised compounds, such as 
SMCSO, which may also play a role in promoting antioxidant defence. However, the 
bioactivity of SMCSO, especially in terms of antioxidant potential, has not been 
demonstrated yet. Data obtained from the in vitro work described in this chapter 
clearly indicates that both sulforaphane and SMCSO do not perturb ROS production 
in normal PNT1A cells. Further work is needed to determine their effects in 
cancerous cells that are characterised by higher ROS levels.  
6.5.2 Monitoring PTEN activity By Measuring Its Oxidation 
As expected, western blot analysis detected a progressive rise in oxidised PTEN in 
PNT1A cells treated for 10 minutes with increasing concentrations of H2O2. The 
increase in oxidised PTEN corresponded to a reduction in PTEN protein that was 
reduced (Figure 6-3). This is consistent with findings of PTEN redox status reported 
in a range of cell types, which correspond to loss of PI3K pathway inhibition and an 
increase in downstream pAKT [90, 190]. Further work is needed to optimise the LC-
MS/MS method described in this chapter in order to achieve an accurate 
quantification of both reduced and oxidised peptides. The use of a validated LC-
MS/MS method will help to improve the sensitivity of analysing biological samples 
collected from in vivo studies, such as small-volume prostate biopsy cores. 
6.5.3 Effect of Sulforaphane and SMCSO on PTEN Response to Exogenous 
Oxidative Stress 
As Lee et al. have previously shown, the inactivation of PTEN by ROS is reversible 
in vitro, predominantly by upregulation of thioredoxin, but also by other Nrf-2 
regulated antioxidant genes, including glutathione and glutaredoxin [90]. Traka and 
colleagues have also demonstrated that treatment with sulforaphane ameliorated 
the effects of PTEN deficiency in a prostate-specific PTEN deletion mouse model by 
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modulating gene expression and alternative splice events [191]. Interestingly, the 
gene changes significantly correlated with changes seen in human prostate tissue 
after consumption of both high-broccoli and pea-rich diets, suggesting that 
additional dietary components within these vegetables may influence cancer risk via 
the PTEN/PI3K pathway [49]. 
To test the hypothesis that either sulforaphane or SMCSO would independently 
protect PNT1A cells from oxidative stress, they were each applied to cultured cells 
for 24 hours. H2O2 was applied at a concentration of 250µM for 10 minutes; the 
minimum level that gave a reproducible oxidised band for PTEN on detection by 
Western blot analysis. Neither the use of sulforaphane nor SMCSO at physiological 
concentrations conferred a protective effect on PTEN redox status. This may be 
related to the use of PNT1A, a non-cancerous prostate cell line, which inherently 
generates lower levels of ROS than cancerous cell lines [192]. The highest levels of 
ROS are generated by prostate cancer cells with the most aggressive phenotype, a 
characteristic that is often shared with PTEN genomic deletions [193]. The 
concentration of H2O2 used was also above the physiological range for normal 
human tissues, which are typically up to 30µM in circulating plasma and 117µM in 
urine [194]. Any potential change to antioxidant defence may, therefore, have been 
insufficient to remove the high-dose exogenous H2O2.  
6.5.4 Effect of Sulforaphane and SMCSO in Removing ROS from PNT1A 
Cells 
To test the hypothesis that sulforaphane and SMCSO would induce an antioxidant 
response capable of removing exogenous H2O2 via an alternative experimental 
approach, ROS fluorescence assays were performed. As previously described, 
sulforaphane exposure has the potential to increase mitochondrial ROS production 
at high concentrations [143, 195]. SMCSO was applied at a range of concentrations 
to PNT1A cells to investigate whether shared biological activity could be 
established. No significant change in ROS was detected when compared to control 
cells, providing in vitro evidence that levels of SMCSO detected in the urine of SAP 
study volunteers would not perturb the homeostasis of benign prostate cells 
(Chapter 4). 
A lower concentration of H2O2 (125µM) was used for fluorescence analysis, which 
still gave a strongly significant rise in detectable ROS compared to negative controls 
(p<0.001). After 24-hour pre-treatment with either sulforaphane or SMCSO, no 
difference was seen in the levels of ROS in H2O2-treated PNT1A cells. This 
confirms that the benign PNT1A cells’ response to exogenous H2O2 is unchanged in 
terms of both ROS detoxification and the redox status of PTEN protein following 
sulforaphane/SMCSO exposure.  
6.5.5 Exogenous Versus Endogenous ROS Production 
A limitation of using exogenous H2O2 in cultured cells is that it is unlikely to replicate 
the endogenous ROS generated in the in vivo prostate microenvironment [196, 
197]. Future work will rely on the development of a more sensitive analytical 
technique (LC-MS/MS) to detect low levels of PTEN oxidation in prostate tissue. 
Samples taken following dietary intervention, including those from SAP study 
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(Chapter 2), could subsequently provide useful information on redox status after a 
broccoli-enriched diet. 
 
6.6 Conclusion 
This chapter has explored a multi-disciplinary approach with three laboratory-based 
techniques for measuring redox status in response to pro- and anti-oxidant agents 
in an in vitro model of the human prostate. Despite the reported antioxidant effects 
of sulforaphane and SMCSO, a direct biological mechanism could not be 
established for prostate cancer prevention by protection of reduced (active) PTEN 
protein against oxidative stress. Future work should combine: (i) the use of a wider 
range of treatment conditions with normal and cancerous prostate cell lines; and (ii) 
the analysis of tissue samples with a more sensitive, quantitative analytical method. 
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7 General Discussion 
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7.1 General Discussion 
The work conducted within this thesis has made a significant contribution to the 
current knowledge in the field of cancer and nutrition by providing further insight into 
the biological activity of broccoli-derived metabolites and their mechanistic links to 
prostate cancer prevention. As the fifth most common cause of cancer-related death 
in men worldwide, prostate cancer remains a global health concern [8]. Incidence 
rates continue to rise, prompting the need for therapeutic strategies with low toxicity 
to intercept the development of prostate cancer. The increasing role of active 
surveillance in managing men diagnosed with low-risk prostate cancer also creates 
an opportunity for lifestyle intervention to reduce the risk of progression to more 
aggressive disease [198].  
The World Cancer Research Fund estimates that 20% of all cancers diagnosed in 
the US could be prevented with modifications to lifestyle. Not including exposure to 
tobacco smoke, these measures include weight loss, increasing physical activity 
and a diet rich in fruit and vegetables [199]. Studying the biological activity of dietary 
components has led to the identification of a long list of candidate compounds with 
protective properties against prostate cancer [200-202]. In vitro and in vivo animal 
models of prostate cancer have confirmed the beneficial effects of phytochemicals 
with a broad spectrum of activity across multiple metabolic and signalling pathways. 
However, the use of isolated compounds in clinical trials against prostate cancer 
has not yet yielded a preventive or therapeutic benefit. The largest trial to date, 
known as Selenium and Vitamin E Cancer Prevention Trial (SELECT), recruited 
over 35,000 healthy men and randomised them to placebo or supplementation with 
individual or combined treatments. No effect on cancer prevention was detected and 
the trial was stopped due to non-significant increases in both prostate cancer and 
type II diabetes incidence in the vitamin E group [203]. 
Observational studies strongly support the cancer-preventive effects of regular 
consumption of cruciferous vegetables [40]. However, their protective effects 
against multiple cancers, including prostate, may not be isolated to the biological 
activity of ITCs (Figure 1-5). At QIB, preliminary analyses of broccoli-enriched, 
dietary-intervention studies have shown fundamental changes in prostate 
metabolism (unpublished data). The use of balanced food products and a 
comprehensive approach to studying metabolic outcomes provides a framework to 
identify both sources of biological activity and mechanisms of action relevant to 
cancer prevention.  
This chapter discusses the novel findings obtained from the in vivo and in vitro work 
performed to meet the objectives of this thesis as follows: 
- Carry out a randomised, parallel-unblinded, high-dose broccoli 
intervention study in men awaiting TPB 
 
- Investigate untargeted global metabolomic differences in tissue samples 
of men enrolled in a high-dose broccoli intervention study  
 
- Develop and apply targeted analytical methods to quantify sulphate, ATP 
and SMCSO in human samples 
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- Investigate the effects of sulforaphane and SMCSO on real-time 
bioenergetics in prostate cell lines 
 
- Test the effects of sulforaphane and SMCSO in protecting the PTEN 
tumour suppressor against oxidative stress. 
7.2 The Window-of-Opportunity Study Design for Dietary Intervention 
The SAP study was conducted in compliance with local and national regulatory 
policies, including registration with a publicly-available database as required by the 
HRA to promote transparency in health research. QIB acted as study sponsor and 
full ethical approval was received just three months after first registration of the 
project on the Integrated Research Application System (IRAS), allowing recruitment 
to begin immediately after receipt of NHS permission.  
Unlike the ESCAPE study, SAP recruited participants who were on a clinical 
pathway for investigation of suspected prostate cancer, rather than following a 
confirmed diagnosis. The waiting list for TPB provided an ideal opportunity for a 
short-term, high-dose intervention. Thus, additional experimental evidence was 
sought for the biological effects of consuming a single broccoli soup each week for 
12 months during the  ESCAPE study. The high demand for TPB at NNUH 
generated a large potential study cohort (23 patients/month during the study), which 
was required to meet the inclusion criteria and recruitment targets. Recruitment was 
highly successful, reflecting both the enthusiasm of the study team and the 
willingness of patients to participate in the research. Recruitment to dietary 
intervention studies is often challenging, reflecting the long-term commitment 
required by participants [204, 205]. The short intervention and negligible risk of 
toxicity from the diet were factors contributing to the participant uptake in the SAP 
study. These observations will be extremely helpful for future dietary-intervention 
studies, highlighting the pre-biopsy window-of-opportunity trial as an optimal study 
design for addressing specific research questions in the field of food and health.  
Block randomisation was chosen to ensure an equal distribution of recruited 
patients to the study arms and to initiate intervention in a time-effective manner. 
Covariates such as GSTM1 genotype, cruciferous vegetable intake and histology 
were assessed during the study, so their effects on metabolism were accounted for 
later by multi-linear regression analysis [206]. The distribution of participants 
between study arms was equivalent by all baseline parameters assessed, allowing 
comparison of similarly heterogenous groups. 
 
The main limitations of the study were the potential for unaccounted differences in 
baseline prostate metabolism between individuals, and lack of paired samples. 
Window-of-opportunity studies in breast cancer overcome this problem by recruiting 
women with a confirmed cancer diagnosis, performing a study-specific biopsy to 
obtain tissue before intervention and then analysing the resected tumour specimen 
following curative surgery [97, 207, 208]. Aside from the risks of complication from 
additional biopsies, a potential hazard of the window-of-opportunity design is that it 
could cause a delay to treatment. The intervention is, therefore, often made over 
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just 2 weeks [209]. In the SAP study, the aim was to further investigate the effects 
observed by consuming a broccoli-enriched diet for 12 months during the ESCAPE 
study, so a longer intervention period (≥ 4 weeks) was required. The risk of 
complications from additional prostate biopsies, especially infection, if not clinically 
necessary is an important consideration from both ethical and recruitment 
perspectives [210]. The impact of ischaemia time from different methods of tissue 
collection would have also had direct implications on levels of labile metabolites 
such as ATP, an outcome measure of the SAP study. However, the results of the 
SAP study will be complemented by those obtained after completion of the ESCAPE 
study, which offers TPB before and after 12 months, providing both samples for 
research and thorough histological assessment of participants’ prostate cancer 
status as part of active surveillance.  
7.3 Metabolomics to Study Dietary Effects on Prostate Metabolism 
The application of global metabolomics to the study of prostate and prostate cancer 
metabolism has increased our understanding of the relationships between diet and 
numerous metabolic pathways [113, 211]. Analysis of SAP study samples by 
Metabolon® allowed not only comparison of metabolic differences between study 
groups, but comparison of different tissue types and body fluids (Chapter 3).  
The extensive list of metabolites reported by Metabolon® in the biological samples 
(Table 3-1) were ranked by p-value from unpaired t-tests between study arms 
(Table 3-3). Relevant to the aims of the study were higher levels of SMCSO in urine 
and ADP in the prostates of men in the intervention arm, which both required further 
investigation. Multiple correction analysis determined that none of the individual 
metabolites reached overall statistical significance (p<0.05). However, this approach 
assumes that the metabolites are independent variables, which explains the need 
for statistical methods capable of integrating individual metabolite levels into 
established pathways [212, 213]. 
The main findings from the pathway analyses of men in the SAP study were 
significant differences between study arms in both caffeine metabolism and steroid 
hormone biosynthesis in the prostate (Figure 3-5). Metabolites in both pathways 
were lower in the intervention group, suggesting either differences between baseline 
characteristics in both groups, or an increased capacity for androgen and caffeine 
detoxification with the study diet [119, 120]. Differences in caffeine metabolism were 
probably caused by higher coffee intake in the non-intervention group, as levels of 
other coffee metabolites (trigonelline and quinate) were also higher and their 
metabolism is unrelated to the caffeine pathway. Steroid hormone levels have little 
evidence of a relationship with constituents of the study diet. A single mouse study 
found induction of 3α hydroxysteroid dehydrogenases and reduced circulating levels 
of dihydrotestosterone with a high-dose sulforaphane diet (10mg/kg body weight), 
and there is some limited evidence of in vitro interaction between sulforaphane and 
the androgen receptor [214, 215]. Alternatively, caffeine may induce an increase in 
androgenic hormones by stimulation of the stress hormone cortisol [114, 115]. In the 
SAP study samples, however, there was no difference in cortisol levels between 
intervention groups. This could reflect either equivalence between groups or 
especially high levels in all participants on the study day due to the stress response 
to surgery [216]. 
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Comparing profiles of urine, prostate and adipose tissue revealed similar differences 
between groups in dietary metabolites trigonelline, quinate and tryptophan betaine 
(Figure 3-2). As differences in coffee metabolite levels and the caffeine metabolism 
pathway were marked by greater statistical significance in prostate than adipose, 
the results do not preclude a role for urinary reflux as a route of metabolite exposure 
[35]. These metabolites have clearly been widely distributed throughout the body by 
systemic circulation, as evidenced by their presence in adipose tissue. Whether 
subsequent glomerular filtration and excretion into urine delivers the metabolites to 
the prostate for a second time via urinary reflux remains a distinct possibility, and 
could explain the greater impact of diet on metabolism in the prostate. 
7.4 Characterisation of Sulphate, ATP and SMCSO Levels in In Vivo and Ex 
Vivo models 
Targeted quantification of specific metabolites was achieved by optimisation of 
extraction techniques and parameters for high-performance LC-MS/MS. There was 
some discordance between the results of tissue analysis by Metabolon® and 
targeted analysis at QIB for both sulphate and ADP. Although the individual results 
did not correlate (Figure 4-6), the conclusion was the same for comparison of tissue 
levels of sulphate between SAP study intervention arms; no significant difference 
occurred due to the study diet (Figure 4-4). However, four individuals in the 
intervention group had sulphate levels that appeared distinctly higher than other 
participants in the group. Variation in dietary intake of sulphate from other sources 
may have caused a potential difference in levels, as could differences in sulphate 
metabolism locally in the prostate and by sulphate-reducing bacteria within the gut 
microbiota [217].  
The method developed for quantification of ATP, ADP and AMP was validated 
against the known effects of ischaemia on cellular energy balance (Figure 4-10) 
[218]. The highly-sensitive analytical technique was then applied to examine the 
effects of the SAP study intervention on net energy metabolism. Ischaemic time 
may also explain the difference in energy status suggested by ADP levels 
determined by Metabolon® and the QIB analysis. The latter technique included 
meticulous tissue extraction at cold temperatures (≤ 4o C) to prevent 
dephosphorylation of ATP, whereas tissue for Metabolon® was incubated at room 
temperature for 24 hours and subsequently dried down. Ultimately, the significant 
difference in ADP levels detected by global metabolomics analysis did not represent 
an overall change in net levels of ATP after independent quantification at QIB. 
Further information on dynamic energy metabolism was sought with in vitro studies 
on the Seahorse Bioanalyser. 
SMCSO was detected in the urine, prostate and adipose tissue samples from the 
SAP study participants. It was the most significant metabolite difference between 
study arms in the Metabolon® analysis of urine (p = 0.004), strongly correlated with 
independent LC-MS/MS analysis, and accumulated significantly in prostate tissue 
after just 4 weeks of dietary intervention (p < 0.01). Interestingly, the levels of 
SMCSO were two to three-fold higher in adipose than in prostate tissue (Figure 4-
9). Accumulation in adipose is a common route for redistribution of lipophilic drugs 
[219]. However, SMCSO is water soluble and highly hydrophilic, which means 
accumulation in adipose would be dependent on alternative methods of uptake 
   Chapter 7 
114 
 
[220]. The lower levels in the prostate could be attributable to lower SMCSO binding 
capacity of the tissue, diffusion into seminal fluid or urine, or greater localised 
metabolism of SMCSO. Currently, there is no evidence to explain the metabolic fate 
of SMCSO within the prostate gland. However, if SMCSO is metabolised locally, the 
potential biological activity of its degradation products may be exerted directly within 
the prostate. Further investigation is required to gain new insights into SMCSO 
metabolism, not only at the systemic level, but also in target organs. This is of 
particular interest as none of the ITCs quantified in the SAP study were detectable 
in prostate or adipose tissue. 
7.5 Real-time Prostate Bioenergetics in Response to Sulforaphane and 
SMCSO 
The changes that occur to mitochondrial function in prostate cancer are designed to 
direct metabolism towards production of both energy (ATP) and the building blocks 
for cell growth and proliferation [22, 29, 30]. Comparing the dynamic oxygen 
consumption rates of human cancerous prostate cell lines (DU145 and VCaP) with 
normal PNT1A on the Seahorse XFp Bioanalyser confirmed some of these 
characteristics. The basal metabolic rate was higher in the cancerous cell lines, 
VCaP had significantly higher spare respiratory capacity than both DU145 and 
PNT1A, and DU145 had a significantly higher capacity for fatty acid beta oxidation 
than PNT1A (Figure 5-8 and Figure 5-14 respectively).  
Diet-derived phytochemicals have previously been shown to reduce levels of ATP in 
both in vitro and in vivo models of prostate cancer [85]. There is also experimental 
evidence potentially linking the biological activity of sulforaphane to both 
maintenance and disruption of ATP production, which is again likely to be dose-
dependent. Oxidative stress may inhibit the activity of rate-limiting enzymes in the 
TCA cycle and mobile electron carriers in the mitochondrial ETC [158]. By inducing 
Nrf-2-regulated anti-oxidant defence, sulforaphane has the capacity to counteract 
these effects and preserve ATP production [147]. Increased levels of NADH have 
been reported after exposure to sulforaphane at physiological concentrations (4 
µM), signalling effective reduction of NAD+ by the TCA cycle [221]. A trend towards 
higher levels of NADH was also seen in the intervention arm of the SAP study 
(Table 3-3), though this did not reach statistical significance (p = 0.056). In some 
cell lines, sulforaphane can also exhibit properties similar to antimycin A, an inhibitor 
of complex III in the ETC [144, 145]. Combining an increase in TCA cycle function 
with inhibition of oxidative phosphorylation could result in higher levels of NADH. 
Degradation of SMCSO to dimethyl disulphide may also contribute to these effects 
by further inhibition of the ETC [222].  
Under the experimental conditions described in chapter 5, no changes to 
mitochondrial or glycolytic function were demonstrated in prostate cells after 24-
hour exposure to either sulforaphane (5 µM) or SMCSO (200 µM). These findings 
were consistent with those of net ATP, ADP and AMP levels in human prostate 
samples collected for the SAP study. To elicit the potential biological activity of 
sulforaphane and SMCSO on prostate energy metabolism, a wider range of 
treatment concentrations will need to be applied. Experimental evidence of SMCSO 
degradation in the prostate will also be required to establish the presence of its 
metabolic intermediates and their potential bioactivity. 
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7.6 The Capacity for Sulforaphane and SMCSO to Preserve PTEN Function 
by Induction of Antioxidant Defence 
Clinical studies support the link between prostate cancer and increasing levels of 
oxidative stress [184, 223]. ROS production is not only sensitive to androgenic 
stimulation, resulting in increased levels within prostate tissue, but also interacts 
with the androgen receptor [224]. Among the numerous damaging effects of ROS to 
cells, many of which are associated with cancer promotion, is development of 
androgen insensitivity and progression to lethal prostate cancer [225, 226]. 
Reversible inactivation of proteins, such as the tumour suppressor PTEN, by 
oxidative stress could lead to uncontrolled growth and proliferation, as well as 
increasing the production of ROS [87, 90]. 
The effects of exogenously applied ROS were investigated separately by Western 
blot for PTEN redox status and by DCFH-DA fluorescence assay for ROS 
production in normal PNT1A cells. H2O2 applied for 10 minutes was sufficient to 
oxidise PTEN and to cause a detectable increase in fluorescence for ROS. The 
capacity for sulforaphane to alleviate these effects by induction of phase II 
detoxification enzymes and antioxidant defence was therefore tested by both 
experimental techniques [227]. SMCSO was also evaluated to see if there was any 
impact on redox status, either by independent generation of ROS or induction of 
antioxidant defence. However, under the treatment conditions described in chapter 
6, no significant protective effects were detected from either compound. The 
application of lower, more physiological concentrations of exogenous ROS (H2O2) 
and analytical techniques (LC-MS/MS) with greater sensitivity will be required for 
future analysis with a wider range of treatment concentrations, cell lines and ex vivo 
tissue. 
 
7.7 Conclusions and Future Work 
The SAP study proved the success of recruiting to a short-term dietary-intervention 
study in the waiting list period for TPB. The study design will, therefore, be 
applicable to future clinical trials undertaken at QIB as we continue to investigate 
the relationship between diet and prostate biology.  
The SAP study revealed a significant accumulation of SMCSO in those receiving 
the broccoli-enriched diet, which was consistent across both global and targeted 
analytical methods of quantification. Not only is SMCSO abundant in cruciferous 
vegetables, but it is also a secondary metabolite of other plant species. This study 
provides the first evidence of tissue distribution of a dietary sulphur-containing 
compound from both Alliaceae and Cruciferae families in humans. The detectable 
presence of this putative anti-cancer metabolite in both adipose and prostate tissue 
may help to further unravel the health-beneficial effects of cruciferous vegetables. 
Consumption of phytochemicals, such as sulforaphane and SMCSO, in 
combination, as they would normally be consumed in the diet, may also confer 
synergistic biological effects.  
In the in vitro models of prostate metabolism described in this thesis, the biological 
activity of sulphur-containing compounds from broccoli has not been linked to either 
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restriction of ATP production or regulation of PTEN redox status. There is, however, 
still further information to be derived from the next-generation RNA sequencing of 
prostate tissue samples from the SAP study. Post-translational differences between 
study arms may guide future work to focus on specific downstream biological 
outcomes. 
Another important area for future work will be to investigate the tissue-specific 
metabolism of SMCSO to its intermediate products (Figure 1-5). To date, extensive 
research has been carried out on ITCs from cruciferous vegetables, which were not 
detectable in prostate tissue in the SAP study. However, mechanisms of action for 
SMCSO are relatively poorly understood and the majority of biological activity is 
reported from its breakdown products [57]. Potential routes of metabolism include 
both thermal degradation and enzymatic breakdown by cysteine lyase. Although 
cysteine lyase activity has not previously been confirmed in the prostate, it could 
either be present endogenously or relate to the bacterial composition of the prostate 
microbiome, for which there is emerging evidence [228, 229]. Thus, specific 
bacterial isolates may affect prostate cancer risk by their interaction with local 
metabolites. Investigating the metabolic fate of SMCSO in prostate tissue could 
support future clinical and laboratory-based research to elicit its potential role in 
prostate cancer prevention. 
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Executive	Summary	
Abstract	
Epidemiological studies provide evidence for a negative association between prostate 
cancer and intake of cruciferous vegetables such as broccoli. Preliminary data from 
on-going intervention trials carried out at the Institute of Food Research suggest that 
diets rich in broccoli can directly influence the metabolic profile of prostate tissue. The 
most significant result observed to date is sulphate accumulation within the prostate. 
The additional sulphate is likely to drive synthesis of 3'-phosphoadenosine-5'-
phosphosulfate, a universal sulphate donor, a process which would consume energy 
from adenosine triphosphate (ATP) and increase adenosine diphosphate (ADP) 
levels. A significant rise in levels of both ADP and phosphate has also been observed 
in prostate tissue from these studies, supporting the potential depletion of cellular 
ATP. Interestingly, our data indicate that the extent of ADP accumulation is negatively 
correlated with prostate cancer progression.  
We now propose to undertake a two arm parallel un-blinded study to test the 
hypothesis that a short-term intervention with an enhanced dose of broccoli soups 
will lead to the accumulation of sulphate and ADP in prostate tissue. We also plan to 
investigate whether these metabolic differences can influence the redox status and 
the activity of specific genes involved in tumour suppression, such as PTEN. 
Furthermore, we aim to determine whether the accumulation of sulphate and ADP is 
specific to the prostate gland through the metabolic analyses of both prostate and 
non-prostate tissues.  
The study will recruit men who have been diagnosed or are under investigation for 
prostate cancer and require a transperineal template biopsy as part of their standard 
clinical care. The proposed study does not require the participants to have any 
additional clinical procedures except that during routine sampling separate tissue 
cores will be taken from the prostate and adjacent adipose tissue. Participants in one 
arm will consume three portions of broccoli and stilton soup per week for at least four 
weeks prior to their transperineal template biopsy, whereas participants randomised 
to the other arm will not have any diet intervention prior to biopsy. The intervention 
will be carried out while the patients are awaiting their operation date, with no delay 
to their clinical care or investigations. Participants in both arms will consent for tissue 
biopsies (prostate and adipose tissues), blood and urine samples to be taken for 
analysis. 
 
Primary	Aim	
a) To determine whether a broccoli intervention (≥ 4 weeks) will result in a 
difference in tissue sulphate levels in men scheduled for prostate biopsies. 
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Secondary	aims	
a) To determine whether a broccoli intervention (≥ 4 weeks) will result in a 
difference in tissue ADP levels. 
 
b) To determine whether a broccoli intervention (≥ 4 weeks) will affect redox 
status of phosphatase proteins such as PTEN in prostate tissue. 
 
c) To determine whether the diet-induced differences observed in tissue are 
specific to the prostate gland. 
 
d) To determine whether the diet-induced differences observed in tissue are 
correlated with differences in urine. 
 
e) To determine whether the metabolite differences induced by diet are 
modulated by glutathione S-transferase Mu 1 (GSTM1) genotype or other 
relevant genotypes.  
 
Study	population	
This study will recruit men (n=18) aged 18-80 years with a BMI between 19.5 and 35 
kg/m2 with a referral for transperineal template biopsy at the Norfolk and Norwich 
University Hospital (NNUH). 
 
Outline	of	study	design	
The study outline is presented in Figure 0-1. Patients recruited onto this study will be 
randomly allocated to one of two arms in which they will be required to consume three 
portions of broccoli and stilton soup per week for at least four weeks prior to their 
biopsy (i) or to follow their normal diet until the operation date (ii). The broccoli and 
stilton soups will contain glucoraphanin-enriched broccoli named Beneforte®. The 
study will not be blinded and will involve tissue, blood and urine collection on the same 
day that patients are scheduled for their diagnostic biopsy at the NNUH. Their habitual 
intake of cruciferous vegetables and dietary supplements will be assessed. 
Annex 1 – SAP Study Protocol 
121 
 
 
 
Figure 0-1. Study outline 
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1 Scientific background 
1.1 Bioactives from cruciferous vegetables and prostate 
cancer 
Prostate cancer is the most common form of cancer in men, accounting for over 25% 
of all new male cancer diagnoses [230]. The aetiology of prostate cancer is not 
understood. Frequently, several apparently independent cancer foci occur within the 
prostate. This multifocal nature implies an important ‘field effect’ in which changes in 
the gene expression and metabolism of apparently healthy tissue may facilitate the 
emergence and proliferation of cancerous clones [10]. Diet may be able to modify the 
metabolism of the prostate and inhibit the emergence of new cancer clones as well 
preventing the proliferation of existing clones, possibly resulting in their elimination.  
Meta-analysis of case-control and prospective epidemiological studies provide 
evidence for a negative association between prostate cancer and intake of cruciferous 
vegetables such as broccoli [40]. This association is consistent with experimental 
studies with cell and animal models that provide evidence that the active compounds 
within these vegetables may be degradation products of glucosinolates, although 
other bioactive compounds within these vegetables may also be of importance [231].  
We have recently obtained evidence of changes in the metabolite profile of prostate 
tissue due to a 12-month dietary intervention with a broccoli soup as part of the 
ESCAPE study (REC 13/EE/0110; NCT01950143). We found that the dietary 
intervention resulted in metabolic changes in non-cancerous prostate tissue, the most 
significant of which was an accumulation of sulphate. The impact of this change in 
metabolism requires further investigation but increasing levels of sulphate are likely 
to drive the production of 3'-phosphoadenosine-5'-phosphosulfate, a universal 
sulphate donor. Utilisation of cellular ATP in this process would correspond to an 
increase in its products ADP and phosphate, which also increased in participants of 
the ESCAPE study (Figure 0-2). Furthermore, the extent of ADP accumulation was 
negatively correlated with cancer progression (Figure 0-3).   
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Figure 0-2. Accumulation of sulphate and ADP in prostate tissue of men on 
active surveillance following a 12-month dietary intervention with broccoli and 
stilton soups 
 
Figure 0-3. Scatter diagram of changes in ADP concentrations with changes 
in extent of prostate cancer in men who consumed broccoli and stilton soups 
for 12-months 
 
In an associated study (REC 14/EE/1121; NCT02300324), we have shown that 
consuming the broccoli and stilton soup results in urinary excretion of the broccoli-
derived, sulphur-containing metabolites glucoraphanin and S-methyl cysteine 
sulfoxide. It is possible that the accumulation of sulphate in the prostate is a result of 
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urinary reflux of these sulphur-containing metabolites directly into the prostate where 
they are metabolised to sulphate [123, 232]. This metabolism depletes the tissue of 
ATP, leading to the observed increase in ADP and phosphate. The result is death of 
cancer clones, which are more sensitive to ATP depletion than normal tissues, as 
they cannot adjust their metabolism [233]. 
These preliminary results provide, for the first time, a mechanistic basis for the 
association between reduction in prostate cancer progression and a diet rich in 
cruciferous vegetables in men, and reveal biological processes that have not been 
apparent from rodent studies. Moreover, while ATP depletion has been theoretically 
proposed as a therapeutic approach to kill cancer clones [234], it is the first time that 
ATP depletion has been shown to be induced through either diet or drug intervention 
in human tissues containing cancerous clones, and represents a promising approach 
to reduce or prevent the progression of prostate cancer.  
 
We propose to undertake a human intervention study to extend these 
preliminary findings by exploring whether a short-term intervention with a 
higher consumption of broccoli will induce accumulation of sulphate and ADP 
in prostate tissue. This would provide further information concerning how it 
may be possible to deplete prostate tissue of ATP as a means to reduce risk of 
cancer progression.  
 
1.2 Redox status of an oncogenic protein phosphatase 
(PTEN) in prostate cancer 
The importance of a phosphatase and tensin homologue known as PTEN in prostate 
cancer progression is now well established. PTEN is a tumour suppressor gene that 
inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, which would otherwise 
promote cell growth and proliferation [87]. It exists as two alleles that are subject to 
mutation or deletion in prostate cancer, corresponding to worse prognosis in terms of 
disease recurrence and progression after treatment [88, 89]. However, the activity of 
expressed PTEN protein is further reduced if it is exposed to oxidative stress in which 
a disulphide bond forms between Cys71 and Cys124, rendering the protein inactive 
(Figure 0-4) [90]. 
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Preliminary analysis carried out in prostate tissue collected from men with early 
prostate cancer before and after a 12-month broccoli-rich diet (ESCAPE study) has 
shown changes in glutathione metabolites in addition to sulphate and ADP 
accumulation described in section 1.1. Changes in glutathione metabolism within 
the prostate tissue could be indicative of modification of tissue redox status. This 
may have consequences on the redox status of proteins that have important 
regulatory roles in metabolism, such as PTEN. The change in glutathione 
metabolism observed in the biopsies from the ESCAPE study may suggest that 
PTEN is maintained in a largely reduced and therefore active state.  
 
Figure 0-4. PTEN activity as result of its redox status 
 
Thus, a secondary endpoint of the proposed study will be to determine the 
effect of the dietary intervention on the redox status of PTEN in prostate 
tissue. 
 
1.3 Diagnostic prostate biopsy as an opportunity for a short 
dietary intervention 
Conventional trans-rectal ultrasound scan (TRUS) and prostate biopsy is indicated 
for investigation of men with a raised prostate-specific antigen (PSA) level and/or 
digital rectal examination (DRE) suspicious for prostate cancer. Current guidelines 
from the National Institute of Clinical Excellence (NICE) recommend the use of 
transperineal template biopsies (TPB) of the prostate for those patients in whom 
cancer is still suspected but who have had a negative or inconclusive TRUS biopsy 
[235, 236]. It is also considered in men on active surveillance, to map the prostate 
prior to focal therapy or as an adjunct to novel imaging modalities.  
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The Norfolk and Norwich Hospital (NNUH) is a tertiary referral centre for 
prostate cancer, and template biopsies are regularly performed under general 
anaesthetic. We propose to undertake a pre-biopsy, window-of-opportunity 
dietary intervention study in men who have decided in clinic to proceed to 
template prostate biopsy. This trial differs from standard window-of-
opportunity (phase 0) trials because it will be carried out before a diagnostic 
procedure rather than surgery. The study design will also avoid any delay in 
the patients receiving their investigation for a potential prostate cancer. A 
similar trial design has been recently published by Atwell and colleagues in 
Cancer Prevention Research [237].  
 
2. Hypothesis, primary and secondary aims 
 
2.1 Hypothesis 
In men awaiting a routine template biopsy of the prostate, a broccoli intervention will 
lead to a higher sulphate concentration within the prostate compared to a non-
intervention control. 
 
2.2 Primary aim 
To determine whether a diet rich in broccoli will result in a difference in sulphate levels 
in tissue samples obtained from men scheduled for prostate biopsy. 
 
 
 
2.3 Secondary aims 
• To determine whether a diet rich in broccoli will result in metabolic differences 
such as increased ADP levels in prostate tissue of men scheduled for prostate biopsy. 
 
• To determine whether differences in sulphate and ADP levels induced by diet 
are specific to prostate tissue. 
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• To demonstrate if the metabolite differences induced by diet will affect the 
redox status of phosphatase proteins such as PTEN in prostate tissue. 
 
• To determine whether the differences in metabolites induced by diet in 
prostate tissue are associated with metabolite differences in urine. 
 
• To demonstrate if the differences in metabolites induced by diet are modulated 
by glutathione S-transferase Mu 1 (GSTM1) genotype or other relevant genotypes.  
 
3. Objectives 
We propose to undertake a two arm parallel un-blinded dietary intervention study. 
This study has been designed in order to provide information about differences in 
sulphate levels within prostate tissue in response to a broccoli-rich diet in men 
scheduled for diagnostic prostate biopsies. Volunteers recruited into the study will be 
randomly allocated to two groups, which will receive either a broccoli-rich diet or no 
intervention prior to a TPB procedure. Participants randomised to the dietary 
intervention arm will consume three portions of a soup containing high-glucoraphanin 
broccoli each week for at least four weeks prior to their biopsy. Secondary endpoints 
of the study will be to evaluate ADP accumulation, ATP depletion and changes to 
PTEN redox status as a consequence of dietary intervention. Rather than investigate 
the effect of the broccoli diet on these individual metabolites within prostate tissue, 
we intend to take a global approach using various techniques described in section  
11. Experimental methods. We also intend to analyse urine samples to obtain 
additional information on the systemic effects of the dietary intervention. Furthermore, 
it will be determined whether any observed differences associated with the dietary 
intervention may be related to key genetic polymorphisms including but not limited to 
glutathione S-tranferase Mu 1 (GSTM1). Several studies have reported that the 
influence of GSTM1 genotypes on the absorption of bioactives from broccoli and so 
we intend to gain information on participants’ specific genotypes [238].  
 
Finally, we intend to assess whether the accumulation of sulphate and ADP is specific 
to prostate tissue through the metabolic analyses of biopsies from prostate and non-
prostate tissue. The metabolite profiling of prostate tissue obtained from participants 
not receiving the broccoli diet and separate core biopsies from pelvic adipose tissue 
will establish whether diet-induced metabolic differences are specific to the prostate 
or occur in other tissue compartments. This study design does not require the 
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participants to have any additional clinical procedures; during the TPB procedure, 
separate cores will be taken from the prostate and adjacent adipose tissue.  
 
4. Study design 
The study will be led by Prof Richard Mithen. Dr Antonietta Melchini and Mr Jack 
Coode-Bate will act as IFR investigators. Mr Jack Coode-Bate is an NHS doctor and 
part of the Urology team at the NNUH. He is also a MD student with the University of 
East Anglia (UEA) and his research activities will be based at the Institute of Food 
Research (IFR). This project is an integral part of his research degree.  
 
The study will be carried out in collaboration with Mr Robert Mills and Professor 
Richard Ball at the Urology and Histopathology Departments of the Norfolk and 
Norwich University Hospital (NNUH) NHS Trust. Urologists at the NNUH will 
specifically help in identifying volunteers who are being scheduled for TPB. The 
‘window of opportunity’ for dietary intervention will be the waiting list time between 
decision to proceed with TPB and the actual operation date. All TPB procedures will 
be carried out by trained urology consultants, and would otherwise form part of the 
volunteers’ routine clinical care for potential diagnosis and staging of prostate cancer. 
 
The study team will recruit 9 volunteers to each arm of the study. 
Volunteers will be randomised to 1 of 2 arms: 
Arm 1- No dietary intervention 
Arm 2- Three portions (300g each) per week of a soup containing 
glucoraphanin-enriched broccoli (Beneforte®)  
 
The randomisation will be undertaken by a third party with the use of an electronic 
randomisation generator (www.randomization.com). This uses a method called 
“Block randomisation” whereby volunteers are equally distributed to both study arms.  
We will request volunteers’ consent for additional cores of prostate tissue to be taken 
during their TPB that would otherwise form part of their routine clinical care. We will 
also seek consent for 2 cores of adipose tissue to be taken through the template grid 
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used for the transperineal biopsy, but outside of the prostate. The collection of 
adipose tissue does not require any additional clinical procedures. 
In addition to prostate and adipose tissue, we will collect blood and urine samples at 
the time of TPB. All study samples will be used for global and targeted metabolite 
analyses. A specific dietary questionnaire will be carried out at the end of the 
intervention to establish their habitual intake of cruciferous vegetables. 
 
5. Recruitment policy 
A fixed 6-month period from the start of the study will be dedicated in order to allow 
recruitment of 18 volunteers and their follow up to the time of biopsy. Men aged 18 to 
80 years and with a BMI of 19.5 to 35 kg/m2 who have agreed to undergo a template 
biopsy of the prostate will be identified and recruited by Mr Robert Mills and other 
consultant urologists at the NNUH. The standard waiting list time between a referral 
for TPB and the actual procedure is currently 6-8 weeks at NNUH, allowing a dietary 
intervention of 4-6 weeks from time of recruitment. 
After deciding to proceed to template prostate biopsy, patients will be provided with 
an information pack either directly from the urology clinic or by arrangement to send 
it out by post. The urologist will provide the information packs and offer patients who 
would like more information on the study an opportunity to either return the response 
letter or contact one of the study team directly with the information provided. Members 
of the study team will construct information packs in advance of the clinics and hand 
them to the relevant collaborator. The study scientist will ensure that the clinics have 
an ample supply of information packs. The information packs will consist of a letter of 
invitation (Annex 2) and participant information sheet (PIS) (Annex 3). It is important 
to stress that non-NHS members of the IFR study team will not have access to any 
patient files. All searches of patient files will be carried out by the NHS staff outlined 
below or their NHS colleagues. Identified patients will be contacted by telephone by 
the NHS members of the study team at least one week after the packs have been 
distributed to ensure that they have been received. Potential volunteers will be asked 
to complete a response slip that includes their contact details and preferred time of 
contact (Annex 3). They will have the option to submit these directly to the urologist 
in clinic or return them to the study team in the pre-paid envelope provided. The 
information packs will also provide contact details of the IFR study scientists (Dr 
Antonietta Melchini and Mr Jack Coode-Bate).  
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If the patient agrees, he will be contacted by telephone to discuss the study in detail 
and establish interest in ongoing participation. IFR study scientists will encourage the 
volunteers to ask questions in order to ensure their full understanding of the study 
protocol prior to obtaining written informed consent (Annex 4). Volunteers are given 
at least 3 days to decide whether they would like to take part or not, and during this 
consideration period the volunteers will not be contacted. After this consideration 
period volunteers will attend the first visit at the Human Nutrition Unit (HNU) to give 
written informed consent and receive the broccoli and stilton soups if they are 
randomised to the intervention arm (Visit 1). Volunteers who are randomised to the 
no intervention arm will give written, informed consent before undergoing the clinical 
procedure (Visit 2). 
Recruitment will continue until 18 volunteers have completed the study. Information 
Services at NNUH have confirmed that 190 TPBs were performed in 2015 and this 
number is likely to continue to increase. It is, therefore, expected that recruitment of 
sufficient numbers will be possible within 6 months.  
 
 
6. Screening criteria 
 
6.1.1 Basic inclusion criteria 
• Males  
• Scheduled for TPB as part of routine investigation or staging for prostate 
cancer 
• Aged 18-80 years 
• BMI between 19.5 and 35 kg/m2 
• Smokers and non-smokers 
 
6.1.2 Basic exclusion criteria 
• Those regularly taking 5α-reductase inhibitors or testosterone replacement 
medicines 
• Those on warfarin treatment 
• Those diagnosed with diabetes 
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• Those diagnosed with or suspected to be high-risk for human 
immunodeficiency virus (HIV) and/or hepatitis 
• Those allergic to any of the ingredients of the broccoli and stilton soups 
• Those taking dietary supplements or herbal remedies which may affect the 
study outcome. Please note that some supplements may not affect the study 
and this will be assessed on an individual basis 
• Those that are unable to understand English or give informed consent 
• Parallel participation in another research project that involves dietary 
intervention  
• Any person related to or living with any member of the study team 
7. Study procedure 
A flow chart of the overall study is presented in Figure 0-5 
 
. This study will involve 18 volunteers aged between 18-80 years who will undertake 
the study as described below.  
 
7.1 Information exchange  
Volunteers who respond positively to the study invitation letter (Annex 2) will be 
contacted by telephone by a member of the study team and all aspects of the study 
will be discussed. The study scientist will go through the PIS (Annex 3) and answer 
any questions. Volunteers will be given at least 3 days to decide and are advised that 
they may withdraw from the study at any time without affecting their clinical care.  
 
7.2 Visit 1 at the HNU 
Volunteers who verbally agree to proceed after the consideration period will be 
randomised to one of the two arms. If allocated to the dietary intervention arm, 
volunteers will be invited to the Human Nutrition Unit (HNU) at the IFR to obtain written 
consent (Annex 4-5) and receive the first batch of frozen soups. In the non-
intervention arm, volunteers will not be required to attend this visit at IFR but will sign 
consent forms on the day of their prostate biopsy (Visit 2). All volunteers willing to 
participate in the study will have the opportunity to discuss the study and tissue bank 
consent forms (Annexes 4-5) with a study scientist in person (Visit 1, intervention 
arm; Visit 2, no intervention arm). Consent for the clinical procedure (TPB) will be 
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carried out by NNUH urologists using a standard NHS consent form on the day of 
biopsy (Visit 2) (Annex 6). In total, volunteers will be asked to sign three consent 
forms (Annexes 4-6). Copies of the consents will be kept in the study records, the 
patient hospital notes and a copy given to the volunteer to keep. GPs will be informed 
by letter of their patients’ participation in the study (Annex 7).  
Volunteers will be assigned a code and only the study scientists will be able to link 
codes to volunteers. All personal information will be kept confidential and known only 
to the Chief and Principle Investigators and NNUH collaborators.  
7.3 Visit 2 at the NNUH  
Volunteers will be provided with a validated Cruciferous Vegetable Food Frequency 
Questionnaire (CVFFQ) to be completed after the biopsy and returned to the study 
team using a pre-paid envelope (Annex 8). We wish to measure the habitual 
consumption of cruciferous vegetables in each group as participants may already 
consume high levels of these vegetables as part of their normal diet. CVFFQ is a 6-
page, 79-item questionnaire that has been designed and validated by the University 
of Arizona Health Sciences and assesses cruciferous vegetable intake over the 
previous 12-month period [92]. Volunteers will be asked to use the CVFFQ to review 
the time period between the biopsy referral and the actual procedure using a pencil 
provided by the study team. 
On the day of the biopsy, volunteers will also be asked to complete a health 
questionnaire detailing their past and current medical history and record all regular 
prescribed and over-the-counter medications (Annex 9).  
With informed, signed and written tissue banking consent (Annex 5) from all 
volunteers as detailed above, study samples (blood, urine and tissue biopsies) will be 
collected at the NNUH and transported to IFR to be stored until analysis. At the end 
of the study, the remaining blood and urine samples will be transferred to the local 
Human tissue bank to help future research studies. Participants will still be eligible to 
take part in the study even if they do not want their remaining samples to be 
transferred to the Norwich Biorepository. 
 
Tissue biopsy samples 
TPB of the prostate is a useful diagnostic tool in diagnosing and staging prostate 
cancer. It is performed under general anaesthetic with intra-vascular aminoglycoside 
Annex 1 – SAP Study Protocol 
133 
 
antibiotic prophylaxis. The patient is positioned flat on their back (supine) with their 
legs supported in stirrups and the skin cleaned with an appropriate antiseptic solution. 
An ultrasound probe is inserted into the rectum and allows direct visualisation of the 
prostate throughout the procedure for accurate targeting. A specially designed grid is 
attached to the ultrasound probe and placed flat against the skin of the perineum. 
Holes in the grid are spaced at 5mm intervals and allow systematic sampling of all 
zones of the prostate, while taking care to avoid the urethra. An average of 25 tissue 
cores is taken, but may vary depending on prostate gland volume.  
We propose to take an additional 8 needle cores of prostate through the template grid 
for study purposes. One core will be transferred immediately to methanol for 
metabolomic analysis, 5 cores will be snap frozen in dry ice and stored at -80oC for 
target metabolomic, oncogene and protein expression analyses, and 2 cores will be 
placed in RNAlater for RNA extraction. 
At the time of template biopsy we also propose to take 2 cores of adipose tissue from 
ischio-rectal (pelvic) fat to act as a control sample. These will be taken through the 
template grid in order to avoid a separate operation site. Both cores will be taken at 
the start of the procedure and using trans-rectal ultrasound to ensure no prostate 
tissue is involved in the core, before being appropriately processed for subsequent 
analyses. 
 
It is important to stress that the collection of additional tissue biopsy cores for this 
research project has been discussed with the consultant urologist (Mr Mills, NHS 
principal investigator) and will not affect patients’ clinical care. It is also important to 
take into consideration that the proposed sample collection is not expected to 
increase the risks of any associated complications. The prostate biopsies will be taken 
from the same zones as routinely sampled during TPB and the peri-prostatic adipose 
tissue samples avoid the need for a separate operation site. Intravenous antibiotic 
prophylaxis will be given as standard to reduce the risk of wound infection. 
 
Blood sample 
During routine venous cannulation prior to administration of general anaesthetic 
(standard procedure for template biopsy), a 5ml blood sample will be collected for 
genotyping. The blood will be mixed with an anti-coagulant (EDTA), divided into 
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aliquots and placed on dry ice until they can be safely transported back to the IFR to 
be stored at -80oC until required. 
 
Urine sample 
Prior to the prostate biopsy a first-pass urine sample (20-30ml) will be collected 
following digital rectal examination (DRE) for metabolomic analysis. The sample will 
be divided into aliquots, placed and transported on dry ice and stored at IFR at -80oC 
until required. 
 
At the end of the study, the remaining blood and urine samples will be transferred to 
the NNUH Human tissue bank (The Norwich Biorepository) to help future research 
studies (participants will give written consent for tissue banking, Annex 5). It is 
important to stress that any further analysis will be carried out in full compliance with 
ethical requirements.  
 
 
8. Post-Intervention Follow Up 
Volunteers will not be required to attend any further clinical follow up as part of the 
study. Their histology results, including both standard and study cores, will be 
reviewed by the clinician responsible and discussed in a multi-disciplinary team 
meeting if cancer is detected. All ongoing care will be determined as per standard 
treatment in the NNUH Urology Department. 
Volunteers in both arms of the study will be offered a 3 month supply of Beneforte® 
broccoli and stilton soup for their own personal consumption if desired but this will not 
form part of the study. They will have the option to collect the soups from the HNU or 
to be delivered directly to their home. In case of collection from HNU, the study team 
will not cover travel expenses. 
 
9. Study diet 
Volunteers will be randomly allocated to either no intervention or consumption of 3 
portions of Beneforte® (glucoraphanin-enriched) broccoli and stilton soup per week 
as part of their normal diet for a minimum of 4 weeks prior to their prostate biopsy. As 
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a day-case, elective procedure the expected waiting time between referral and the 
actual TPB procedure is currently 6-8 weeks at the NNUH. Volunteers will be asked 
to continue the soup intervention until the day of the biopsy in case the clinical 
procedure is delayed. The maximum waiting list duration set by the UK government 
is 18 weeks, but as an investigation for potential cancer TPBs are prioritised by the 
NNUH [239]. 
Beneforte® broccoli variety has been developed by conventional breeding and has 
the same appearance and flavour as standard broccoli. The broccoli and stilton soups 
will be prepared by Bakkavor®, a leading international producer of freshly prepared 
foods. Ingredient declarations, nutritional information and allergy statements for the 
soups have been provided from the producer (Annex 10). Bakkavor will make frozen 
soups and then arrange to deliver them to IFR (Figure 0-5). Once delivered to IFR, 
soups will be stored in a dedicated freezer (IFR West Side A). IFR study team 
members who have successfully completed “level 2” training in food safety will be 
responsible for providing the frozen broccoli and stilton soups either directly to 
volunteers attending IFR or delivering them to volunteers’ homes. Volunteers will be 
informed on how to consume the soups by reading the participant information sheet 
(Annex 3) and a specific soup information sheet (Annex 10). 
 
 
Figure 0-5. Broccoli and stilton soups provided by Bakkavor® will be packed 
in a carton designed to freeze soups in individual portions 
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9.1 Monitoring of diet and compliance 
Volunteers randomised to the intervention arm will be asked to fill in a soup record 
sheet during the pre-biopsy intervention period, recording each time they eat their 
soups (Annex 11). This is intended to aid compliance with the dietary interventions 
and also to be used in conjunction with the Arizona cruciferous vegetable intake 
questionnaire (Annex 8). Volunteers will also be asked to return the record sheets 
with the lids of empty soup containers, which will be counted by members of the study 
team to monitor compliance. 
We appreciate that volunteers may wish to go on holiday during the intervention 
period. Volunteers will be allowed to go on holiday during the course of the 
intervention provided they are able to transport and store the soups appropriately and 
continue to incorporate them into their diet. We will ask the volunteers to inform us of 
any planned holiday dates so that we can keep a record and review each case on an 
individual basis.  
 
10. Withdrawal of a participant from the study 
Volunteers may withdraw from the study at any time, without giving a reason, without 
affecting their clinical care at the NNUH Urology Department or their participation to 
other research studies. A withdrawal letter will be sent to the participant by the study 
team (Annex 13) and his withdrawal will be appropriately documented in the study 
withdrawal/termination log.  
11. Experimental methods 
11.1 Prostate biopsy sampling and processing 
We intend to collect 8 prostate biopsies and 2 adipose tissue biopsies from each 
volunteer through a TPB procedure:  
 
• Two cores will be used for global metabolomics: 
Biopsy samples (1 prostate core, 1 adipose core) will be deposited individually into 
pre-labelled sample vials containing room temperature extraction solvent (methanol). 
Following incubation at room temperature (up to 48 hours), biopsy samples will be 
removed from the extraction solvent. The removed prostate core will be used for 
histological analysis; instead the adipose core will be disposed by incineration. 
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Histological analysis of prostate biopsies will be carried out by Professor Richard Ball, 
consultant histopathologist at the NNUH, as part of normal diagnostic procedure for 
patients under investigation for prostate cancer. 
The vials containing extracted metabolites in methanol will be stored at IFR at -80°C 
until required for analysis. 
 
• Six cores will be used for target analyses 
Biopsy cores (5 prostate cores, 1 adipose core) will be placed individually into pre-
labelled vials and transported in dry ice until they can be safely transported back to 
the IFR to be stored at -80°C until required for analysis. 
 
• Two cores will be used for gene expression analyses 
Two biopsy cores will be immersed in RNAlater solution at the point of collection, 
safely transported to IFR and subsequently snap frozen in liquid nitrogen before being 
stored at -80°C.  
 
11.2 Blood sampling and processing 
A single blood sample (5ml) will be collected by a clinician in the operating theatre 
before starting the biopsy procedure. This will be divided into aliquots, transported on 
dry ice to IFR and stored at -80oC until required for genotyping. 
 
11.3 Urine sampling and processing 
A first-pass urine sample will be collected following prostate massage immediately 
before the patient undergoes the prostate biopsy procedure. This will be divided into 
aliquots, transported on dry ice and stored at -80oC until required for global and 
targeted metabolomic analysis. 
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11.4 Genotype determination 
The genomic DNA will be extracted from the blood sample using the QIAamp DNA 
Mini kit protocol (Qiagen Inc.) prior to genotyping for selected genotypes considered 
relevant for the purposes of this study.  
11.5 Gene expression analysis 
We will undertake both global and targeted gene expression analysis from prostate 
tissue biopsies. Total RNA will be extracted following snap freezing of samples in 
RNAlater™ (Ambion). This product ‘freezes’ gene transcription and stabilises the 
RNA present so that it can be extracted at a later stage. Total RNA isolation will be 
performed using RNeasy kits (Qiagen) according to the manufacturer’s instructions; 
these are used routinely for the extraction and purification of RNA. Preliminary 
investigation has demonstrated that sufficient RNA of high quality can be obtained 
from a single needle biopsy sample [63]. RNA extracted from the biopsy samples will 
be concentrated and the quality assessed using Agilent technologies lab-on-a-chip 
RNA 6000 nano assay. RNA of sufficient quality will be analysed by using new 
technologies such as Next generation sequencing. In addition, a selection of genes, 
including established prognostic biomarkers and interesting candidates identified 
through the global approach, will be confirmed by target analysis if considered 
relevant for the purposes of this project. 
 
11.6 Metabolite profiling 
The metabolomic analysis of tissue and urine samples will be carried out by an US 
company called Metabolon®. Metabolon® is a service and diagnostic products 
company with the ability to identify and produce a profile of up to 350 known 
metabolites using standard metabolomics techniques including liquid 
chromatography/mass spectrometry (LC/MS) and gas chromatography/mass 
spectrometry (GC/MS) [104].  
Tissue and urine samples will be sent for analysis at: 
Metabolon Sample Acceptance,  
800 Capitola Drive, Suite 1 
Durham, NC 27713, USA. 
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Briefly, the sample preparation process will be carried out using the automated 
MicroLab STAR® system from Hamilton Company. Standards will be added prior to 
the first step in the extraction process for quality control purposes. Samples will be 
prepared using a series of organic and aqueous extractions to remove the protein 
fraction while allowing maximum recovery of small molecules. The resulting extract 
will then be divided into two fractions; one for analysis by LC and one for analysis by 
GC. Samples will be placed briefly on a TurboVap® (Zymark) to remove the organic 
solvent. Each sample will then be frozen and dried under vacuum and thus prepared 
for the appropriate instrument, either LC/MS or GC/MS. 
Metabolon® will provide detailed reports on the difference in levels of sulphate, ADP 
and phosphate as well as a much wider range of metabolites following dietary 
intervention. The Metabolon® platform can identify sulphate with very high confidence 
levels, even without an internal standard. Sulphate has a unique mass defect and 
isotope pattern which are highly characteristic of the sulphur atom, ensuring 
fragmentation is accurate.  
Sulphate and other relevant metabolites will also be measured in tissue and urine 
samples by chromatography methods following IFR standard operating procedures. 
Sulphate quantification will be performed by liquid chromatography/mass 
spectrometry using an external standard calibration curve. IFR scientists have 
established a standard operating procedure for sulphate quantification that will be 
followed for the purposes of this study.    
Target analyses to determine ADP/ATP levels in tissue samples will be carried out 
using commercially available assay kits. 
 
11.7 Protein expression analysis 
The redox status of PTEN and associated proteins will be evaluated from snap frozen 
biopsy cores. Semi-quantitative analysis of PTEN oxidation will be performed using 
SDS-Page protein electrophoresis and Western blot analysis. A chromatography 
method based on liquid chromatography tandem mass spectrometry (LC/MS-MS) for 
detecting the reduced and oxidised PTEN (disulphide bond between Cys71 and 
Cys124) will be used for further quantitative analysis. 
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12. Confidentiality 
Volunteers who are successfully recruited onto the study will be assigned a unique 
code number which will be kept in a secure file. A lockable filing cabinet or cupboard 
will be used to keep paper documents that include the file linking the volunteer to the 
code and personal information. All electronic data will be stored on a password 
protected shared data file. Confidential data will be accessed only by the study 
scientists. The samples sent to the other laboratory facilities will be known only by 
their code number. All data collected will also be identified by code only.  
Volunteers’ personal data will be held in a locked cabinet or password protected 
electronic file in the IFR. Only the study scientists will have access to these data. Data 
will be stored for at least 15 years after completion or discontinuation of the study. 
The data will be stored in the IFR human studies archive. Access to archived data will 
be limited to the study scientist and chief investigators (CI) of the study or the CI's 
successor. The quality assurance auditors may also be allowed access with the 
permission, and in the presence, of the CI. The main computer storage will be on one 
main IFR computer, but as part of a password protected shared network. All IFR 
computers are individually password protected and the shared network access is 
limited to those working within the research area. Only the study scientists will have 
access to the file linking personal data to the volunteers’ unique code. Manual 
files/folders will consist of separate named and numbered files for each participant. 
No data with the volunteers’ name will be filed in the numbered file and vice versa. 
 
13. Statistical Analysis 
13.1 Sample size calculation 
There are no data (from previous literature) reporting the effect of a diet rich in broccoli 
on sulphate levels within prostate and at the systemic level. The sample size for the 
proposed study has been estimated taking into consideration the preliminary data 
obtained from the metabolomic analysis of samples collected as part of the ESCAPE 
study (REC 13/EE/0110; NCT01950143). The metabolite profiling of prostate tissue 
from patients (n=15) randomised to a 12-month broccoli intervention has shown a 
significant accumulation of sulphate in prostate tissue after the intervention period 
compared to baseline. 
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To detect a difference of 1.735 (normalised ion count) at a 5% significance level with 
90% power and assuming a within group standard deviation of 1.056 (normalised ion 
count) requires a sample size of 9 individuals in each group (total 18). These sample 
sizes were calculated for a two-group study design (broccoli intervention vs no 
intervention) assuming a two-sided comparison (i.e. to detect a difference rather than 
a higher level). 
 
13.2 Data analysis 
The statistical analysis for data generated from this study will be performed by using 
different methods. 
To determine if the dietary intervention affects sulphate levels, a Welch’s t-test ( or 
unequal variance test) will be used for data obtained from the two groups (broccoli 
intervention vs no intervention).   
One of the secondary aims of this study is to determine whether metabolic differences 
occurring in response to diet within prostate tissue are correlated with metabolite 
levels in urine. The association between the metabolic differences in prostate and 
those measured in urine will be assessed using an appropriate correlation test.  
The analysis will use ANCOVA to test for the effect of the diet whilst taking account 
of the glutathione S-transferase Mu 1 (GSTM1) genotype or other relevant genotypes. 
Genotype will be included as an explanatory variable in this analysis.  
 
14. Ethical considerations 
 
Food safety: IFR has standard operating procedures for the storage and delivery of 
food (broccoli and stilton soups) to study participants. Those procedures will be 
adhered to when processing and handling our food items, in accordance to 
Environmental Health Guidelines. 
 
Toxicity: There is no evidence from animal or human studies that broccoli is harmful.  
The level of glucoraphanin that will be consumed in the soup will be similar to that 
being consumed in a current intervention study carried out at IFR (Effect of 
Sulforaphane on Prostate CAncer PrEvention; REC ref: 13/EE/0110).  
Annex 1 – SAP Study Protocol 
142 
 
 
Risk of complications: The additional prostate and adipose tissue biopsies are not 
expected to increase the risk of potential complications. Antibiotic prophylaxis will be 
offered as standard and the operation site will not extend beyond the template grid. 
To date the incidence of complications in participants undergoing TPB, including 8 
additional prostate tissue cores, as part of the ESCAPE study has been lower than 
reported in the British Association of Urological Surgeons’ information sheet. 
 
The use of study samples for future research: Volunteers will be asked to sign a 
consent form agreeing to the storage of their samples in the tissue bank for research 
purposes. It is envisaged that the banking of the remaining blood and urine samples 
at the end of the study at The Norwich Biorepository will be valuable for obtaining 
additional information for this study and for designing further studies.  
 
Travel expenses: Volunteers will be reimbursed travel expenses to and from the HNU. 
This will be reimbursed at the IFR's current mileage rate or by reimbursing public 
transport costs on production of a ticket or receipt. If volunteers require transport by 
taxi, this will be arranged by prepayment.  
 
Use of documents previously approved by RECs: Volunteers will be provided with 
detailed information on how to consume and store the study diet (Annexes 10 and 
12). They will be also asked to complete some paperwork for the purpose of this study 
(Annexes 9 and 11). The annexes stated above are currently used in other dietary 
intervention studies; they have been reviewed and approved by the NRES Committee 
East of England- Cambridge South as part of two separate ethical applications (REC 
ref: 13/EE/0110; REC ref: 14/EE/1149). 
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Annex 3 
     Institute of Food Research 
PARTICIPANT INFORMATION SHEET 
Sulphate Accumulation in Prostate (SAP) 
You are being invited to take part in a research study. Before you decide it is important 
for you to understand why the research is being done and what it will involve for you. 
Please take time to read the following information carefully. Talk to others about the 
study if you wish. 
 
• Part 1 tells you the purpose of this study and what will happen if you 
take part 
• Part 2 gives you more detailed information about how the study will be 
conducted 
Please ask us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part. 
This information sheet is yours to keep. 
Thank you for reading this. 
…………………………………………………………………………………………. 
Study scientist contact details: 
Dr Antonietta Melchini  Mr Jack Coode-Bate 
+44 (0)1603 255 030   +44 (0)1603 255 030 
antonietta.melchini@ifr.ac.uk   jack.coodebate@ifr.ac.uk 
Chief investigator contact details: 
Professor Richard Mithen 
+44 (0) 1603 255 259 
richard.mithen@ifr.ac.uk
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PART 1 of the information 
sheet 
What is the purpose of the study? 
This study is part of a research project 
currently running at the Institute of 
Food Research (IFR) in collaboration 
with the Norfolk and Norwich 
University Hospital (NNUH) (Urology 
and Histopathology departments). 
 
It is also part of a research project for 
Mr Jack Coode-Bate, a Specialty 
training Registrar (StR) in Urology in 
the East of England deanery, and MD 
student at the University of East Anglia 
(UEA) and IFR. 
 
Current research suggests that diets 
rich in cruciferous vegetables (like 
broccoli) are beneficial to our health 
and may reduce the risk of some 
cancers, including prostate cancer. 
 
We have designed this study to 
investigate the relationship between 
diets rich in broccoli and prostate 
metabolism. We hope to expand our 
understanding of how eating these 
vegetables will influence prostate 
metabolism and so, ultimately, we can 
find ways to improve prostate health.  
 
The SAP study will explore the effects 
of consuming three portions of broccoli 
and stilton soup per week for at least 
four weeks prior to a template biopsy 
of the prostate (biopsies taken through 
a specially designed grid placed on the 
skin of the perineum). The broccoli 
used for production of 
the soups is a 
specially cultivated, 
glucoraphanin-
enriched variety 
known as Beneforte®. 
Once processed by the body this 
delivers high concentrations of 
sulforaphane – the naturally occurring 
chemical thought to be responsible for 
the beneficial effect of these 
vegetables. However, Beneforte® 
broccoli also retains the same 
compounds as normal broccoli, which 
could also be important. 
Previous studies carried out at IFR 
have identified specific changes in 
prostate metabolism, and particularly 
sulphate levels, as a result of a 12 
month broccoli-enriched diet in men 
with prostate cancer. 
 
We now aim to measure sulphate 
levels and expand our understanding 
  Annex 3– SAP PIS 
 
147 
 
of key genetic changes and products 
of metabolism in the prostate and urine 
after consuming Beneforte® broccoli 
and stilton soups. 
Why have I been invited to take 
part? 
 
We are contacting men who are under 
investigation for a potential, or 
previously diagnosed, prostate cancer 
and have been scheduled for a 
template biopsy of the prostate at the 
NNUH.  
We aim to recruit 18 men aged 18-80 
to take part in our study.  
 
You will not be able to take part if:  
• Your Body Mass Index (BMI) is 
lower than 19.5 kg/m2 or greater than 
35 kg/m2  
• You are being prescribed 5α-
reductase inhibitors (e.g. finasteride or 
dutasteride) 
• You are receiving testosterone 
replacement medicines 
• You are receiving warfarin 
treatment 
• You have been diagnosed with 
diabetes 
• You have been diagnosed with 
human- immunodeficiency virus (HIV) 
or hepatitis  
• You have a food allergy to the 
ingredients of the study diet  
• You are taking dietary 
supplements or herbal remedies, 
which may affect the study outcome. 
(Please note that some supplements 
may not affect the study and this will be 
assessed on an individual basis) 
• You are unable to understand 
English or give informed consent to 
take part. 
• You are participating in another 
research project involving dietary 
intervention. 
• You are related to or living with a 
member of the study team. 
 
Do I have to take part? 
It is entirely up to you to decide 
whether or not to take part. If you do 
decide to take part you will be asked to 
sign the relevant consent forms. You 
are free to withdraw from the study at 
any time without giving a reason. A 
decision to withdraw or not to take part 
will not affect the standard of care you 
receive.  
An expression of interest does not 
mean you are committed to 
participating in the study.  
After reading this information sheet 
if you are interested in taking part in 
the study you should contact the 
study scientists named on the first 
page, or complete the attached 
response form (page 20) and return 
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it either directly to your urologist in 
clinic or using the pre-paid 
envelope enclosed. 
Please feel free to say no by not 
returning the response letter we 
have provided.  
 
A member of the study team will 
contact you by telephone after one 
week to ensure you have received 
the information pack but will not 
attempt to persuade you to join the 
study. 
 
What do I have to do? 
 
If you decide to take part your 
involvement in the study will last 
until the day of your biopsy at the 
NNUH. This will be at least four 
weeks from the point of decision to 
participate, but will continue until 
the biopsy has been performed 
(depending on hospital waiting list 
times). We do not expect your 
participation in the study to exceed 
6 weeks. 
 
Your participation in the study will 
not delay your biopsy for any 
reason. 
 
During this period you can contact 
the study team at any time to ask 
any questions that might arise. We 
will request details of any holiday 
arrangements in case this may 
affect the study. 
 
What will happen to me if I take 
part? 
 
You will be contacted by a member 
of the study team by telephone at a 
mutually convenient time. At this 
point the details of the study will be 
discussed and any initial questions 
answered. 
 
If you decide to participate you will 
be randomly allocated into one of 
two groups (arms) of the study.  
 
Arm I: You will consume 3 
portions of broccoli and stilton 
soup per week until your biopsy 
day. 
Volunteers in this group will be 
asked to visit the Human Nutrition 
Unit (HNU) at the IFR on one 
occasion to sign consent and 
receive the first batch of frozen 
soups. All travel expenses will be 
reimbursed and if transporting the 
frozen soups is not convenient we 
will arrange for them to be delivered 
directly to your home.  
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Arm II: You will continue your 
normal diet until the biopsy day. 
Written consent from volunteers in 
this group will be taken at the 
hospital on the day of their biopsy, 
so will not require any additional 
study visits. 
 
On the day of the biopsy, all 
volunteers will be asked to 
complete a health questionnaire 
and a food frequency questionnaire 
to measure your normal intake of 
cruciferous vegetables.  
While under anaesthetic for the 
template biopsy of the prostate, 
additional samples for the study will 
be taken of both prostate tissue and 
the fat surrounding the prostate 
through the template grid.  
You will not be asked to undergo 
any additional surgical procedures 
outside of your routine clinical care. 
The collection of tissue samples for 
the purpose of this research will not 
affect the clinical procedure and will 
not increase your risk of any 
potential complications. All usual 
precautions surrounding the biopsy 
will be maintained and these are 
discussed in greater detail later. 
 
Single blood and urine samples will 
also be collected on the day of your 
prostate biopsy. 
 
Study talk over the phone  
 
If you have replied to tell us you are 
interested in participating, a study 
scientist will contact you by 
telephone. The details of the study 
will be discussed, as well as the 
content of this participant 
information sheet.  
 
This will be a good opportunity to 
ask any questions you may have. 
 
At the end of the discussion you will 
be given a 3-day consideration 
period to decide whether you would 
like to participate. We will not 
contact you during this period in 
order to allow you time to think 
about the study and discuss it with 
friends and family if you wish. 
If you decide to participate, you will 
be asked to contact one of the 
study scientists and he/she will 
arrange for you to be randomly 
allocated into either arm of the 
study.  
Depending on whether or not you 
will be receiving soups we will then 
arrange to meet with you either at 
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the IFR HNU (Arm I) or at the 
hospital on the day of your biopsy 
(Arm II). 
 
Health and diet questionnaires 
 
On the day of your biopsy you will 
be asked to complete two 
questionnaires: Health 
questionnaire and Arizona Food 
Frequency Questionnaire. 
 
Health questionnaire  
The health questionnaire will be 
carried out by a member of the 
study team at the NNUH and all 
your information will be considered 
strictly confidential.  
This will include a list of prescribed 
and over-the-counter medications 
as these can occasionally influence 
your metabolism. 
 
This questionnaire will inform us 
about your general health, your 
past and current medical history. 
 
Arizona Food Frequency 
Questionnaire 
We will ask you to complete a 
dietary questionnaire called the 
Arizona Cruciferous Vegetable 
Food Frequency Questionnaire. 
This has been specifically 
developed by the University of 
Arizona to assess cruciferous 
vegetable intake over the time 
period you have been asked to 
review. In your case this will be 
between your biopsy referral and 
the actual procedure.  
It is a 6-page questionnaire that will 
ask you questions related to the 
frequency and portion size 
(small/medium/large) of the range 
of individual cruciferous vegetables 
in your normal diet. It must be 
completed using the pencil 
provided by the study team. 
Questions are asked regarding 
both raw and cooked vegetables 
including typical methods of 
cooking. There is also a section to 
assess intake of oriental mixed 
dishes and condiments such as 
mustard that contain compounds of 
a similar nature to those delivered 
by eating cruciferous vegetables.  
The questionnaire should take 
approximately 20 minutes for you to 
complete. You have the option to 
return the completed questionnaire 
to the study team on the day of your 
biopsy or to send it by post using a 
pre-paid envelope.  
 
This questionnaire will help us to 
calculate what is normal for you and 
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which additional nutrients are likely 
to have come from the soups. 
 
 
Prostate biopsy procedure 
 
You have been invited to take part 
in this study because you have 
been scheduled for a template 
prostate biopsy (TPB) at the NNUH. 
This means that your urology 
consultant has already discussed 
the type of procedure, its intended 
benefits and serious or frequently 
occurring risks. Consent for this 
procedure will be carried out by 
NNUH urologists using a standard 
NHS form on the day of the biopsy. 
A copy of this consent is retained in 
your hospital notes.  
 
You already know that TPB is a 
surgical method for taking a larger 
number of prostate biopsies 
through the perineum (skin 
between scrotum and anus). TPB is 
performed under general or spinal 
anaesthetic with you flat on your 
back and legs supported in stirrups. 
The prostate is examined and an 
ultrasound probe inserted via the 
back passage (anus) to view and 
measure the prostate directly. The 
template grid is then placed flat 
against the skin of the perineum, 
which accurately guides the biopsy 
needle to sample regions 
throughout the whole prostate. The 
total number of biopsies taken may 
be as high as 50 depending on the 
size of your prostate, and allows 
access to regions of the prostate 
that would not otherwise be 
possible. A dressing is applied at 
the end of the procedure and most 
patients go home on the same day. 
 
For this study we will ask your 
permission to take an additional 8 
prostate biopsies and 2 fat biopsies 
during a TPB that would otherwise 
form part of your routine clinical 
care.  
It is important to stress that these 
samples will be collected only if you 
have given written informed 
consent for the study before 
undergoing TPB.  
 
These will not affect the histology or 
sampling of the prostate and all 
research samples will be 
independently reviewed by a 
consultant histopathologist.  
 
The biopsies taken from the fat 
(adipose) surrounding the prostate 
can also be directed through the 
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template grid and will therefore 
avoid the need for a separate 
operation site.  
 
The analysis of these fat biopsies 
will provide very useful information 
to assess metabolic changes 
elsewhere in the body (outside the 
prostate) as a result of eating the 
soups. 
 
We do not expect an increase in the 
risk of complications as a result of 
taking additional samples for the 
study. 
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 Flow chart detailing the different stages throughout the SAP study 
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When do I give consent for this 
study? 
 
If you agree to participate you will 
be asked to sign three separate 
consent forms confirming your 
enrolment (study consent), your 
consent to undergo the biopsy 
procedure (NHS standard consent) 
and permission to store your 
samples in the tissue bank for 
research purposes (The Norwich 
Biorepository consent). You will still 
be eligible to take part in the study 
even if you don’t want to store your 
samples in the tissue bank. These 
forms will also be signed by the 
study scientists and/or your 
urologist and you will be given a 
copy to keep.  
According to the study arm to which 
you have been allocated, you will 
either be asked to attend the HNU 
at IFR where we can go through the 
consent forms with you (Arm I), or 
meet us for the first time face-to-
face on the day of your prostate 
biopsy where all three consent 
forms will be signed (Arm II).  
 
After signing the consent form you 
are still free to withdraw at any time 
without giving a reason. This 
means that additional samples for 
this research will not be collected 
during your biopsy procedure. 
 
 
Broccoli and stilton soup provision 
Broccoli and stilton soups will be 
prepared by Bakkavor®, one of the 
world’s leading fresh prepared food 
providers in the UK (Spalding, 
Lincolnshire). 
Bakkavor® 
make the 
soups using 
fresh 
Beneforte® broccoli. 
You will not be able to choose which 
arm of the study you are allocated to. 
The random allocation will be 
performed by a computer-based 
programme (equivalent to a coin toss 
or roll of a dice), and so members of 
the study team could not influence this 
choice. 
If you are allocated to the arm 
receiving the diet intervention, you 
will be asked to eat three portions 
(300g) of this soup a week for the 
duration of the study (at least 4 
weeks prior your biopsy). 
Volunteers will be offered their 
soups in frozen 300g portions 
directly from the HNU. Depending 
on the number that is convenient for 
you, we can arrange for any further 
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batches of soup to be delivered 
directly to your home.  
The delivery of soups will be tailored to 
each participant taking into account 
their availability and storage space.  
The soups are provided frozen, so you 
will be asked to follow the cooking 
instructions (described separately in 
this information pack). We will contact 
you by telephone every fortnight to 
check that everything is going OK with 
the trial.  
 
What happens on the day that my 
biopsy has been scheduled at the 
NNUH? 
 
It is important for you to know that your 
biopsy procedure scheduled at the 
NNUH will not be delayed for any 
reason related to your participation in 
this study.  
Questionnaires, blood and urine 
sample collection 
On arrival at the NNUH you will be 
met by your urologist and the study 
scientists. Once all consent forms 
have been signed, we will help you 
to complete the brief health 
questionnaire and the diet 
questionnaire. 
 
After a digital rectal examination 
(DRE) of your prostate by an 
urologist, we will ask you to provide 
a urine sample of 25-30ml. This will 
be divided into portions and will be 
stored at the IFR until analysis. The 
remaining samples will then be 
transferred to the Norwich 
Biorepository (tissue bank) for 
future research. 
 
A 5ml (1 teaspoon) blood sample 
will be collected when the venflon 
(fine plastic drip tube) is inserted 
into a vein on your hand or arm by 
a urology or anaesthetic doctor. 
The venflon will remain in place as 
it will later be used during your 
anaesthetic. The blood sample will 
be transported to the IFR and 
stored until analysis. The remaining 
samples will then be transferred to 
the Norwich Biorepository (tissue 
bank) for future research. 
 
Prostate and adipose tissue biopsy 
The study samples will be collected 
first, targeting adipose (fat, 2 biopsies) 
and prostate (8 biopsies) with the 
ultrasound and template grid. The 
method of TPB will not alter in terms of 
anaesthetic type or approach to the 
biopsy. A full, standard set of prostate 
biopsies will then be taken and sent for 
histology to meet the needs of your 
routine clinical care.  
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Results of the prostate biopsies 
 
Analysis of tissue needs to be done 
carefully; it usually takes 2-3 weeks to 
complete. After obtaining the results of 
your biopsy procedure your doctor may 
decide that you need further 
investigations or treatment.  
 
The study will have no effect on your 
ongoing treatment options, and 
subsequent decisions will be made 
between you and your urologist.  
Your routine follow up visits at the 
hospital 
 
Your participation in this study will not 
change your hospital appointments to 
see your urologist.  
 
It is important to stress that you will not 
be required to attend any additional 
urology outpatient appointments 
before or after your biopsy for the 
purposes of this study.  
 
 
What will happen to my samples? 
 
The samples will be collected from the 
hospital and taken to IFR for analysis. 
Some of your samples will be sent for 
analysis in the USA. These specimens 
will not carry any personal information. 
Instead they will be labelled with an 
identification code. Transport of such 
material will be arranged with a 
specialist courier service. With your 
consent the remaining samples will be 
stored at the Norwich Biorepository 
(tissue bank). Otherwise they will be 
destroyed. 
Blood samples will be used for genetic 
tests. It is important to find out if the 
genetic characteristics of each 
individual may influence the effects of 
the diet. This study will involve genetic 
analysis that will help us understand 
how the volunteers respond to the 
intake of broccoli. In the future, it may 
be possible to recommend specific 
diets to people with certain genetic 
characteristics.  
 
It is important to stress that genetic 
analysis has no clinical relevance to 
you, your relatives or the treatment you 
receive; therefore participants will not 
receive results of this test. 
Are there any benefits of taking 
part? 
 
The information we obtain from this 
study may help in the prevention and 
treatment of prostate cancer in the 
future. We also hope the dietary 
modifications used in this study may be 
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of benefit to you. However, this cannot 
be guaranteed. 
 
Will my GP be informed? 
 
Yes, it is routine practice for us to 
inform your GP that you are 
participating in a study at IFR. This is 
one of the things you are agreeing to 
when you sign the consent form for 
taking part in the study.  
 
Are there any risks or side effects 
from participating in this study? 
 
There can be a small amount of 
discomfort associated with taking 
blood. This generally only occurs on 
insertion of the needle. You should not 
experience pain during the procedure 
or afterwards. You may develop a 
small bruise at the site of the blood 
sample but this will fade like any 
bruise. 
The surgical procedure of template 
biopsy carries a risk of certain 
complications. There is a small risk of 
infection. In order to reduce this risk, 
you will be given some intravenous 
antibiotics with your anaesthetic. This 
is normal practice for everyone having 
a prostate biopsy.  
A small proportion of men will suffer 
from urinary retention (less than 1 in 
10) as a result of the procedure, 
requiring a short-term catheter to be 
inserted into the bladder. This would 
later be removed once the swelling 
from surgery had subsided. 
It is normal to see blood in your urine 
or with bowel motions for a few days 
after the procedure. Blood can also be 
present in the semen and may persist 
for several months. 
Major complications from general 
anaesthesia are related to your health 
and whether you suffer from other 
medical conditions. The anaesthetist 
you meet will discuss these with you 
and advise you on the best anaesthetic 
technique. It is important to inform the 
pre-operative assessment nurse or the 
anaesthetist if you have other medical 
conditions or if there is family history of 
serious reactions to anaesthetics. 
 
 
Do I get paid for doing this? 
 
Participating in this study is voluntary. 
However, we do recognise that being 
involved in the study can cause you 
some inconvenience and there are 
travel costs associated with visiting us. 
Therefore, travelling expenses will be 
reimbursed for journeys to and from 
the HNU where parking is provided 
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free of charge. Expenses will be 
reimbursed on production of a receipt/ 
ticket for buses or trains or at the 
current mileage rate (45p per mile). If 
you require transport to and from the 
HNU, please let us know. We will 
arrange and pay for a taxi.  
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This completes Part 1 of the information sheet. 
If the information in Part 1 has interested you and you are 
considering taking part, it is important that you read the 
additional information in Part 2 before making any decision
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PART 2 of the information 
sheet 
 
Access to your personal 
information 
 
Any information relating to you will be 
held in strictest confidence. Once 
recruited, you will be issued with a 
volunteer code number. This number 
will be used on all your samples so that 
no one outside the study group will be 
able to link them to you.  
 
Access to your records is restricted to 
scientists who are running the study, 
research nurses, hospital medical staff 
and your GP. 
 
Will my taking part be kept 
confidential? 
 
Yes. We follow Ethics and Research 
Governance and Good Clinical 
Practice (GCP) requirements.  
All information collected about you 
during the course of this study will be 
kept strictly confidential. Information 
will be stored in locked filing cabinets 
at the IFR.  
Your volunteer code number will be 
used to protect your personal 
information and samples so no one will 
be able to link them to you. These 
codes are kept in a separate filing 
cabinet at IFR that is also kept locked. 
Access to your personal records is 
restricted to the study team, study 
nurses, NHS medical staff and your 
GP. Your data will be kept for up to 15 
years after the end of the study in a 
secure archive at the IFR.  
All research is subject to inspection 
and audit and although your records 
may be accessed for this purpose any 
personal information remains 
confidential. 
Please note that IFR has CCTV 
cameras in use for security purposes. 
However, provision has been made so 
that volunteers attending the HNU will 
not be identified. 
 
What if relevant new information 
becomes available or changes to 
the study are made? 
 
If this happens, we will tell you. If 
changes to the study have to be 
made, you may be asked to sign 
another consent form. 
 
What happens when the research 
study stops?  
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Findings of this study will be reported 
in the scientific literature. No individual 
data will be identified. 
 
 
Will I be told the results of the 
study? 
 
The results of the study will be 
published in scientific journals and 
presented at national and international 
scientific meetings. We are unable to 
tell you any of your individual results 
since it is only possible to draw 
conclusions from the group as a whole. 
 
At the end of the study, we will try to 
provide feedback of what we have 
found as a result of your help and what 
it may mean for future research. 
 
What if there is a problem? 
 
If you have a concern about any aspect 
of the study, you should ask to speak 
to the study scientists who will do their 
best to answer your questions (Dr 
Antonietta Melchini, 01603 255030; Mr 
Jack Coode-Bate, 01603 255030). If 
you remain unhappy and wish to 
complain formally, you can do this 
through the chairperson of the Human 
Research Governance Committee 
(HRGC) at the IFR – Dr Linda Harvey. 
 
What if something happens to me 
while I am on the study? 
 
If you are harmed by taking part in this 
research project there are no special 
compensation arrangements. If you 
are harmed due to someone’s 
negligence, you may have grounds for 
legal action, but you may have to pay 
for it. Regardless of this, if you wish to 
complain or have any concerns about 
the way you have been treated whilst 
taking part in this study at the NNUH 
clinics, there will be a local hospital 
complaints procedure that you can 
follow. If you wish to complain you 
should contact the Patient Advice and 
Liaison Service (PALS) on 01603 
289036 (email: pals@nnuh.nhs.uk). 
Their offices are located next to 
Kimberley Ward, East Block Level 2 or 
please ask at the main reception desks 
at the Inpatient and Outpatient hospital 
entrances. The office has an 
answerphone which is available 24 
hours a day and messages will be 
responded to as quickly as possible. 
IFR accepts responsibility for carrying 
out trials and as such will give 
consideration to claims from 
participants for any harm suffered by 
them as a result of participating in the 
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trial, with the exception of those claims 
arising out of negligence by the 
participant. IFR has liability insurance 
in respect of research work involving 
human volunteers. Please note that 
the Institute will not fund any legal 
costs arising from any action unless 
awarded by a court. 
 
 
 
What will happen at the end of the 
study? 
 
After the prostate biopsy you will be 
offered a 3 month supply of the 
Beneforte® broccoli and stilton soups 
for your own personal consumption if 
desired. You will have the option to 
collect the soups from the HNU or to be 
delivered directly to your home. In case 
of collection from the HNU, we will not 
cover travel expenses. This will not 
form part of the clinical trial, which will 
finish once we have collected all 
samples and questionnaires.  
You will not be asked to attend for any 
further clinics, tests or procedures as 
part of the trial. Instead, you will 
continue with routine clinical care at 
the NNUH. 
 
 
Who has reviewed this study? 
 
To protect your safety, rights, 
wellbeing and dignity the study was 
reviewed by the Institute of Food 
Research Human Research 
Governance Committee (HRGC) and 
an independent group called the 
National Research Ethics Service 
(NRES) Research Ethics Committee 
(REC) (insert REC name once 
approval issued).  
 
What should I do now? 
 
If you are interested in taking part in 
the study then please complete the 
response slip in your invitation letter 
and return it to your urologist directly, 
or in the FREEPOST envelope. If you 
are not interested in taking part you 
need not do anything. No one will 
contact you about the study. 
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Taking part in the research is entirely voluntary! You are free to withdraw from 
the study at any time without giving a reason. 
 
For further information or to arrange a study appointment, please contact study 
scientists: 
 
Ø Dr Antonietta Melchini 
+44 (0)1603 255 5030 
antonietta.melchini@ifr.ac.uk 
 
 
Ø Mr Jack Coode-Bate 
+44 (0)1603 255 030 
jack.coodebate@ifr.ac.uk 
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Sulphate Accumulation in Prostate (SAP) 
I am interested in taking part and/or finding out more information about this 
study (please complete the personal details below). 
Name:	………………………………………………………………………………………………………………..	
	
Address:	…………………………………………………………………………………………………………….	
	
………………………………………………………………………………………………………………………….	
	
Daytime	telephone	no.:	
………………………………………………………………………………………	
	
Evening	telephone	no.:	
……………………………………………………………………………………….	
	
Mobile	no.:	..............................................................................................................	
	
I	am	happy	for	a	message	to	be	left	via	my	daytime/evening	number:	
YES/NO	
*please	circle	as	applicable	
	
Preferred	time	to	call:	
.............................................................................................	
	
E-mail	address:	
……………………………………………………………………………………………………	
	
Please	return	this	form	in	the	FREEPOST	envelope	provided	to:	
	
Dr	Antonietta	Melchini/Mr	Jack	Coode-Bate	
Institute	of	Food	Research	
FREEPOST	NC	252	
Norwich	Research	Park	
Conley	
Norwich	
NR4	7BR	
	
Expressing	an	interest	does	not	commit	you	to	taking	part	in	the	study	
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